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D. ABSTRACT 
Poor absorption and bioavailability of drugs adopt challenges in efficient 
treatment of the patients. One of the widely used approaches to solve this 
issue is co-administration of absorption promoters. Synthetic absorption 
promoters have been found to be associated with mucosal damage and 
cytotoxicity. Herbal absorption promoters (HAPs) provide extremely promising 
alternative to the synthetic chemical counterparts in terms of safety and many 
times efficacy.  
 
About 90 % of the absorption in gastro intestinal (GI) tract occurs in the small 
intestine. Mostly drugs are metabolized by cytochrome P (CYP) 450 and P-
glycoprotein (P-gp) enzymes at intestinal cell wall. From these about 90 % of 
the drugs were metabolized by CYP 450 and more than 50 % of drugs were 
metabolized by CYP 3A4 which is the most abundant CYP 450 isoenzymes in 
humans and was responsible for the metabolism of the widest range of drugs. 
Some of these substrates i.e. amiodarone, carbamazepine, amitriptyline, 
nefazadone, sertraline, benzodiazepines, Ca+2
In this research we selected three HAPs i.e. silymarin, morin and naringin. 
These selected herbal constitutes are studied on laboratory animals with 
selected modern drugs to check the effect of this herbal constituents on their 
permission through intestine. The major mechanism found for drug absorption 
retardation through intestine is CYP 450 and P-gp efflux pump so on basis of 
the mechanism drugs were selected. Atorvastatin calcium and sildenafil 
citrate which is reported to metabolize by CYP 450 while zidovudine and 
carvedilol phosphate reported to metabolize by the P-gp efflux pump. So in 
 channel blockers, astemizole, 
terfenidine, buspirone, ciprofloxacin, lansoprazole, statins, and cisapride, 
sildenafil citrate, zidovudine, macrolide antibiotics, fluoxetine, fluvoxamine, 
grapefruit juice (GFJ), Indinavir, Itraconazole, ketoconazole and kitonavir etc.  
Some flavanoidal component i.e. silymarin, morin and naringin which are 
mostly found in fruits and plants and recognized as safe by FDA are and 
reported to interact with CYP 450 and P-gp and inhibit them and increases 
absorption of drugs.  
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present study these four allopathic drugs for with three HAPs for were studied 
for their effect on intestinal permission of selected drugs.  
 
For the proving the compatibility study of selected HAPs with selected 
allopathic drug the Infra red (IR) spectroscopy and differential scanning 
colorimeter (DSC) analysis was performed and from these studies it was 
observed that there were not any major changes reported. So we can say that 
mixing of selected allopathic drugs with selected HAPs and can not cause any 
serious compatibility problems and HAPs i.e. silymarin, morin and naringin 
can be used together as additives with selected drugs i.e. atorvastatin 
calcium, sildenafil citrate, zidovudine and carvedilol phosphate. 
 
The methods for analysis of selected drugs were developed on very sensitive, 
selective and precise instrument of HPLC binary system and analyzed by LC 
solution software approved by US-FDA and subsequently the methods were 
validated and results were found within the range in validation parameter. So 
this method is used for the analysis of selected drugs. 
 
Atorvastatin in oral dose of 75 mg/kg when administered alone (control group) 
as well as with selected HAPs in oral dose of 100 µmol (test group) i.e. with 
naringin the Cmax was increased significantly by 19.66 % in test group and 
with silymarin the Cmax was increased significantly by 32.31 % in test group 
and the, while with morin the Tmax remains 35 min in both control and test 
groups while Cmax was decreased by 14.23 % in test group.  
 
Sildenafil citrate in oral dose of 30 mg/kg when administered alone (control 
group) as well as with selected HAPs in oral dose of 100 µmol (test group) i.e. 
with naringin the Cmax was decreased by 1.91 % in test group and with 
silymarin the Cmax was increased significantly by 24.88 % in test group, while 
with morin the Cmax 
Zidovudine in oral dose of 75 mg/kg when administered alone (control group) 
as well as with selected HAPs in oral dose of 100 µmol (test group) i.e. with 
was increased significantly by 11.09 % in test group. 
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naringin the Cmax was increased significantly by 60.49 % in test group and  
with silymarin the Cmax  was increased significantly by 28.32 % in test group, 
while morin was increased the Cmax by 16.17 % in test group.  
 
Carvedilol phosphate in oral dose of 60 mg/kg when administered alone 
(control group) as well as with selected HAPs in oral dose of 100 µmol (test 
group) i.e. with naringin the Cmax was increased significantly by the 28.01 % in 
test group and with silymarin the Cmax was increased significantly by the 31.95 
% in test group, while with morin the Cmax was increased significantly by 5.67 
% in test group.  
 
HAPs may exhibit a very high benefit to risk ratio. Proposed study will provide 
an alternative approach to reduce the therapeutic dose and thereby 
minimizing the side effects of drugs and decrease the dose of drug and 
cutting down the cost of therapy. 
 
 
 
 
                                                                                              Introduction 
 
Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat, India.  1 
 
1.0 INTRODUCTION 
The absorption of drugs from the oral route via GI track is a subject of interest 
and continuous investigation in pharmaceutical industry as good bioavailability 
implies that the drug is able to reach the systemic circulation by mouth. Oral 
drug absorption is affected by both drug properties and the physiology of the 
GI tract or patient properties, including drug dissolution from the dosage 
forms, the manner drugs interacts with aqueous environment and membrane, 
permeation across membrane and irreversible removal by first-pass organs 
such as the intestine liver and lung (Martinez et al., 2002). 
 
Oral route is most preferred for drug delivery due to high patient compliance, 
non-invasive administration and low cost of therapy. Sufficient absorption of 
administered drugs from the GI tract is one of the prerequisites for successful 
therapy (Bohets et al., 2001). Drugs under biopharmaceutical classification 
system (BCS) class- I absorb well after oral administration and not pose 
bioavailability related problems; whereas drugs of classes II-IV (i.e. with low 
solubility, low permeability or both) pose challenges to the pharmaceutical 
development scientists in developing drug products with acceptable oral 
bioavailability. Low oral bioavailability of drugs also results in erratic 
pharmacokinetics (Aungst et al., 1996) and sometimes needs careful 
management of therapy. Several approaches are employed in alleviating oral 
bioavailability related problems. One such approach is the concomitant use of 
absorption promoters (Sharma et al., 1999). Recent in vitro studies (Aungst et 
al., 2000) have demonstrated that synthetic/chemical absorption promoters, 
such as sodium lauryl sulfate, palmitoylcarnitine, sodium caprate etc., when 
used at effective concentrations cause cytotoxicity or membrane damage. 
Limitations of these absorption promoters have suddenly increased interest in 
herbal absorption promoters (HAPs), once in dormant state.  
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According to the BCS drug substances are classified as follows (Amidon et 
al., 1995): 
Class I - High Permeability, High Solubility  
Example: Metoprolol  
The bioavailability of drugs from this class is not having much 
problem as drug is solvated with fast rate and also absorbed 
well.  
Class II - High Permeability, Low Solubility  
Example: Glibenclamide  
The bioavailability of those products is limited by their solvation 
rate.  
Class III - Low Permeability, High Solubility   
Example: Cimetidine  
The absorption and hence bioavailability of drugs of this class is 
limited by the permeation rate but the drug is solvated very fast.  
Class IV - Low Permeability, Low Solubility  
Example: Hydrochlorothiazide  
Those compounds have a poor bioavailability. 
 
1.1   Bioavailability and drug absorption  
Bioavailability is one of the essential tools in pharmacokinetics, it must be 
considered when calculating dosages for administration of non-intravenous 
routes. Bioavailability may define as measurement of the extent of active   
therapeutically drug that reaches the systemic circulation and is available at 
the site of action. By definition, when a drug is administered intravenously, its 
bioavailability is 100 %. However, when drug is administered via other routes 
(such as orally), its bioavailability decreases (due to incomplete absorption 
and first-pass metabolism). 
  
1.1.1  Absolute bioavailability 
Absolute bioavailability compares the bioavailability (estimated as area under 
the curve or AUC) of the active pharmaceutical drug in systemic circulation 
following non-intravenous administration (i.e. after oral, rectal, transdermal 
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and subcutaneous administration), with the bioavailability of the same drug 
following intravenous administration. The comparison must be consist of dose 
normalized if different doses are used; consequently, each AUC is corrected 
by dividing the corresponding dose administered. It is expressed as the letter 
F (Hoag and Hussain, 2001). 
 
In order to determine absolute bioavailability of a drug, a pharmacokinetic 
study must be done to obtain a plasma drug concentration vs. time plot for the 
drug after both intravenous (i.v.) and non-intravenous administration. For 
example, the formula for calculating F for a drug administered by the oral 
route (p.o.) is given below. 
 
 
 
Therefore, a drug given by the i.v. route will have an absolute bioavailability of 
1 (F=1) while drugs given by other routes usually have an absolute 
bioavailability of less than one. 
 
This measures the bioavailability (estimated as area under the curve, or AUC) 
of a certain drug when compared with another formulation of the same drug 
(i.e. Formulation A and B), usually an established standard, or through 
administration via different route. When the standard consists of intravenously 
administered drug, it is known as absolute bioavailability. 
1.1.2 Relative bioavailability 
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The absolute bioavailability of a drug, when administered by an extravascular 
route, is usually less than one (i.e. F<1). Various physiological factors reduce 
the availability of drugs prior to their entry into the systemic circulation Such 
factors may include, but are not limited to (Robert, 2001): 
1.1.3 Factors influencing bioavailability 
 Physical properties of the drug (hydrophobicity, pKa, solubility). 
 The drug formulations i.e. immediate release, modified release, 
delayed release, extended release, sustained release, excipient used, 
manufacturing methods etc. 
 If the drug is administered in a fed or fasted state. 
 Gastric emptying rate. 
 Circadian differences. 
 Enzyme induction/inhibition by other drugs/foods: 
Interactions with other drugs (e.g. antacids, alcohol, nicotine). 
Interactions with other foods (e.g. GFJ, pomello, cranberry juice). 
 Transporters: Substrate of an efflux transporter  (e.g. P-gp). 
 Health of the GI tract. 
 Enzyme induction/inhibition by other drugs/foods: 
Enzyme induction (increase rate of metabolism) e.g. phenytoin 
(antiepileptic) induces CYP1A2, CYP2C9, CYP2C19 and CYP3A4 
Enzyme inhibition (decrease rate of metabolism) e.g. GFJ inhibits 
CYP3A higher nifedipine concentrations. 
 Individual variation in metabolic differences. 
Age: In general, drugs metabolized more slowly in fetal, neonatal, and 
geriatric populations. 
Phenotypic differences, enterohepatic circulation, diet and gender. 
 Disease state: e.g. hepatic insufficiency and poor renal function. 
 
Sufficient absorption of administered drugs from the GI tract is one of the 
prerequisites for successful therapy (Bohets et al, 2001).  
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1.2  Drug absorption through GI tract 
Majority (approximately 90 %) of the absorption in the GI tract occurs in the 
small intestine, the surface of which has various projections (circular folds, villi 
and microvilli) that significantly increase the absorptive surface area of small 
intestine compared to other segments of GI tract. The enterocytes are the 
most abundant cells which account for majority of the absorption in the small 
intestine (Engman et al., 2003). The tight junctions present between the 
enterocytes and the lipophilic nature of the intestinal epithelium serve as a 
physical barrier for absorption of orally administered drugs (Jackson, 1987). 
Whereas the metabolizing enzymes, such as aminopeptidases, dipeptidyl 
peptidase-IV, isoenzymes of CYP450 superfamily, esterases, phenol 
sulfotransferase, UDP glucuronyltransferase and P-gp etc. expressed by the 
enterocytes serve as biochemical barrier (Hidalgo, 2001). Drug absorption 
across the intestinal epithelium may occur by one or more of five different 
transport pathways, shown in Figure 1.1.  
 
  
FIGURE 1.1: Schematic representation of routes and mechanisms of drug 
transport across the intestinal epithelium. 1. Passive transcellular route, 2. 
Passive paracellular route, 3. Carrier mediated transport, 4. Carrier mediate 
efflux and 5. Vessicular transport 
 
1.2.1 Passive Transcellular Route 
 It involves the movement of solute molecules across the apical membrane 
through the cell cytoplasm and across the basolateral membrane (Hidalgo, 
2001). Most drugs are relatively lipophilic and rapidly partition from the luminal 
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fluid into the cell membranes of the intestinal epithelium via this route. These 
drugs are normally rapidly and completely absorbed from the GI tract. The 
surface area of the transcellular route (i.e. cell membrane) is > 1000 fold 
larger (i.e. 99.9 % vs. 0.01 %) than that of the paracellular route (i.e. tight 
junctions), (Hidalgo, 2001; Pappenheimer and Reiss, 1987). 
 
1.2.2 Passive paracellular route 
The paracellular pathway is an aqueous, extracellular route across the 
epithelium. Many hydrophilic drugs and peptides partition poorly into the cell 
membranes and are subsequently not transported via the transcellular 
pathway. It is therefore generally assumed that these drugs are transported 
across the intestinal epithelium through the aqueous filled pores of the 
paracellular pathway (Fig. 1.1). These drugs are incompletely absorbed 
because the paracellular pathway occupies a very small surface area (0.01-
0.1 %) of the total surface area of the intestine. Moreover, the apical and 
basolateral domains are separated by the tight junctions, providing a seal 
between adjacent epithelial cells that further restricts transport via this route 
(Jackson at el., 1987).  
 
Evidence that the tight junctions can be modulated in response to various 
stimuli, such as hormones, nutrients etc., has stimulated investigations into 
ways to enhance the permeability by this route. The reversible opening of the 
tight junctions is of considerable interest in pharmaceutics since it shows a 
way by which the absorption of more hydrophilic drugs (that do not partition 
significantly into the cell membranes) canincreased (Artursson et al., 1990). 
 
1.2.3 Carrier-mediated transport  
A large numbers of transporters (carriers), expressed in the small intestinal 
mucosa are responsible for the absorption of nutrients and vitamins (Hidalgo 
et al., 2001). Structural analogs within a series of xenobiotics are able to 
utilize these transport pathways (Fig.1.1). These influx transporters can bind 
compounds that are dissolved in the intestinal fluid and translocate them 
across the apical membrane of enterocytes, thus facilitating drug absorption 
                                                                                              Introduction 
 
Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat, India.  7 
 
process. Compounds that are substrates for the influx transporters exhibit 
intestinal absorption higher than expected from their diffusion across cell 
membranes (Raeissi et al., 1999; Artursson et al., 1991; Hidalgo et al., 1990)
Incomplete oral bioavailability has various causes e.g. poor dissolution or low 
aqueous solubility degradation of the drug in to the GI fluids poor membrane 
permeation and pre-systemic GI metabolism or hepatic metabolism. Out of 
various approaches used one most acceptable approach is incorporation of 
.  
 
1.2.4 Carrier-limited transport (apical efflux) 
In contrast to the role of influx transporters, which can enhance intestinal drug 
absorption, efflux transporters mediate the extrusion of compounds from the 
cell cytoplasm to the intestinal lumen through a process known as apical 
efflux (Fig. 1.1). Two families of transporters, multidrug resistance (MDR) and 
multidrug resistance associated protein (MRP) (Marttin et al., 1995; Merkus et 
al., 1993), mediate apical drug efflux. P-gp the product of the MDR1 gene, is 
located on the apical membrane of normal enterocytes. It is the most studied 
member of the apical efflux transporters and has been shown to limit intestinal 
absorption of a large number of drugs.  Here, saturation of the carrier could 
result in an increase in absorption of the drug (Phung-Ba et al., 1995; Hunter 
et al., 1993). 
 
1.2.5 Vesicular transport 
The vesicular transport (Fig. 1.1) includes fluid-phase endocytosis, receptor-
mediated endocytosis and transcytosis. This complex route has a very low 
capacity and is only of relevance for highly potent macromolecular drugs that 
are active at low concentrations (Swaan et al., 1998). The membrane vesicles 
contain large amount of proteolytic enzymes which are responsible for 
significant degradation of most of the exogenous proteins. These reasons limit 
this pathway as general drug transport route (Lazarova et al., 1993; Heyman 
et al., 1982). 
  
1.3  Oral bioavailability and herbal absorption promoters 
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absorption promoters for enhancement of bioavailability of otherwise poorly 
absorbed drugs. 
 
Despite tremendous innovations in the drug delivery methods in the last few 
decades, the oral route still remains as most preferred route of administration 
for most new chemical entities (NCE). The oral route is preferred by virtue of 
its convenience, low costs, and high patient compliance compared to alternate 
routes. However, compounds intended for oral administration must have 
adequate aqueous solubility and intestinal permeability in order to achieve 
therapeutic concentrations. With the explosive growth in the field of genomics 
and combinatorial chemistry coupled with technological innovations in the last 
few years, synthesizing a large number of potential drug candidates is no 
longer a bottleneck in the drug discovery process. Instead, the task of 
screening compounds simultaneously for its clinical biological activity and 
biopharmaceutical properties (e.g. solubility, permeability/absorption, stability 
etc.) has become the major challenge. This has provided a great impetus 
within the pharmaceutical industry to implement appropriate screening models 
that have high capacity are cost-effective and highly predictive of in vivo 
permeability and absorption. 
 
An absorption promoter can function by one or more of the following 
mechanisms: 
i. Improve the permeant’s solubility. 
ii. Improve the permeant’s diffusivity and permeability across the 
epithelium. 
iii. Protect the permeant from pH, luminal and/or brush border enzymes. 
iv. Protect the permeant from nonspecific binding sites.  
v. Reduce the activity of or compete for uptake by efflux pumps in the 
apical side of intestinal membrane.  
 
With various types of absorption promoters available, narrowing the selection 
requires a comparison of the benefits and risks of these agents. The three 
most important criteria for evaluating absorption promoters are effectiveness 
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of the absorption promoter, potential to cause toxicity and the mechanisms by 
which absorption is promoted. Certainly, the most obvious indicator of 
success associated with absorption promoter is the extent of bioavailability 
enhancement realized. Many studies have shown that the absorption 
enhancing effects of the synthetic absorption promoters, including surfactants, 
bile salts and fatty acids, are often accompanied by damage to the epithelial 
cell membrane when they are used at an effective concentration (Marttin et 
al., 1995). As a result, only a few formulations containing these absorption 
promoters are available in the market for clinical use. 
 
HAPs are isolated components or extracts of plants and employed to promote 
absorption of several drugs and nutrients (Badmaev et al., 2000; Odou et al., 
2005; Nabekura et al., 2005). The concentrations employed for the absorption 
promotion by HAPs are very low as compared to their concentrations which 
can cause toxicity. This concept of enhancement of drug bioavailability/ 
bioefficacy is not new but is based on clues from Ayurveda wherein it has 
been found that certain herbals, either individually or as a group, are 
repeatedly found along with the active medicament in large number of 
prescriptions recommended for a variety of diseases.  The addition of the 
chosen herbs or part of it helped in the availability and absorption of the 
drugs. Earlier, the Ayurvedic Physicians used black pepper or Trikatu 
(1:1:1mixture of dried fruits of Piper nigrum and Piper longum and dried 
rhizomes of Zingiber officinalis) in several drug formulations to enhance drug 
activity and to minimize side effects. Out of the 370 compound formulations, 
210 contain either Trikatu or its individual components (Hand Book of 
Domestic Medicine and Common Ayurvedic Remedies, 1979). In the last few 
years, the scientists have tried to explore the scientific basis of the use of the 
herbs prescribed by Ayurvedic physicians. Their efforts have resulted in better 
understanding of mechanism of action of HAPs, isolation and characterization 
of individual compounds and generating toxicity data. Improved understanding 
of HAPs has made it evident that these herbs were not included in the herbal 
formulations just for sake of rhyme but had definite role to play in promoting 
absorption and enhancing bioavailability.  
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In this research work we selected three HAPs i.e. silymarin, morin and 
naringin. This selected herbal constitutes are studied on laboratory animals 
with selected modern allopathic drugs to check the effectiveness of this HAPs 
for their permission through intestine. The major mechanism found for drug 
absorption retardation through intestine is CYP 450 and P-gp efflux pump so 
on basis of the mechanism drugs were selected. Atorvastatin and sildenafil 
which is reported to metabolize by CYP 450 while zidovudine and carvedilol 
phosphate reported to metabolize by P-gp efflux pump. So in present study 
these four allopathic drugs for with three HAPs for were studied for their effect 
on intestinal permission of selected drugs.  
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2. REVIEW OF LITERATURE  
2.1 Anatomy and physiology of small intestine  
The human small intestine is approximately 2-6 m and is loosely divided into 
three sections: duodenum, jejunum, and ileum, which comprise 5 %, 50 %, 
and 45 % of the length (Ganong et al., 1995). Approximately 90 % of all 
absorption in the gastrointestinal tract occurs in the small intestinal region. 
The intestinal surface of the small intestine has surface projections that 
increase the potential surface area for digestion and absorption. Macroscopic 
valve like folds called circular folds, encircling the inside of the intestinal 
lumen is estimated to increase the surface area of small intestine threefold. 
Villi increase the area 30-fold and the microvilli increase it by a factor of 600 
Thus, such unique structures lead to a tremendous increase in surface area 
available for absorption in the small intestine  
 
The major role of the small intestine is the selective absorption of major 
nutrients and to serve as a barrier to digestive enzymes and ingested foreign 
substances. The epithelial cells in the intestinal region are a heterogeneous 
population of cells that include enterocytes or absorptive cells, goblet cells 
that secrete mucin, endocrine cells, paneth cells, M cells, tuft and cup cells 
(Carr et al., 1984; Madara et al., 1987). The most common epithelial cells are 
the enterocytes or the absorptive cells. These cells are responsible for the 
majority of the absorption of both nutrients and drugs in the small intestine. It 
is polarized with distinct apical and basolateral membrane that are separated 
by tight junctions. Thus, bulk of absorption takes place in small intestine by 
mechanisms such as passive diffusion (paracellular and transcellular), carrier-
mediated process (facilitated and active) and endocytosis. In the present 
study objective targeted, to perform solid state study of different drugs with 
different HAPs by FTIR and DSC technique to conduct the study regarding 
improvement of bioavailability of some poorly absorbed synthetic drugs using 
HAPs and to find out the effective concentration of selected HAPs.  
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2.1.1 CYP3A4 in intestine involve in drug metabolism  
There is a first pass extraction progress when drugs orally absorbed, which 
are metabolized by the microsomal cytochrome superfamily of enzymes. The 
CYP P450 enzymes are responsible for the majority of oxidative metabolism 
of drugs. Although approximately 15 forms of CYP participate in metabolism 
of drugs, four forms i.e. CYP 3A4, CYP 1A2, CYP 2C9 and CYP 2D6 together 
account more than 90 % of oxidative metabolism of drugs. CYP 3A4 (P450 
NF, P 450 3A4, Hpcn1) a major phase-I drug metabolizing monooxygenase, 
by itself participants in the metabolism of greater than 50 % of drugs that are 
metabolized oxidatively. CYP 3A4 also can metabolize inherent metabolite, 
aflatoxin B1,precarcinegen, etc (Dantzig et al., 1999). The site of such first 
pass oxidative metabolism has usually been considered to be the liver 
because of its site, its relatively high level of P 450 activity and its anatomic 
location relative to the site absorption. However, recent studies indicate that 
CYP 3A4 metabolic activity in the intestinal mucosa may substantially 
contribute to the over all first pass effect. Enzymes of the CYP 3A family are 
very abundant, according for approximately 30 % of hepatic CYP and greater 
than 70 % of small intestinal CYP (Wacher et al., 1998). The expression of 
CYP 3A4 in the intestine is site dependent that means the concentration of 
CYP 3A4 is different in different portion. Abnormally CYP3A4 is greatest in the 
duodenum and lowest in the ileum. That is to say, the upper small intestine 
(duodenum and proximal jejunum) serves as the major site for intestinal first 
pass metabolism of drugs (Paine et al., 1997). Because of the absorption of 
chemical inducers and the polymorphism of gene, it is possible for an 
individual to have relatively high liver CYP3A4 activity but present low 
intestinal CYP 3A4 activity or to have relativity low liver CYP3A4 activity while 
having relatively high intestinal CYP3A4 activity and the CYP3A4 levels is 
variable with 10 to 100 fold variations was reported (Lown et al., 1997; Lown 
et al., 1994).  
 
Furthermore, despite hepatic and intestinal CYP3A4 appear to the some 
enzymes, having identical cDNAs and demonstrating almost identical Km 
values for midazolam 1’ hydroxylation, CYP3A4 in the liver and small intestine 
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are not coordinately regulated (Wacher et al., 1998). For some drugs, such as 
grapefruit juice (Lown et al., 1997), only influence the level of CYP3A4 in 
small intestine, but not affect that in liver, and other drugs, such as 
erythromycin (Ryoko et al., 2001) only increase activity of CYP 3A4 in hepatic, 
but not increase that in small intestine. All the facts above bring the complex 
and difficulty of the studies of CYP 3A4.  
 
2.1.2 Effect of P-gp as a drug efflux pump involve in drug metabolism 
 In the intestine of human, P-gp is located almost exclusively within the brush 
border on the apical surface of the enterocyte, and other normal tissues such 
as the liver, brain, kidney and so on also express P-gp. P-gp is the product of 
the multidrug resistance gene MDR1 and belongs to a member of a large 
multigene family of ATP binding cassette (ABC) membrane transporters 
(Yumoto et al., 1999; Fischer et al., 1998; Zhang et al. 1998) and is composed 
of about 1280 amino acids. Although, CYP 3A4 in the intestine has an effect 
in the first pass elimination of oral drugs, more and more researches conclude 
that the intestinal P-gp probably plays a mojor significant role (Schinkel et al., 
1997; Sparreboom et al., 1997; Masuda et al., 2000; Kim et al, 1998). Similar 
with CYP 3A4 the expression level of P-gp in each small intestine varies with 
maximal expression in ileum and moderate express in duodenum and jejunum 
and then a decrease in expression through the proximal and distal colon. In 
addition, the expression of P-gp does not show some relationship in the liver 
and the small intestine (Ryoko et al., 2001). In addition, the special 
relationship of P-gp in the plasma membrane and CYP 3A4 inside the cell on 
the endoplasmic reticulum suggests that P-gp may act to regulate exposure of 
substrates to metabolism by CYP 3A4. A substrate from P-gp is repeatedly 
circulates between the gut lumen and epithelial cell, leading to increased 
metabolism due to prolonged exposure to the metabolic enzyme, resulting in 
reduced absorption of the drug into blood (Zhang et al., 1998; Mayo et al., 
1997). Moreover, when P-gp transfer drug from the cell, it also remove 
metabolites of drug from the cell interior, and lead to increasing of metabolism 
by CYP3A4 (Dantzig et al., 1999, Hochman et al., 2000). 
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2.1.3 Coordination of CYP3A4 and P-gp involve in drug metabolism  
Recent studies have revealed that CYP 3A4 and P-gp not only function in a 
complementary fashion to reduce systemic exposure to drugs but there is also 
considerable to overlap in the drugs which interact with the two proteins 
(Wacher et al., 1995) Many important clinical drugs i.e. immunosuppressant 
agents, antibiotics, calcium channel antagonists, cancer chemotherapeutic 
agents, antiarrhythmics and so on, are metabolized by CYP 3A4 (Yumoto et 
al., 1999) and some of them are not only substrate or inhibition of CYP 3A4 
but also the substrate or inhibition of P-gp. That is to say, when these drugs 
induce or inhibit CYP 3A4, they probably induce or inhibit P-gp at the same 
time. Recent studies shows expression of the CYP 3A4 and P-gp in human 
parental colon carcinoma cell line LS 180, and found the strong inducer of 
CYP 3A4, such as reserpine, rifampicin, phenobarbital etc. were also the 
powerful inducers of P-gp (Schuetz et al., 1996). Otherwise, it was also 
suggested that, although many P-gp inhibitors were potent inhibitors of 
CYP3A4, a varying degree of selectivity was present (Ohnishi et al., 2000). 
For example, GFJ can significantly reduce the content of CYP 3A4 but not the 
content of P-gp in human body (Wacher et al., 1998; Ohnishi et al., 2000; 
Fontana et al., 1998). However, some studies have also shown that GFJ 
compounds not only inhibit drug metabolism by CYP 3A4, but also enhance 
drug absorption by the inhibition of drug efflux via P-gp in a human colon 
carcinoma cell line, Caco-2 cells used as a model of intestinal absorption 
(Takanaga et al., 1997) and HMF, langeretin and nobiletin, which separated 
from the orange juice are all P-gp inhibitors, However none of them inhibited 
CYP3A4 (Takanaga et al., 2000).  Although, there are striking overlaps of 
substrates and inhibitors between CYP3A4 and P-gp, an important finding 
was that no significant correlation exists between the ability of the compounds 
to inhibit P-gp and their ability to inhibit CYP3A4. Probably, the molecular 
recognition sites of P-gp and CYP3A4 differ in ways that result in differential 
effects of compounds at the two sites (Hall et al., 1999; Ohnishi et al., 2000).  
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2.2 CYP 450 enzyme system   
The CYP P450 enzyme system consists of a superfamily of hemoproteins that 
catalyze the oxidative metabolism of a wide variety of exogenous chemicals 
clouding drugs, carcinogens, toxins and endogenous compounds such as 
steroids, fatty acids and the prostaglandins (Shimada et al., 1994). The CYP 
450 enzyme family plays an important role in phase-I metabolism of many 
drugs. The broad range of clinical medicines undergoes CYP 450 mediated 
oxidative biotransformation is responsible for the large number of clinically 
significant drug interactions during multiple drug therapy. Clinical case reports 
or studies usually provide the first evidence of interaction between drugs. 
Several recent studies discuss such drug interactions at the molecular or 
enzyme level and therefore constitute an important link between clinical and 
experimental research. Central to this approach is an understanding of 
catalytic importance of individual CYP 450 iso-enzymes in particular metabolic 
pathways. 
 
2.2.1 Nomenclature of CYP 450 
Nomenclature of CYP 450 enzyme system has been established by CYP 450 
nomenclature committee. The name CYP 450 family is derived from the fact 
that these proteins have a heme group and an unusual spectrum (Shimada et 
al., 1994). These enzymes are characterized by a λmax of 450 nm in the 
reduced state in the presence of carbon monoxide. Naming a CYP450 gene 
include root symbol “CYP” for humans (“CYP” for mouse and Drosophila), an 
Arabic numeral denoting the CYP family (e.g. CYP 1, CYP 2), letters A, B, C 
indicating subfamily (e.g. CYP 3A, CYP 3C) and another Arabic numeral 
representing the individual gene/isoenzyme/isozyme/isoform (e.g. CYP 3A4, 
CYP 3A5). Of the 74 gene families so far described, 14 exist in all mammals. 
These 14 families comprise of 26 mammalian subfamilies. Each isoenzyme of 
CYP 450 is specific gene product with characteristic substrate specificity. 
Isoenzymes in the same family must have >40 % homology in their amino 
acid sequence and members of the same subfamily must have >55 % 
homology. In the human liver there are at least 12 distinct CYP 450 enzymes.  
At present it appears that from about 30 isozymes, only six isoenzymes from 
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the families CYP 450 1, 2 and 3 are involved in the hepatic metabolism of 
most of the drugs. These include CYP 1A2, 3A4, 2C9, 2C19, 2D6 and 2E1 
(Nelson et al., 1996). 
 
Isoenzymes and drug interactions: The advances in CYP enzyme system 
has made it possible to associate specific enzyme activity with the formation 
of a particular metabolite and in some cases to identify the major isoenzyme 
responsible for the total clearance of a drug. Individual isoenzymes involved in 
the metabolism of large number of important drugs. Induction or inhibition of 
these isoenzymes leads to clinically significant drug interactions. Individual 
isoenzymes and their drug interactions are as follows:  
 
3A Isoenzymes: Members of the 3A subfamily are the most abundant CYP 
450 enzymes in the liver and account for about 30 % of CYP proteins in the 
liver. High levels are also present in the small intestinal epithelium and thus 
makes it a major contributor to presystemic elimination of orally administered 
drugs. There is considerable interindividual variability in hepatic and intestinal 
CYP 3A activity (about 5-10 fold). Since 40 to 50 % of drugs used in humans 
involve 3A mediated oxidation to some extent, the members of this subfamily 
are involved in many clinically important drug interactions. 3A4 is the major 
isoenzyme in the liver. 3A5 is present in the kidneys. Inducers of 3A4 usually 
do not upregulate 3A5 activity. Noteworthy is high concentration of 
terfenadine, astemizole and cisapride when these drugs are taken 
concomitantly with azole antifungals or macrolide antibiotics or fluoxetine or 
fluvoxamine. High concentration of these drugs lead to life threatening cardiac 
arrhythmias like torsades de pointes and ventricular fibrillation. Terfenadine 
has been withdrawn in USA and the European Union. Fexofenadine, the 
active metabolite of terfenadine, is now marketed as a noncardiotoxic 
alternative to terfenadine. US-FDA is currently considering to contraindicate 
the use of selective serotonin reuptake inhibitors (SSRI) with the non-sedating 
antihistamines. Mibefradil, a newer calcium channel blocker, that preferentially 
blocks T-type calcium channels, has already been voluntarily withdrawn from 
the market because of large number of drug interactions. GFJ is often taken 
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at breakfast in the western countries when drugs are also often taken. GFJ 
having bioflavonoids mainly naringin and furacoumarin which cause 
mechanism based inhibition of presystemic elimination of a number of drugs 
and increase their bioavailability. An important interaction involving induction 
of CYP 3A is the reduction in efficacy of contraceptives taken orally by 
rifampicin and rifabutin, because of an induction of the CYP 450 3A mediated 
metabolism of estradiol and norethisterone, the components of oral 
contraceptives (Badayal et al, 2001).  
 
2D6: This isoenzyme represents <5 % of total CYP proteins. It has aroused 
great interest because of its large number of substrates (30-50 drugs) and its 
genetic polymorphism. It is also called debrisoquine hydroxylase after the 
drug that led to the discovery of its genetic deficiency. Many psychotropic, 
antiarrhythmic and β-adrenergic receptor blocker drugs are substrates as well 
as inhibitors of 2D6.  
 
IA2: This is the only isoenzyme affected by tobacco. Cigarette smoking may 
lead to threefold increase in CYP 1A2 activity. Theophylline is metabolised in 
part by 1A2, which explains why smokers require higher doses of theophylline 
than non-smokers. Alcohol inhibits metabolism of caffeine, a substrate of CYP 
1A2. Alcohol has been reported to mask the CYP 1A2 inducing potential of 
smoking. Exposure to polyaromatic hydrocarbons found in charbroiled food 
can also induce this isoenzyme (Crewe et al., 1992). This isoenzyme also 
causes metabolic activation of procarcinogens to carcinogens e.g. aromatic 
and heterocyclic amines.  
 
2C9: S-warfarin and phenytoin, both involved in large number of drug 
interactions, are metabolised mainly by CYP 2C9 (Rettie at el., 1992) St. 
John’s wart a herbal antidepressant has been reported to decrease levels of 
warfarin by induction of CYP 2C9.  
 
2C19: This iso-enzyme also exhibits genetic polymorphism. CYP 450 2C19 is 
involved in major metabolism of a number of clinically important drugs i.e. 
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omeprazole, diazepam, anti-depressants, anti-malarials etc. (Lamba at el., 
1998).  
 
2E1: This iso-enzyme is involved with metabolism of low molecular weight 
toxins, fluorinated ether, volatile anesthetics, procarcinogens etc. This iso-
enzyme is inducible by ethanol and is responsible in part for metabolism of 
acetaminophen. The metabolite of acetaminophen formed is highly reactive 
and hepatotoxic. Alcohol dependant patients may be at increased risk of 
acetaminophen hepatotoxicity because of induction of 2E1 by alcohol (Raucy 
at el., 1989). Isoniazid has biphasic effect on 2E1 activity, a direct inhibitory 
effect immediately after its administration followed by an inducing effect 
because of CYP protein stabilization (Nelson et al., 1996). Knowledge of 
substrates, inhibitors and inducers of CYP isoenzymes assists in predicting 
clinically significant drug interactions. 
 
2.3 P- glycoprotein 
2.3.1 Structure, Tissue distribution and physiological function of the P-
glycoprotein 
P-gp is a type of ATPase, and an energy-dependent trans-membrane drug 
efflux pump which belongs to members of ABC drug transporters. P-gp, a 
1280 amino acid long (molecular weight 170 kDa) glycoprotein, is expressed 
as a single chain containing two homologous portions of equal length, each 
containing six transmembrane domains and two ATP binding regions 
separated by a flexible linker polypeptide region between the Walker A and B 
motifs (Varma et al, 2003; Ambudkar et al. 1999).   
 
Immunohistochemical analysis using monoclonal antibody provided evidence 
for localization of P-gp in a wide range of tissues, particularly in columnar 
epithelial cells of lower GI tract, capillary endothelial cells of brain and testis, 
canalicular surface of hepatocytes and apical surface of proximal tubule in 
kidney. Due to selective distribution at the port of drug entry and exit, P-gp 
has been speculated to play a major physiological role in absorption, 
distribution and excretion of xenobiotics. Overall P-gp function as a 
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biochemical barrier for entry of xenobiotics and as a vacuum cleaner to expel 
them from the brain, liver, etc. and ultimately from systemic circulation 
(Thiebut . et al, 1987). 
 
P-gp is mainly described in cancer research as being a resistance factor to 
chemotherapies, also called MDR for multidrug resistance. P-gp globally 
confers a chemoresistance to cells for numerous xenobiotics by actively 
pumping these molecules outside cells, and consequently decreasing their 
intracellular concentrations. This ability to extrude xenobiotics gives this 
protein some physiological properties of protection and detoxification. For 
example, knock out mice (mdr1a−/−) are described as being more sensitive to 
ivermectine and as developing a central  neurotoxicity, while wild-type animals 
are healthy (Balayssac et al., 2005; Schinkel et al., 1994). 
 
The anatomical localization of P-gp in various tumors (where it confers the 
MDR phenotype) and at the apical membrane of polarized cells in several 
normal human tissues with excretory (liver, kidney, adrenal gland) and barrier 
(intestine, blood brain barrier(BBB), placenta, blood testis and blood ovarian 
barriers functions  suggests for P-gp a physiological role in detoxification and  
protection of the body against toxic xenobiotics and metabolites by secreting 
these compounds into bile, urine, and the intestinal lumen and by preventing 
their accumulation in the brain, testis, and fetus (Fig. 2.2) (Beijnen et al., 
2007; Thiebut et al., 1987). 
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FIGURE 2.1: Schematic representations of the main sites of localization of P-
gp in the body 
 
2.3.2 Mechanism of drug efflux by P-gp 
Various models were proposed to explain the mechanism of xenobiotic 
extrusion by P-gp, however, the exact site of substrate interaction with the 
protein is not well resolved. The three prevalent models pore model, flippase 
model and hydrophobic vacuum cleaner (HVC) model, explains the efflux 
mechanism to certain extent (Fig. 2.1). Among these HVC model has gained 
wide acceptance in which P-gp recognizes substrates embedded in the inner 
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leaflet of plasma membrane and transported through a protein channel. 
Recently, reported that three-dimensional conformation of P-gp changes upon 
binding of nucleotide to the intracellular nucleotide-binding domain (Higgings 
and Gottesman , 2003; Varma et al., 2003) 
 
In the absence of nucleotide, the two transmembrane domains form a single 
barrel with a central pore that is open to the extracellular surface and spans 
much of the membrane depth, while upon binding nucleotides, the 
transmembrane domains reorganize into three compact domains that open 
the central pore along its length in a manner that could allow access of 
hydrophobic drugs directly from the lipid bilayer to the central pore of the 
transporter. ATP binding and hydrolysis was found to be essential for 
functioning of P-gp, where one molecule of drug is effluxed at the expense of 
two molecules of ATP. The catalytic cycle of P-gp, which expands the 
opportunity for the development of P-gp inhibitors, comprises of two cycles 
where drug and nucleotide binding sites coordinately function to efflux out the 
substrates by an ATP driven energy-dependent process.  
 
FIGURE 2.2: Models proposed to explain the mechanism of drug efflux by P-
gp (a) Pore model (b) Flippase model and (c) hydrophobic vacuum cleaner 
model 
 
In pore model, drugs associate with P-gp in the cytosolic compartment and 
are transported out of the cell through a protein channel. In Flippase model, 
drugs embed in the inner leaflet of the plasma membrane, bind to P-gp within 
                                                                                           Review of literature 
 
Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat, India.  22 
 
the plane of membrane and are translocated to the outer leaflet of the bilayer 
from which they passively diffuse into extracellular fluid. The hydrophobic 
vacuum cleaner model combines the features of ‘pore’ and ‘Flippase’ models. 
 
The drug and ATP initially binds to the protein at their own binding sites, 
where nucleotide hydrolyses to ADP yields energy for the extrusion of drug. 
The release of ADP from nucleotide binding site ends the first catalytic cycle 
followed by a conformational change that reduces affinity for both substrate 
and nucleotide. Further, the second catalytic cycle starts by hydrolysis of 
another molecule of ATP and released energy is utilized to reorient the protein 
to its native conformation. Subsequent release of ADP completes another 
catalytic cycle, bringing P-gp molecule back to the original state, where it 
again binds to both substrate and nucleotide to initiate the next cycle (Sauna 
et al., 2001; Varma et al., 2003) 
 
2.3.3 P-glycoprotein inhibitors 
P-gp is found on the different barriers that limit the passage of xenobiotics into 
the organism. P-gp is described as an important mechanism decreasing the 
bioavailability of oral drugs by limiting intestinal absorption. Moreover, P-gp 
can directly eluate drugs from the general circulation into the bile and 
intestinal lumen via hepatocytes and enterocytes, respectively. Thus it can be 
supposed that compounds able to interact with P-gp activity could induce 
modifications of the bioavailability for numerous concomitantly administered 
drugs. Compounds able to modulate or inhibit P-gp activity would increase 
xenobiotic levels and also P-gp substrates (Aungst, 1999; Suzuki and 
Sugiyama, 2000; Schinkel and Jonker, 2003). Based on the specificity and 
affinity, P-gp inhibitors are classified to three generations. (Hunter and Hirst, 
1997)  
 
i. First-generation inhibitors are pharmacological actives, which are in 
clinical use for other indications but have been shown to inhibit P-gp. 
These include calcium channel blockers i.e. verapamil, immune-
suppressants like cyclosporine-A, antiestrogens like tamoxifen, anti-
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hypertensives, quinidine, reserpine, yohimbine and toremifena. The 
usage of these compounds is limited by their toxicity due to the high 
serum concentrations achieved with the dose that is required to inhibit 
P-gp.  
ii. Second-generation madulator agents that lack in the pharmacological 
activity of the first-generation compounds and usually possess a higher 
P-gp affinity. However, inhibition of two or more ABC transporters leads 
to complicated drug–drug interactions by this class of compounds, 
which include non-immunosuppressive analogues of cyclosporine A, 
PSC 833; D-isomer of verapamil, dexverapamil; and others such as 
biricodar (VX-710), GF120918 and MS-209.  
iii. Third generation P-gp blockers are under development, however, 
primarily with the purpose to improve the treatment of multidrug 
resistant tumours and to inhibit P-gp with high specificity and toxicity. 
Modulators such as LY 335979, OC 144093 and XR 9576 are identified 
to be highly potent and selective inhibitors of P-gp with a potency of 
about 10 fold more than the first and second-generation inhibitors. 
 
P-gp can be inhibited by: 
(i) Blocking drug binding site either competitively, non-competitive or 
allosterically. 
(ii) Interfering ATP hydrolysis.  
(iii)  Altering integrity of cell membrane lipids.  
 
Although most of the drugs inhibit P-gp function by blocking drug binding 
sites, presence of multiple binding sites complicate understanding as well as 
hinder developing a true, conclusive Structure activity relationship for 
substrates or inhibitors. Compounds inhibiting ATP hydrolysis could serve as 
better inhibitors, since they are unlikely to be transported by P-gp, and these 
kind of agents will require at low dose which is well desirable to use locally at 
gut lumen. Quercitin, a naturally occurring flavanoid, has been proposed to 
block P-gp function by an unknown mechanism but in general by interfering 
ATPase activity (Shapiro and Ling, 1997; Drori et al., 1995). Following Tab. 
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2.1 shows the few therapeutic agent that are have its known P-glycoprotein 
inhibition activities (Linardi and Natalini, 2006) 
 
Table 2.1 : Therapeutic agent that are P-glycoprotein inhibitors  
 
Class of Drug Name of Drugs 
Antiarythmics 
Amiodarone, atorvastatin, simvastatin, quinidine, 
verapamil, amiodarone, carvedilol, nicardipine. 
Anticancer drugs  Actinomycine D, doxorubicin, vinblastine 
Antibiotics Erythromycin,  Itraconazole, ketoconazole 
Antidepressants 
Paroxetine, sertraline, desmethylsertraline, 
Fluoxetine, Saint John’s Wort 
Proton pump 
inhibitors 
Esomeprazole, lansoprazole, omeprazole, 
pantoprazole 
Opioids 
Methadone,  pentazocine, fentanyl, loperamide, 
asimadoline 
Immunosuppressants Cyclosporine A, tacrolimus, sirolimus. 
Steroids 
Dexametasone, aldosterone, progesterone, 
hydrocortisone, corticosterone. 
Miscellaneous 
Bromocriptine, chlorpromazine, tamoxifen, 
grapefruit juice, ivermectin, phenothiazines, 
colchicine, itraconazole. 
 
Commonly used pharmaceutical surfactants are emerging as a different class 
of P-gp inhibitors, which act by altering integrity of membrane lipids. The 
change in secondary and tertiary structure is found to be the reason for loss of 
P-gp function due to disturbance in hydrophobic environment by surfactants. 
Series of study was observed that the change in fluidity of cell membrane 
facilitates influx of P-gp substrates by surfactants like polyethylene glycol, 
cremophor EL and Tween 80, demonstrated in Caco-2 cell line. Surfactants 
seem to be better choice since they were already approved for routine use in 
pharmaceutical formulations. However, until now it has been tested at in vitro 
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level, which should be further evaluated by animal or human studies. (Hugger 
et al.,2002; Audus et al., 2002) 
 
2.3.4 Herbal modulation of P-gp 
P-gp is vulnerable to inhibition, activation, or induction by herbal constituents. 
This was demonstrated by using an ATPase assay, purified P-gp protein or 
intact P-gp expressing cells, and proper substrates and inhibitors. Curcumin, 
ginsenosides, piperine, some catechins from green tea, and silymarin from 
milk thistle were found to be inhibitors of P-gp, while some catechins from 
green tea increased P-gp mediated drug transport by heterotropic allosteric 
mechanism, and St. John’s wort induced the intestinal expression of P-gp in 
vitro and in vivo. Some components (e.g., bergamottin and quercetin) from 
GFJ were reported to modulate P-gp activity. Many of these herbal 
constituents, in particular flavonoids, were reported to modulate P-gp by 
directly interacting with the vicinal ATP-binding site, the steroid-binding site, or 
the substrate-binding site. Some herbal constituents (e.g., hyperforin and 
kava) were shown to activate pregnane X receptor, an orphan nuclear 
receptor acting as a key regulator of MDR1 and many other genes (Zhou et 
al., 2004). The modulation of P-gp activity and expression by these herb 
constituents may result in altered absorption and bioavailability of drugs that 
are P-gp substrates. This is exemplified by increased oral bioavailability of 
phenytoin and rifampin by piperine and decreased bioavailability of indinavir, 
tacrolimus, cyclosporine, digoxin, and fexofenadine by coadministered St. 
John’s wort. However, many of these drugs are also substrates of CYP 3A4. 
Thus, the modulation of intestinal P-gp and CYP 3A4 represents an important 
mechanism for many clinically important herb drug interactions. 
 
Twenty-nine phenolic compounds, isolated from four Clusiaceae species 
(Garcinia and Calophyllum) and classified into four chemical classes 
(coumarins, chroman acids, xanthones and benzophenones), were tested on 
a human erythroleukemic cell line (K562/R7) overexpressing the P-gp in order 
to evaluate their activity as inhibitors of this protein. Among the twenty-nine 
natural products tested, only six of them exhibited moderate modulation of the 
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P-gp-mediated daunorubicin efflux. The class of coumarin presented the 
greatest number of active derivatives in this test (Raad et al., 2007). 
 
The extent of herb-drug interactions (H-DIs) is still largely unknown, although 
the use of herbal medicines among the general public is increasing. The 
theoretical and clinical evidence for some important H-DIs is presented, 
together with an explanation of pharmacodynamic interactions and 
pharmacokinetic effects involving P-gp and CYP 450 enzymes. Currently, 
research is being undertaken to identify potential interaction problems by 
means of in vitro and in vivo experimental methods; these, together with the 
most important H-DI’s are summarized. The most commonly reported herb in 
H-DIs is St John’s wort. It has proven enzyme-inducing properties and should 
be avoided in patients taking oral contraceptives, anticoagulants, immune 
suppressants, anti-neoplastics, protease inhibitors, digoxin, fexofenadine, 
statins, omeprazole, verapamil and other antidepressants (Williamson, 2006). 
 
The effects of citrus flavonoids on P-gp mediated drug efflux was examined in 
human intestinal Caco-2 cells. The cellular accumulation of rhodamine-123 
was measured using 10 citrus flavonoids for preliminary screening. Among 
the flavonoids tested, diosmin significantly increased the accumulation of 
rhodamine-123 in Caco-2 cells. In the bidirectional transport of digoxin, 
diosmin increased the apical-to-basal (A-to-B) transport but decreased the 
basal-to-apical (B-to-A) transport in both concentration- and time-dependent 
manners. The digoxin transport ratio (B-A/A-B) was estimated to be 2.3 at a 
concentration of 50 µM of diosmin, which was significantly lower than the 15.2 
found in the control. The apparent Ki values for P (app,A-B) and P (app,B-A) 
were 16.1 and 5.7 µM, respectively. These results demonstrated that diosmin 
effectively inhibited the P-gp mediated efflux in Caco-2 cells. Diosmin is one 
of the main components in citrus fruits, and the intake of food supplements 
containing this compound may potentially increase the absorption of drugs 
able to act as P-gp substrates (Yoo et al., 2007). 
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The chemical structure and physical chemical properties (with SAR analysis) 
of the limonoids and a number of known P-gp substrates are also provided. 
The limonoids selected lie within the 3D (MW, Clogp, Hb) parameter-frame-
setting of known P-gp substrates so could potentially be substrates 
themselves. Based on phytochemical and structure activity relationship (SAR) 
analyses of available literature data, it is suggested that limonoids found in 
citrus fruits and other Chinese herbs, when consumed in moderate amount 
are beneficial to health and may have preventive effect on carcinogenesis. 
However, due to potential interactions of limonoids with a wide range of drugs 
via P-gp and other drug metabolizing enzyme systems, it is advisable not to 
take citrus juices with therapeutic drugs simultaneously (Lien et al., 2002). 
 
2.4 HAPs: Silymarin, naringin and morin 
The effect of flavonoids on P-gp mediated cellular efflux and to determine the 
molecular mechanism of the flavonoid-drug interaction. Studies were 
conducted in the sensitive and multidrug resistant human breast cancer cell 
lines MCF-7 and MDA435/LCC6 and examined the effects of the flavonoids 
biochanin A, morin, phloretin, and silymarin on daunomycin (DNM) 
accumulation and doxorubicin cytotoxicity. The potential mechanism involved 
in the interaction was evaluated by determining flavonoid effects on 1) P-gp 
ATPase activity, 2) [3H]azidopine photoaffinity labeling of P-gp, and 3) cellular 
P-gp levels. Biochanin A and silymarin potentiated doxorubicin cytotoxicity in 
P-gp positive cells. Biochanin A and phloretin stimulated, whereas morin and 
silymarin inhibited P-gp ATPase activity, confirming that these flavonoids 
interact with P-gp. In conclusion, biochanin A, morin, phloretin and silymarin 
all inhibited P-gp mediated cellular efflux and the mechanism of the interaction 
involved, at least in part, a direct interaction. The findings of this study indicate 
a potential for significant flavonoids drug interactions with the P-gp substrates 
(Zhang and Morris, 2003). 
 
The flavonoids are present in fruits, vegetables and beverages derived from 
plants (tea, red wine), and in many dietary supplements or herbal remedies 
including Ginkgo biloba, soy Isoflavones, and milk thistle. This review will 
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summarize the current literature regarding the interactions of flavonoids with 
ABC efflux transporters, mainly P-gp, MRP1, MRP2 and BCRP and discuss 
the potential consequences for flavonoid and the drug transport interactions 
(Zhang and Morris, 2003). 
 
GFJ was an inhibitor of the intestinal CYP 450 3A4 system, which is 
responsible for the first-pass metabolism of many medications. Through the 
inhibition of this enzyme system, GFJ interacts with a variety of medications, 
leading to elevation of their serum concentrations. Most notable are its effects 
on cyclosporine, some 1,4-dihydropyridine calcium antagonists, and some 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CO-Enz-A) reductase inhibitors. 
In the case of some drugs, these increased drug concentrations have been 
associated with an increased frequency of dose-dependent adverse effects. 
The P-gp pump, located in the brush border of the intestinal wall, also 
transports many cytochrome P-450 3A4 substrates, and this transporter also 
may be affected by grapefruit juice. In vitro data show that grapefruit juice 
activates P-gp in intestinal cell monolayers (Garvan and James, 2000). 
 
The effect of silymarin on the pharmacokinetics of osuvastatin in systems 
overexpressing OATP1B1 or BCRP transporters and in healthy subjects.  The 
concentration-dependent transport of rosuvastatin and the inhibitory effect of 
silymarin were examined in vitro in OATP1B1-xpressing oocytes and MDCKII-
BCRP cells. Based on the concentration dependency of rosuvastatin transport 
in the OATP1B1 and BCRP overexpression systems, rosuvastatin is a 
substrate for both transporters. Silymarin inhibited both OATP1B1- and 
BCRP-mediated rosuvastatin transport in vitro (Ki 0.93 μmol and 97 μmol 
respectively). However, no significant changes in AUC, half-life, Vd/F, or Cl/F 
of rosuvastatin were observed in human subjects following pretreatment with 
silymarin. Silymarin does not appear to affect rosuvastatin pharmacokinetics 
in vivo, suggesting that silymarin, administered according to a recommended 
supplementation regimen, is not a potent modulator of OATP1B1 or BCRP in 
vivo (Deng et al., 2008). 
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The effect of naringin on the bioavailability and pharmacokinetics of paclitaxel 
after oral administration of paclitaxel or its prodrug coadministered with 
naringin to rats. Paclitaxel (40 mg/kg) and prodrug (280, 40 mg/kg paclitaxel 
equivalent) were coadministered orally to rats with naringin (1, 3, 10 and 
20 mg/kg). The bioavailability of paclitaxel coadministered as a prodrug with 
or without naringin was remarkably higher than the control. Paclitaxel prodrug, 
a water-soluble compound concerning with its physicochemical properties, 
passes through the GI mucosa more easily than paclitaxel without obstruction 
of P-gp and CYP 450 in the GI mucosa. Oral paclitaxel preparations which is 
more convenient than the i.v. dosage forms could be developed with a 
prodrug form with naringin (Choi and Shin, 2005). 
 
Some well-know flavonoids from vegetables and fruits were tested for their 
potential ability to modulate the function of P-gp in the multidrug resistant 
(MDR) human cervical carcinoma cell line, KB-V1. The data demonstrated 
that kaempferol and daidzein stimulated vinblastine sensitivity of KB-V1 cells 
(P<0.05) and revealed that the inhibitory concentration at 50 % growth (IC50) 
of vinblastine was decreased markedly in the presence of these flavonoids in 
a dose dependent manner. Kaempferol also increased the intracellular 
accumulation, and reduced the efflux of rhodamine 123 (Rh123), which is 
known to be a good substrate of P-gp in KB-V1 cells. These findings provide 
evidence that the flavonoid, i.e. kaempferol, could reverse the vinblastine 
resistant phenotype by inhibiting P-gp activity in KB-V1 cells, and the ability to 
affect the P-gp activity could be of relevance to the chemosensitization of this 
flavonoid towards anticancer drugs (Khantamat et al., 2004).  
 
The metabolic breakdown of albendazole by mucosal CYP 3A4 enzymes was 
studied by coadministering albendazole (10 mg/kg) with GFJ. Concentrations 
of albendazole sulfoxide (ABZSX), the active metabolite of albendazole, were 
compared with those after albendazole was administered with water, a fatty 
meal or GFJ plus cimetidine (10 mg/kg). In comparison to water, maximum 
ABZSX concentration (Cmax) was enhanced 6.5 fold by a fatty meal (from 0.24 
± 0.09 mg/l to 1.55 ± 0.30 mg/l; mean ± SD; P < 0.001) and 3.2 fold by the 
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GFJ (from 0.24 ± 0.09 mg/l to 0.76 ± 0.37 mg/l; P<0.031). When GFJ was 
combined with cimetidine, Cmax was significantly lower than with GFJ alone 
(0.41 ± 0.29 mg/l and 0.76 ± 0.37 mg/l respectively; P<0.022). The area under 
the concentration-time curve from 0 to infinity followed a comparable pattern. 
Half-life (T1/2) was 8.8 ± 4.2 hr and 8.2 ± 4.3 hr after administration with water 
or a fatty meal (P<0.001). GFJ shortened T1/2 by 46 % (P<0.026). We 
hypothesize that albendazole is metabolized by CYP 3A4 enzymes in the 
intestinal mucosa. This process can be inhibited by the GFJ. The cimetidine 
decreased albendazole bioavailability (Nagy et al., 2002). 
 
2.5 Herbal Absorption Promoters (HAPs) 
HAPs are isolated components or extracts of plants and employed to promote 
absorption of several drugs and nutrients. The concentrations employed for 
the absorption promotion obtained by HAPs are very low as compared to their 
concentrations which can cause toxicity. This concept of enhancement of drug 
bioavailability is not new but is based on clues from Ayurveda wherein it has 
been found that certain herbals, either individually or as a group, are 
repeatedly found along with the active medicament in large number of 
prescriptions recommended for a variety of diseases.  The addition of the 
chosen herb or part of it helped in the availability and absorption of the drugs.  
 
In the last few years, the scientists have tried to explore the scientific basis of 
the use of the herbs prescribed by Ayurvedic physicians. Their efforts have 
resulted in better understanding of mechanism of action of HAPs, isolation 
and characterization of individual components and generating toxicity data. 
Improved understanding about HAP has made it evident that these herbs 
were not included in the herbal formulations just for sake of rhyme but had 
definite role to play in promoting absorption and enhancing bioavailability 
(Badmaev et al., 2000; Odou et al., 2005; Nabekura et al., 2005). The 
following example highlights the modulating effects of herbal constituents on 
P-gp arising from in vitro and in vivo studies and the potential role in herb-
drug interactions. 
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2.5.1 Alkaloid 
Alkaloids are a major class of compounds present in plants. They are used for 
a variety of disorders. Few alkaloids known to possess absorption promoting 
activity are described below: 
 
2.5.1.1 Piperine 
Piperine (1-Piperylpiperidine), a pungent alkaloid, is the major constituent 
present in black (Piper nigrum Linn) and long pepper (Piper longum Linn) 
which was used in spices and herbal medicines. Piperine was reported to 
have antidiarrheal, anti-inflammatory, hepatoprotective, chemopreventive, 
immunomodulating, anticonvulsant, and antioxidant activities. A clinical study 
in healthy volunteers showed that coadministration of piperine (5 mg/day) for 
21 days increased the AUC of coenzyme Q10 (120 mg) by approximately 30 
% (Badmaev et al., 2000). Thus, piperine may be used as a bioavailability 
enhancer of drugs in humans. Animal studies indicated that piperine 
enhances drug absorption and bioavailability by inhibiting certain metabolizing 
enzymes, by modulating P-gp efflux by producing a local thermogenic action 
and by modulating membrane dynamics and forming apolar complex with 
drugs and solutes (Bhardwaj et al., 2002; Badmaev et al., 2000; Khajuria et 
al., 1998) as shown in (Tab. 2.2) 
 
 
 
 
 
 
   
 
 
 
 
 
Piperine  
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 Table 2.2: Drugs showing enhanced absorption/bioavailability on co-               
  administration of Piperine 
 
2.5.1.2 Capsaicin 
Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) is a pungent component 
present in chilli peppers and related plants of capsicum species. This alkaloid 
is reported to cause significant increase in bioavailability of theophyline in 
rabbits (Bouraoui et al., 1988). Capsaicin has been proposed to inactivate 
CYP 450 2E1 by irreversibly 
 
binding to the active sites of the enzyme. The 
enhanced accumulation was attributed to inhibition of P-gp (Surh et al., 1995).  
 
 
 
 
 
 
Absorption promotion 
Mechanism 
Drugs Reference 
Inhibition of CYP 450 
isoenzymes and other 
drug metabolizing 
enzymes 
Propranolol and 
Theophylline 
Curcumin 
Verapamil 
Vasicine and Sparteine 
Amoxicillin trihydrate  
Cefotaxime sodium 
Nimesulide 
Pentobarbitone  
Aflatoxin B
Bano et al., 1991 
 
Shoba et al., 1998 
Bhardwaj et al., 2002 
Atal et al., 1981 
Hiwale et al., 2002 
 
Gupta et al.,  2000 
Mujumdar et al., 1990 
Allameh et al., 1992 1 
Inhibition of P-gp 
mediated drug efflux 
Phenytoin  
 
Rifampicin  
Digoxin and Cyclosporine 
Velpandian et al., 2001; 
Bano et al., 1987  
Zutshi et al., 1985 
Bhardwaj et al., 2002 
Capsaicin 
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2.5.1.3 Furanocoumarins: 
6’, 7’-dihydroxybergamottin and Bergamottin: 
6’, 7’-dihydroxybergamottin (DHB) and its more lipophilic analog, bergamottin 
are the furanocoumarins present in GFJ and seville orange juice (Malhotra et 
al., 2001; Gray, 1983). DHB is a potent inhibitor of CYP450 3A4 enzymes 
(Bailey et al., 1998; Schmiedlin-ren et al., 1997; Lown et al., 1997). Lipophilic 
furanocoumarins also inhibits P-gp mediated drug transport and hence can 
increase the absorption and bioavailability of P-gp substrates (Table 2.3). 
 
 
 
 
 
 
 
  
 
Table 2.3: Drugs showing increased absorption/bioavailability on  
               consumption of GFJ 
Absorption promotion 
mechanism 
Drugs Reference 
Inhibition of P-gp 
mediated drug efflux 
Diltiazem 
Talinolol 
 
Vinblastine 
Rhodamine-123, 
Fexofenadine and 
Saquinavir 
Digoxin 
Felodipine 
Saquinavir  
Christensen et al., 2002 
Spahn-Langguth at el., 
2001 
Takanaga et al., 1998 
Tian et al., 2002 
 
 
Xu et al., 2003 
Lown et al., 1997 
Honda et al., 2004 
 
 
6’, 7’-Dihydroxybergamottin Bergamottin Bergamottin 
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2.5.1.4 Bergapten 
Bergapten (5-Methoxypsoralen), a furanocoumarin present in Seville orange 
juice in addition to 6',7'- dihydroxybergamottin and bergamottin were also 
found to be a mechanism-based inhibitor of CYP 450 3A4. Relative to the 
control, bergapten (10 µmol/l) inhibited significantly the CYP 450 3A4 activity 
in cultured intestinal epithelial cells by 34 %. The bioavailability of felodipine 
was increased by 76 % after Seville orange juice ingestion compared to 
common orange juice (Malhotra et al, 2001).  
 
 
 
 
 
 
 
 
2.5.2 Flavonoids 
Flavonoids, classified into four subgroups namely flavone, flavonol, flavonone 
and isoflavonone, are low molecular weight polyphenolic compounds that 
usually exist in plants as secondary metabolites. Flavonoids modulate P-gp by 
directly interacting with the vicinal ATP-binding site, the steroid binding site or 
the substrate-binding site. They are also able to inhibit CYP 450 metabolizing 
the enzymes (Conseil et al., 1998; Hodek et al., 2002; Doostdar et al., 2000).  
 
2.5.2.1 Naringin 
Naringin (7-(2-O-(6-deoxy- α - L- mannopyranosyl)- β- D-glucopyranosyloxy) -
2, 3-dihydro-4', 5, 7-trihydroxyflavone) is the most prevalent flavonoid in GFJ. 
Naringin has been reported to possess the ability to inhibit the P-gp efflux 
pump (Conseil et al, 1998; Takanaga et al., 1998; Bailey et al., 1993). It also 
has been reported to inhibit selectively intestinal CYP450 3A, which is the 
main subfamily of the CYP450 (Hodek et al., 2002; Doostdar et al., 2000) It 
was reported that naringin increased the bioavailability of paclitaxel (a P-gp 
substrate) and its prodrug after oral administration (Choi and Shin, 2005). 
Bergapten 
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2.5.2.2 Quercitin 
Quercitin (2-(3, 4-dihydroxyphenyl)-3, 5, 7-trihydroxy-chromen-4-one), a water 
soluble plant pigment. Quercitin is also found in Ginkgo biloba, Hypericum 
perforatum (St. John’s Wort), Sambucus canadensis (Elder), and many 
others. Quercitin acts as a natural modulator of P-gp efflux pump (Conseil et 
al., 1998, Chieli et al. 1995). 
                                    
            
                                       
Co-administration of paclitaxel or its prodrug with quercitin in rats led to a 
significant improvement in bioavailability as compared to control (Choi et al., 
2004). Quercitin inhibite P-gp mediated Hoechst 33342 efflux and enhanced 
its accumulation in multidrug resistant CHRC5 cells (Shapiro and Ling, 1997). 
 
2.5.2.3 Catechins 
Green tea (Camellia sinensis) a common beverage worldwide, contains many 
polyphenolic compounds. A typical brewed green tea beverage contains 30 to 
42 % catechins by dry weight (Balentine et al., 1997).  Six catechins present 
in green tea, the most abundant being (-)-epigallocatechin gallate (EGCG) 
 Quercitin 
Naringin 
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followed by (-)-epicatechin gallate, (-)-epigallocatechin, (-)-epicatechin, (-)-
catechin gallate and (+)-catechin (Chu and Juneja, 1997).  
                                       
                                                 
 
Catechins were shown to inhibit P-gp activity in vitro using several marker 
substrates. Among the catechins present in green tea, EGCG was the most 
potent inhibitor of P-gp (Jodoin et al., 2002).  
  
2.5.2.4 Milk Thistle (Silymarin) 
Milk thistle (Silybum marianum) is one of the most commonly used herbal 
medicines. It contains mainly contains Silymarin, a mixture of various 
flavonolignans (Barreto et al, 2003; Wallace et al, 2003). Silymarin is 
composed of mainly silybinin (50-80 %), with small amounts of other 
flavonolignans such as silychristin and silydianin (Kvasnicka et al, 2003). 
silymarin increased daunomycin accumulation in P-gp positive cells, but not 
P-gp negative cells, in a flavonoid concentration and P-gp expression level-
dependent manner. Silymarin potentiated doxorubicin cytotoxicity in P-gp 
positive cells, while it cab be inhibited the P-gp ATPase activity and azidopine 
photoaffinity labeling of P-gp, suggesting a direct interaction with the P-gp 
substrate binding (Zhang and Morris, 2003). These findings indicated that 
silymarin and its metabolites inhibited P-gp mediated cellular efflux, raising a 
potential for significant drug interactions with P-gp substrates. 
 
 Silybinin 
 
 
 Epigallocatechin gallate 
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2.5.2.5 Resveratrol 
Resveratrol (trans-3, 5, 4'-trihydroxystilbene) is a polyphenol obtained in 
abundance from Vitis vinifera, labrusca, and muscadine grapes and in small 
quantities from eucalyptus, spruce, and lily. It has been shown to cause 
mechanism-based inactivation of CYP 450 3A4 and may cause clinically 
relevant drug interactions with CYP 450 3A4 substrates (Chan and Delucchi, 
2000). 
                                           
                                             
 
 
 
2.5.3 Glycosides 
2.5.3.1 Ginsenosides 
Ginseng (Panax ginseng) major constituents include ginsenosides 
(panoxosides), sterols, flavonoids, peptides, vitamins, polyacetylenes, 
minerals, β-elemine, and choline (Deyama et al., 2001; Han et al., 2001). 
Ginsenosides are considered the major pharmacologically active constituents, 
and approximately 12 types of ginsenosides were isolated and structurally 
identified. Ginsenoside Rg3 promoted accumulation of Rho-123, inhibited 
vinblastine efflux, and reversed the resistance to doxorubicin and vincristine in 
multidrug resistant KBV20C cells in a dose-dependent manner (Kim et al., 
2003). 
 
 
 
 
 
 
 
 
  Ginsenoside Rg3 
 
 Resveratrol 
 
 
                                                                                           Review of literature 
 
Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat, India.  38 
 
2.5.3.2 Glycyrrhizin 
Glycyrrhizin a chief constituent (6-10 %) of Liquorice (Glycyrrhiza glabra), is a 
triterpenoid saponin glycoside and is a potassium and calcium salt of 
glycyrrhizinic acid. Glycyrrhizinate dipotassium has been reported to enhance 
the in vivo transmucosal absorption of antibiotics and insulin (Tanaka et al., 
1992; Mishima et al., 1989).  
 
 
 
 
 
 
 
 
2.5.4 Fatty acids 
Drug absorption has been increased by a wide variety of long chain fatty acids 
(Williams and Barry, 2004). The mechanisms by which fatty acids increase 
intestinal absorption have been shown to involve both paracellular and 
transcellular routes (Aungst et al, 1996). These lipoidal absorption promoters 
may enter the lipid bilayer structure in intestinal brush border membrane and 
disrupt the configuration of the lipid region (Wang et al., 1994; Muranishi, 
1990). 
 
The effects of various fatty acids on cefoxitin absorption from rat intestinal 
loops in situ, using emulsion vehicles containing 10 % fatty acid. The rank 
order of absorption enhancement was lauric acid > palmitic acid > caprylic 
acid > oleic acid (Palin et al., 1986). Oleic acid, linoleic acid and linolenic acid 
as absorption promoters into the oily phase of insulin W/O/W multiple 
emulsion. Strong hypoglycemic effects were observed with the emulsions 
containing these absorption promoters with more pronounced effects in the 
colon than in the ileum (Morishita et al., 1998).  
        
 
 Glycyrrhizin 
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2.5.5 Oils 
2.5.5.1 Peppermint oil 
Peppermint oil significantly enhanced oral bioavailability of cyclosporine in 
rats (Wacher et al., 2002). Peppermint oil is an effective inhibitor of 
cyclosporine metabolism in vitro. Inhibition of cyclosporine metabolism in the 
small intestine and possibly on first-pass through the liver are potential means 
by which peppermint oil may improve cyclosporine bioavailability in vivo. 
Similar finding in the case of felodipine and peppermint oil co-administration 
(Dresser et al., 2002). 
 
2.5.5.2 Sunflower oil  
Significant improvement in bioavailability of moxidectin in rabbits when co-
administered with sunflower oil. The enhanced moxidectin bioavailability was 
attributed to greater extent of intestinal lymphatic transport in presence of 
sunflower oil (Bassissi et al., 2004).  
 
2.5.6 Miscellaneous 
2.5.6.1 Rosemary extract  
Rosemary extract has been reported to cause a substantial increment in the 
intracellular accumulation of doxorubicin and vinblastine and inhibit the efflux 
of these P-gp substrates in drug resistant MCF-7 human breast cancer cells. 
Rosemary extract directly binds to P-gp binding site and exerts its action via 
competitive inhibition of substrate binding (Plouzek et al., 1999). 
 
2.5.6.2 Chinese herbal enhancers 
Chinese herbal enhancers (CHEs) are used in over 30-75 % Chinese 
medicines since thousands of years. Toxicities of CHEs are expected to be 
much mild than synthetic agents (Hu, 2004). The Cmax and AUC of 
simvastatin increased 39 and 23 times, respectively, after oral administration 
simvastatin with HUCHE 015 enhancer in rats. Co-administration of HUCHE 
011 with paclitaxel has been reported to cause a significant increase in 
intracellular accumulation of Rho-123 in vitro in HCT-15 cell lines and 
bioavailability of paclitaxel in rats. These effects of HUCHE 011 due to the 
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inhibition of P-gp. CHEs may act as enzyme inhibitors and efflux inhibitors, in 
the case of CYP 450 and P-gp substrates, carriers for drug thereby facilitating 
their transport and catalyst (Hu, 2004). 
 
2.5.6.3 Curcumin 
 Curcumin (5-hydroxy-1, 7-bis (4-hydroxy-3-methoxy-phenyl)-hepta-1, 4, 6-
trien-3-one) is a natural polyphenol found in rhizomes of Curcuma longa 
(turmeric). In primary cultures of rat hepatocytes as well as in human cervical 
carcinoma cell line KB-V1 expressing high levels of P-gp, curcumin increased 
Rho-123 accumulation and inhibited its efflux in a dose-dependent manner 
(Zhou et al., 2004). 
                      
O
OH
O O
O
OH  
                                                              
 
curcumin inhibited verapamil stimulated ATPase activity and the photoaffinity 
labeling of P-gp with the prazosin analog iodoarylazidoprazosin in a 
concentration-dependent manner, indicating direct interaction of curcumin 
with P-gp and possible binding to the same site as other agents such as 
prazosin and verapamil (Anuchapreeda et al., 2002). 
 
2.5.6.4 Ginger 
 Dried rhizomes of Zingiber officinale are reported to increase the 
bioavailability of certain drugs by promoting rapid absorption from the GI tract 
or by protecting the drug from being metabolized or oxidized in first passage 
through the liver after absorption. Absorption of sulfaguanidine increased in 
male rats on co-administration of ginger (Sakai et al., 1986). Accumulation of 
daunorubicin and Rho-123 increased in KB-C2 cells on co-administration of 6-
gingerol due to P-gp inhibition (Nabekura et al., 2005).  
 
 
Curcumin 
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2.5.6.5 St. John’s Wort 
St. John’s wort (Hypericum perforatum) is one of the most common herbal 
medicines used in the therapy of depression. Several studies indicate that St. 
Johns wort induces the intestinal P-gp in vitro and in vivo (Durr et al., 2000; 
Hennessy et al., 2002; Perloff et al., 2001). Treatment of LS-180 intestinal 
carcinoma cells with St. John’s wort or hypericin at 3–300 mmol caused a 
four- to sevenfold increase in the expression of P-gp (Perloff et al., 2001). 
Cells chronically treated with St. John’s wort had decreased accumulation of 
rhodamine 123. Oral administration of St. John’s wort for 14 days in healthy 
volunteers resulted in 1.4 fold increase in P-gp expression (Durr et al., 2000). 
The probe substrates of P-gp, fexofenadine and cyclosporin were found to 
have increased clearance in healthy subjects treated with St. John’s Wort 
(Dresser et al., 2003)                                 
 
2.6 Cytotoxicity study by using cell lines 
The SRB assay is used for cell density determination, based measurement of 
cellular protein content. The method described here has been optimized for 
the toxicity screening of compounds to adherent cells in a 96-well format. 
After an incubation period, cell monolayersﬁxed with 10 % (w/v) trichloroacetic 
(TCA) acid and stained for 30 min, after which the excess dye is removed by 
washing repeatedly with 1 % (v/v) acetic acid. Then the protein bound dye is  
dissolved in 10 mmol Tris base solution for OD determination at 510 nm using 
a microplate reader. The results are linear over 20 fold range of cell numbers 
and sensitivity is comparable to those of ﬂuorometric methods. The method 
not only allows a large number of samples to be tested within a few days, but 
also requires only simple equipment and inexpensive reagents. The SRB 
assay is therefore an efficient and highly cost-effective method for screening. 
 
2.6.1 SRB assay  
SRB assay, which was developed in 1990, remains one of the most widely 
used methods for in vitro cytotoxicity screening (Skehan, P. et al., 1990). The 
assay relies on the ability of SRB to bind to protein components of cells that 
have been ﬁxed to tissue  culture plates by the TCA. SRB is a bright pink dye 
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of aminoxanthene with two sulfonic groups that bind to basic amino-acid 
residues under mild acidic conditions, and dissociate under basic conditions 
(Lillie et al., 1977). As the binding of SRB is stoichiometric, the amount of dye 
extracted from stained cells is directly proportional to the cell mass. The 
strong intensity of SRB staining allows the assay to be carried out in a 96-well 
format. The assay can detect densities as low as 1,000–2,000 cells per well, 
and with a signal-to-noise ratio of 4.83 at a density of 5,000 cells per well. 
This level of sensitivity is comparable to those of ﬂuorescent dye-staining 
methods and is superior to those of other protein staining methods using 
conventional dyes (Skehan, et al., 1990; McCaffrey et al., 1988). Results from 
the SRB assay exhibit a linear dynamic range over densities of 7,500–
180,000 cells per well, corresponding to B1-200 % conﬂuence. Furthermore, 
the SRB method has proven to be practical, because after the TCA-ﬁxed and 
SRB-stained cell monolayers are dried they can be stored indeﬁn itely. Color 
extracted from SRB stained cells is also stable. With its high level of 
sensitivity, adaptability to the 96 well format and endpoint stability, the SRB 
assay is well suited to large-scale screening applications as well as research.  
 
This assay has been widely used for drug-toxicity testing against different 
types of the cancerous and non cancerous cell lines (Monks et al., 1991). 
Other cell-growth assays have been employed to assess drug efficacy against 
both intracellular pathogens and host cells simultaneously in co-cultures 
(McLaren et al., 1983; Kleymann et al., 2004) and it is possible to use SRB 
method for this purpose. An antiviral assay using SRB has been developed at 
our facility for the screening of natural compounds against herpes simplex 
virus type 1 (HSV-1), (Pittayakhajonwut et al., 2005). In addition, the SRB 
method has also been shown to be effective for in vitro testing of cancer cell 
sensitivity to radiation and for the study of interactions between radiotherapy 
and chemotherapy with sensitivity comparable to the standard of clonogenic 
assay (Griffon et al., 1995; Pauwels et al., 2003). The effectiveness of the 
SRB assay is frequently compared to that of another method using the 
tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT). The MTT assay requires cellular metabolic activity to convert the 
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colorless tetrazolium to the purple-colored formazan dye (Plumb et al., 1989) 
therefore it detects only viable cells, whereas the SRB method does not 
distinguish between viable and dead cells. This difference, however, does not 
compromise the ability of the SRB assay to detect cytotoxic effects of a drug.  
 
Studies undertaken by several groups showed that results from the SRB 
assay correlated well with those of the MTT assay, although the inhibitory 
concentration (IC) values of compounds tested using the SRB method were 
slightly higher 50 (Rubinstein et al., 1990; Haselsberger et al., 1996; Perez et 
al., 1993). However, the SRB assay has several advantages over the MTT 
assay. For example, some compounds can directly interfere with MTT 
reduction without having any effects on cell viability (Plumb et al., 1989), while 
SRB staining is rarely affected by this type of interference. Furthermore, SRB 
staining is independent of cell metabolic activity; therefore, fewer steps are 
required to optimize assay conditions for speciﬁc cell lines than in the MTT 
assay (Keepers et al., 1991). The application of the SRB assay is limited to 
manual or semiautomatic screening due to the multiple washing and drying 
steps, which, at present, are not amenable to automation. This method 
nevertheless provides an efficient and sensitive tool for screening, especially 
for use in less well-equipped laboratories. The protocol presented here has 
been slightly modiﬁed from the original SRB assay des cribed by Skehan et 
al., because we found that the concentrations of TCA and SRB required for 
the ﬁxation and staining of several cell lines could be decreased, therefore 
reducing the health risks to technicians and the burden of toxic waste of the 
disposal.  
 
The method is suitable for ordinary laboratory purposes and for very large-
scale applications, such as the National Cancer Institute's disease-oriented in 
vitro anticancer-drug discovery screen, which requires the use of several 
million culture wells per year. Cultures fixed with TCA were stained for 30 min 
with 0.4 % (w/v) sulforhodamine B (SRB) dissolved in 1 % acetic acid. Then 
unbound dye was removed by four washes with 1% acetic acid, and protein-
bound dye was extracted with the 10 mmol in to the buffered Tris base [tris 
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(hydroxymethyl) aminomethane] for determination of the optical density in a 
computer-interfaced, 96-well microtiter plate reader. The SRB assay results 
were linear with the number of cells and with values for the cellular protein 
measured by both Lowry and Bradford assays at the densities ranging from 
sparse sub-confluence to multilayered supra-confluence. The signal to noise 
ratio at 564 nm was approximately 1.5 with 1,000 cells per well. The 
sensitivity of the SRB assay compared favorably with sensitivities of several 
fluorescence assays and was superior to those of both the Lowry and 
Bradford assays and to the those of 20 other visible dyes. The SRB assay 
provides a colorimetric end point that is nondestructive, indefinitely stable, and 
visible to the naked eye. It provides a sensitive measure of the drug induced 
cytotoxicity is useful in quantitating clonogenicity, and is well suited to high-
volume, automated drug screening. SRB fluoresces strongly with the laser 
excitation at 488 nm and it can be measured quantitatively from the single cell 
level by static fluorescence cytometry (Anne et al., 1991). 
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3.  OBJECTIVES 
Oral route is most preferred for drug delivery due to high patient compliance, 
noninvasive administration and low cost. Drugs of classes II-IV (with low 
solubility, low permeability or both) pose challenges to the pharmaceutical 
development scientists in developing drug products with acceptable oral 
bioavailability. Low oral bioavailability of the drugs also results in erratic 
pharmacokinetics and sometimes needs careful management of therapy. One 
such approach is the concomitant use of absorption promoters. Recent in vitro 
studies have demonstrated that the synthetic absorption promoters such as 
sodium lauryl sulfate, palmitoyl carnitine, sodium caprate etc., when used at 
effective concentrations produced any cytotoxicity or the membrane damage. 
Limitations of synthetic absorption promoters suddenly increased interest in 
herbal absorption promoters. HAPs provide promising alternative to synthetic 
counterparts in terms of safety and many times in the efficacy of intestinal 
wall. Majority (approximately 90 %) of the absorption in the GI tract occurs in 
the small intestine. 
  
Several of the HAPs have been shown in to possess enormous potential to 
improve the oral bioavailability of poorly absorbed drugs without causing local 
or systemic toxicities. Several in vitro and in vivo studies and few clinical 
studies with HAPs have exhibited a very high benefit to risk ratio. These 
findings have renewed interest of the pharmaceutical scientists in exploring 
established and newer herbal origin compounds for possible application in 
enhancement of bioavailability of otherwise poorly absorbed drugs. Improved 
oral bioavailability due to the concomitant administration of HAPs reduce the 
therapeutic dose of the drug thereby minimizing side effects and cutting down 
on the cost of therapy. This can be panacea in addressing the problems of 
absorption/bioavailability of drugs presently posed in effective drug delivery. 
Efforts should be made to add to the list of HAPs acting through various 
mechanisms in promoting absorption not only through oral route but also 
through other routes of drug administration. However, role of these absorption 
promoters can only be settled after acute and chronic toxicological studies 
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followed by clinical evaluation of the pharmaceutical products containing 
HAPs on case to case basis.  
 
In this study we have investigated the three HAPs i.e. silymarin, naringin and 
morin which are natural flavanoids it was studies with drugs which are 
metabolized by the first pass metabolism intensively particularly by enzyme 
CYP 450 and its various subtract and P-gp efflux mechanism and having a 
very poor bio-availability i.e.  sildenafil citrate, atorvastatin calcium, zidovudine 
and carvedilol phosphate. 
 
The objectives of the present investigation are: 
i. To study the absorption promotion activity of selected isolated 
chemicals component of herbal origin. 
ii. To develop suitable sensitive analytical methods for selected drugs in 
blood plasma and in presence of HAPs. 
iii. To study detail mechanism by which the selected HAPs enhance the 
absorption. 
iv. To find out the effective concentration of selected HAPs. 
v. To study the toxicity of selected HAPs in its effective concentration. 
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4.   MATERIALS AND METHODS 
All the common chemicals were used were of analytical grade and glasswares 
were of borosilicate glass. The details of important chemicals are as under. 
 
4.1 Reagents and Materials 
• Atorvastatin Calcium (Gift sample from  Strides Arco ltd, Bangalore) 
• Sildenafil Citrate  (Gift sample from Zydus Research Center, 
Ahmedabad) 
• Zidovudine (Gift sample from  Strides Arco ltd, Bangalore) 
• Carvedilol Phosphate (Gift sample from Zydus Research Center, 
Ahmedabad) 
• Silymarin (Gift sample from Cadila Pharmaceutical Company)  
• Morin (Purchased from Sigma chem., USA) 
• Naringin (Purchased from Sigma chem., USA) 
• Methanol (HPLC grade – Rankem) 
• Acetonitrile (HPLC grade – Rankem) 
• Ammonium acetate ( Merck) 
• Ortho Phosphoric Acid (Ultrapure-Merck) 
• Wattman filter paper no. 1 
• Triple distill water 
• HCT-15 cells (Procured from National Cancer Institute, Frederick, USA) 
• MCF-7 cells (Procured from National Cancer Institute, Frederick, USA) 
• SRB dye (Sigma chem., USA) 
• Sodium Carboxy Methyl Cellulose (Himedia) 
• Saline solution 
 
4.2 Apparatus and Instruments 
• Shimadzu Prominence UFLC system 
• Sonicator (Equitron) 
• Precision balance (swisser Insrument Gandhinagar)  
• Analytical balance (shimadzu,Japan) 
• pH meter (Elico, Ahmedabad) 
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• Cooling Centrifuge (Remi ,vasai) 
• Deep freez (-20°c) (Remi,vasai) 
• Vortexer (Genei, Banglore) 
• Micro pipettes (eppendroff) (2-20 µl, 10-100µl, 100-1000 µl) 
• Volumetric flask of 10 ,25 , 50, and 100 ml 
• Syringe (2.0 mL) 
• Oral Canula 
 
4.2.1 Softwares 
• SAS, version 9.1 
• Maglon software 
• Graph pad 
• Prism 5 
• Micro Soft office excell  
 
4.3 HPLC Analytical method development and Validation 
The drug analysis i.e. sildenafil citrate, zidovudine, atorvastatin calcium and 
carvedilol phosphate were performed on high performance liquid chromato- 
graphy (HPLC) for high accuracy and for each drug the analytical method was 
developed and validated according the analytical parameters recommended 
for HPLC. Typical analytical performance characteristics that should be 
considered in validation of the method were performed for the all the drugs 
selected for the current study i.e sildenafil citrate, zidovudine, atorvastatin 
calcium and carvedilol phosphate. The analytical methods for atorvastatin 
calcium were mentioned as below. 
 
4.3.1 Typical Analytical Parameters for HPLC Analysis 
4.3.1.1 System suitability 
Replicate injections of standard preparation used in standard curve solution 
are compared to ascertain whether requirement for precision are met. Five 
replicate injections of analyte are used to calculate the relative standard 
                                                                                     Materials and methods 
 
Department of pharmaceutical Sciences, Saurashtra University, Rajkot, India.  49 
 
deviation (RSD) if the requirement is 2 % or less and data from six replicate 
injections are used if RSD requirement is more than 2 %. 
 
2ml of drug solution (100 μg/ml) was taken in 10 ml volumetric flask and 
diluted up to mark with methanol. 20 μl of this solution (20 μg/ml) was injected 
six times in to HPLC system and analyzed at 230 nm and RSD was 
calculated. 
 
4.3.1.2 Linearity 
The linearity of analytical method is its ability to elicit test results that are 
directly proportional to concentration of analyte in sample within given range. 
The linearity range of analytical method is interval between upper and lower 
level of analyte including level that been demonstrated to be determining with 
precision and accuracy using method.  
 
The linearity is expressed in terms of correlation co-efficient of linear 
regression analysis. The linearity of response for drug was assessed by 
analysis of eight independent levels of calibration curve in range of 100-50000 
ng, in terms of slope, intercept and correlation coefficient values. 
 
4.3.1.3 Precision 
The precision is measure of either the degree of reproducibility or repeatability 
of analytical method. It is indication of random error. Precision of analytical 
method is usually expressed as a standard deviation, relative standard error 
or co-efficient of variance of series of measurement. The value of % CV 
should be not more than 5 %. 
 
4.3.1.4 Reproducibility 
Variations of result within same day and amongst days are called as 
reproducibility. It includes following parameter: 
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4.3.1.4.1 Intraday reproducibility 
A variation of result within same day is called intraday variation. It was 
determined by repeating calibration curve as describe by three times on same 
day and % CV was calculated. 
 
4.3.1.4.2 Interday reproducibility 
Variation of result amongst day is called interday variation. It was determined 
by repeating calibration curve daily for 3 different days as and % CV was 
calculated. 
 
4.3.1.5 Accuracy 
Accuracy of analysis is determined by systemic error. It is defined as 
closeness of agreement between actual (true) value and analytical value. 
Accuracy may expressed as % recovery by analysis of known added amount 
of analyte. It is measure of exactness of analytical method. It is determined by 
calculating recovery by standard addition method. 
Accuracy data of drug: 
Pre-analyzed drug solution (A) = 100 μg/ml 
Standard drug solution (B) = 100 μg/ml 
Sample solution was prepared from combination of above solution. 
Solution was injected (10 μg/ml) in to HPLC system and analyzed at suitable 
wavelenght. The difference in area of each sample solution (sample no. 2 to 
5) to sample solution (sample no. 1) obtained was used to calculate the % 
recovery. 
 
4.3.1.6 Limit of detection 
It is the lowest concentration of an analyte in a sample that can be detected 
but not necessarily quantified under the stated analytical conditions. Limit of 
detection (LOD) is commonly used to substantiate that analyte concentration 
is above or below a certain level different concentration of standard drug 
solution were used and minimum detectable limit was found. 
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1 ml of drug (100 μg/ml) was taken in 10 ml volumetric flask and diluted up to 
mark with methanol. Aliquots of the solution (1, 2, 3, 4, 5, 6, 7, 8 ml) were 
transferred into series of 10 ml volumetric flask and diluted with methanol up 
to mark. 20 µl of each solution were injected in to HPLC system and analyzed 
at 230 nm and find the lowest concentration that was detectable.   
 
4.3.1.7 Limit of quantification 
It is the lowest concentration of analyte in a sample that can be determined 
with acceptable precision and accuracy under the stated experimental 
condition. The limit of quantification (LOQ) is commonly used for impurities 
and degradation assay of bulk and drug product.  
 
4.3.1.8 Specificity 
The specificity of an analytical method is ability to measure accurately an 
analyte in presence of interferences like synthetic precursor, excipient, 
degradant or matrix component. It was determined by spiking 20 µl of solution 
containing suitable concentration of test drug and 20 µl of internal standard. 
Internal standard drug solution were added in to the 80 µl rat blood plasma 
and mixed well. Then added 300 µl of the acetonitrile and vortexed for 2 min. 
centrifuged at 12000 rpm for 10 min at 4 o
 
C. Taken out supernant and injected 
to HPLC. 
 
4.3.1.9 Recovery 
Six replicates of standard (STD) 1 and STD 5 were analyzed by following the 
procedure for preparation of standard solution and compared with same 
concentration level STD samples processed by following the procedure for 
extracted sample preparation. 
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4.3.1.10 Chromatographic system for HPLC Analysis 
• Work station : Class – VP 10 Shimadzu. 
• Binary solvent delivery system : SCL-10 Avp Shimadzu solvent   
Delivery module 
• Universal injector : Shimadzu 7D Rheodyne 7725i, 100 µl 
injector. 
• Detector : Photodiodarry Detector (SPD-10 M 10 
Avp) 
• Integration of data : Lc Solution software 
• Syringe : Hamilton syringe 25 µl. 
 
4.3.2 Atorvastatin Calcium 
4.3.2.1 Solution and sample preparation 
♦ Mobile phase buffer solution (20mmol potassium dihydrogen 
phosphate) 
Weigh accurately 680.45 mg of potassium dihydrogen phosphate in 250 
ml triple distilled water, and pH adjusted to 3.10 using the orthophosphoric 
acid. The solution was filtered by using wattman filter paper (No. 1) and 
sonicated for 10 min and then used. 
 
♦  Mobile phase 
Mobile phase buffer solution: Methanol (20:80) 
 
♦ Drug stock solution 
Accurately weighed quantity of atorvastatin calcium equivalent to 10 mg. 
atorvastatin was transferred in to 10 ml volumetric flask and dissolved in 5 
ml of methanol and diluted with methanol up to mark to give stock solution 
having a strength of 1 mg/ml. Appropriate dilution of stock solution were 
made with distilled water to obtain working solutions from 1.0 -188.0 µg/ml 
of atorvastatin by serial dilution method.  
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♦ Internal standard stock solution 
Accurately weighed quantity of atorvastatin calcium equivalent to 10 mg. 
atorvastatin was transferred in to 10 ml volumetric flask and dissolved in 5 
ml of methanol and diluted with methanol up to mark to give stock solution 
having a strength of 1 mg/ml. Transferred 1.75 ml of stock solution into 25 
ml volumetric flask and dissolved in 10 ml distilled water and diluted with 
distilled water up to mark to give stock solution having a strength of 70 
µg/ml.  
 
♦ Preparation of atorvastatin calcium suspensions 
A suspension of atorvastatin calcium of concentration 20 mg/ml. Sodium 
CMC (1 % w/v) was used as suspending agents. The vehicle sodium CMC 
(1 % w/v) in distilled water] was used as negative control. 
 
4.3.2.2 Preparation of calibration curve 
Aliquots of the drug tock solution (1, 2, 3, 4 and 5 ml) were transferred in 
to series of 10 ml volumetric flask and diluted with methanol up to mark. 
20µl of each solution were injected in to HPLC system and analyzed at 
230 nm. Calibration curve was obtained by plotting respective peak area 
against concentration. 
 
4.3.2.3 Chromatographic condition 
♦ Pumping mode : Binary 
♦ Mobile phase : 20 mMol Potassium Dihydrogen phosphate  
(pH-3.30 adjusted with Ortho-phosphoric 
acid) Buffer : Methanol (20:80) 
♦ Column  : Phenomax C18,  (250 x 4.6 mm i.d., 5µm) 
♦ ۸max   : 230 nm 
♦ Injection volume :  20  µl 
♦ Run time  : 10 min 
♦ Flow rate  :  1.0 ml/min 
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4.3.3 Carvedilol 
4.3.3.1 Solution and sample preparation 
♦ Mobile phase buffer solution (30 mMol ammonium formate, pH-
4.00) 
Weigh accurately 472.95 mg of ammonium formate in 250 ml triple 
distilled water, and pH was adjusted to 4.00 using formic acid. The 
solution was filtered using Wattman filter paper (No. 1) and sonicated 
for 10 min and then used. 
♦ Mobile phase 
Mobile phase buffer solution: Methanol (25:75) 
♦ Drug stock solution 
Accurately weighed quantity of carvedilol phosphate equivalent to 10 
mg. carvedilol was transferred in 10 ml volumetric flask and dissolved 
in 5 ml of methanol and diluted with methanol up to mark to give stock 
solution having a strength of 1 mg/ml. Appropriate dilution of stock 
solution were made with distilled water to obtain working solutions from 
0.5-208.0 µg/ml of carvedilol by serial dilution method.  
♦ Internal standard stock solution 
Accurately weighed quantity of diclofenac sodium equivalent to 10 mg. 
Diclofenac was transferred in to 10 ml volumetric flask and dissolved in 
5 ml of methanol and diluted with methanol up to mark to give stock 
solution having a strength of 1 mg/ml. Transferred 1.50 ml of stock 
solution into 25 ml volumetric flask and dissolved in 10 ml distilled 
water and diluted with distilled water up to mark to give stock solution 
having a strength of 70 µg/ml.  
♦ Preparation of carvedilol suspensions 
A suspension of carvedilol of concentration 22 mg/ml. Sodium CMC (1 
% w/v) was used as suspending agents. The vehicle sodium CMC (1 % 
w/v) in distilled water] was used as negative control. 
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4.3.3.2 Chromatographic condition 
♦ Pumping mode : Binary 
♦ Mobile phase : 30 mmol ammonium formate Buffer (pH-4.00 
with formic acid): Methanol (25:75) 
♦ Column : Phenomax C18,  (250 x 4.6 mm i.d., 5µm) 
♦ Injection volume : 20 µl 
♦ Run time : 7.50 min. 
♦ Flow rate : 1.2 ml/min. 
 
4.3.3.3 Preparation of calibration curve 
Aliquots of the drug stock solution [0.01, 0.02, 0.04, 0.160, 0.320 ml (from 50 
μg/ml), 0.320,0.64, 1.28 and 2.08 ml (from 1000 μg/ml) were transferred into 
series of 10 ml volumetric flask and diluted with distill water up to mark which 
gives concentration range 0.500-208.00 µg/ml. 20 µl of each solution were 
injected in to HPLC system and analyzed. Calibration curve was obtained by 
plotting respective peak area ratio against concentration.  
 
4.3.4 Zidovudine 
4.3.4.1 Solution and sample preparation 
♦ Mobile phase 
  Methanol : Triple distill Water ( 70 : 30 ) 
♦ Drug Stock Solution 
Accurately weighed quantity of zidovudine 10 mg was transferred to 10 
ml volumetric flask and dissolved in 5 ml of triple distill water and 
diluted with Triple distill water up to mark to give stock solution having a 
strength of 1 mg/ml  
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4.3.4.2  Chromatographic  condition  
♦ Pumping mode : Binary 
♦ Mobile phase : Methanol : Water (70 : 30) 
♦ Column  : Phenomax C18,  (250 x 4.6 mm i.d., 5µm) 
♦ λmax
♦ Injection volume : 20  µl 
   : 266 nm 
♦ Run time  : 5 min 
♦ Flow rate  : 1.0 ml/min 
 
4.3.4.3 Preparation of calibration curve 
Aliquots of the drug stock solution (1, 2, 3, 4 and 5 ml) were transferred 
into series of 10 ml volumetric flask and diluted with Triple distill water up 
to mark. 20 µl of each solution were injected in to HPLC system and 
analyzed at 266 nm. Calibration curve was obtained by plotting respective 
peak area against concentration.  
 
4.3.4 Sildenafil citrate 
4.3.4.1 Solution  and sample preparation 
♦ Mobile phase buffer solution  
 It was prepared by mixing 500 ml of 30 mMol ammonium acetate, and 
 the pH was adjusted to 6.00 using 1 N sodium hydroxide solution. The 
 solution was filtered using Wattman filter paper (No. 1) and sonicated 
 for 10 min and then used. 
♦ Mobile phase       
 Mobile phase buffer solution : Acetonitrile  (35:65) 
♦ Drug stock solution 
 Accurately weighed quantity of  sildenafil citrate 10 mg was transferred 
 in to 10 ml volumetric flask and dissolved in 5 ml of methanol and 
 diluted with methanol up to mark to give stock solution having a 
 strength of 1 mg/ml 
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♦ Preparation of suspensions 
 A suspension of sildenafil citrate of concentration 3 mg/ml. Sodium 
 CMC (1% w/v) was used as a suspending agents. The vehicle [sodium 
 CMC (1% w/v)  in distilled water] was used as negative control. 
 
4.3.4.2 Chromatographic  condition 
♦ Pumping mode : Binary 
♦ Mobile phase : Acetonitrile: 30 mMol ammonium acetate  
                                                       buffer, ( pH- 6.00 with    1 N NaOH) 65:35 
♦ Column  : Phenomax C18,  (250 x 4.6 mm i.d., 5µm) 
♦ λmax
♦ Injection volume : 20  µl 
   : 230 nm 
♦ Run time  : 10 min 
♦ Flow rate  : 1.0 ml/min 
 
4.3.4.3  Preparation of calibration curve 
Aliquots of the drug stock solution (1, 2, 3, 4 and 5 ml) were transferred into 
series of 10 ml volumetric flask and diluted with methanol up to mark. 20 µl of 
each solution were injected in to HPLC system and analyzed at 230 nm. 
Calibration curve was obtained by plotting respective peak area against 
concentration.  
 
4.4 in vivo bioavailability study  
4.4.1 Atorvastatin calcium 
Healthy wistar albino rats (250–300 g) had free access to normal standard 
chow diet and tap water. Animals were fasted for 24 hr prior to the 
experiments and were given water freely. Each rat was anaesthetized by 
inhalation of diethyl ether. Drug suspension was prepared by adding 
atorvastatin calcium (30 mg/kg) to the 1% CMC solution (3 mg/mL). In the 
present study, rats were divided in to following groups as mentioned below. In 
each group rats (n = 6 per each treatment) were given orally a 30 mg/kg of 
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atorvastatin calcium along with selected HAPs i.e. silymarin, morin and 
naringin in concentration of 100 µm in each dose. 
Group i:  Rats were given orally a 30 mg/kg of atorvastatin Calcium 
with silymarin (100 µm) subsequent to atorvastatin 
calcium administration 
Group ii: Rats were given orally a 30 mg/kg of atorvastatin Calcium 
with morin (100 µm) subsequent to atorvastatin calcium 
administration 
Group iii: Rats were given orally a 30 mg/kg of atorvastatin calcium 
with (100 µm) subsequent to atorvastatin calcium 
administration 
Group iv: Rats were given orally a 30 mg/kg of atorvastatin calcium 
without any subsequent administration 
 
Blood samples were withdrawn from the retro orbital plexus according to a 
predetermined time schedule at 0.5, 1, and 2 hr post dose and collected in 
EDTA containing tubes. Blood samples were centrifuged at 12000 rpm for 10 
min and the plasma was removed and process for extraction and analyzed by 
HPLC.  
 
4.4.2 Procedure for Extracted sample preparation 
♦ 0.5 ml of the spiked plasma in the eppendrof tube was taken. 
♦  50 µl of TCA was added in the same eppendrof tube and vortex the 
samples thoroughly for 3 min. 
♦ The sample was then centrifuged at 12000 rpm for 10 min at 4 o
♦ 300µl of supernant was transferred in to another pre-labeled eppendrof 
tube. 
C 
♦ The sample was injected into HPLC system. 
 
4.4.3 Data processing 
The chromatograms were acquired by using Class VP, version 1.6 supplied 
by HPLC manufacturers. The calibration curve was plotted as the peak area 
ratio (drug) on Y-axis vs. the nominal concentration of drug on the X-axis. The 
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concentrations of the unknown samples were calculated by using the linear 
regression equation with 1/x2 weighing factor. 
 
4.4.4 Pharmacokinetics and statistical analysis 
Pharmacokinetic and statistical analysis for plasma concentration vs. time 
profile of atorvastatin calcium was performed on the data obtained from male 
wistar rat. 
 
4.4.4.1 Pharmacokinetic parameters  
Pharmacokinetic parameters i.e. Tmax, Cmax were calculated using plasma 
concentration vs. time profile (Actual time of the sample collection) data of 
atorvastatin calcium in individual wistar rat by using the graph pad software. 
Pharmacokinetic parameters were calculated by non-compartmental analysis 
using graph pad software. The peak level Cmax and time to reach peak level 
Tmax was estimated from the plasma concentration time profile data.  
 
4.4.4.2 Statistical Analysis 
SAS, version 9.1 was used for the statistical analysis of the pharmacokinetic 
parameters i.e. Cmax, Tmax. etc. 
 
4.4.4.3 Analysis of variance 
The untransformed and ln-transformed pharmacokinetic parameters i.e. Cmax
4.5.5.1 Blood sample collection and processing  
, 
was subjected to Analysis of Variance (ANOVA). ANOVA model was included 
sequence, subject (sequence), period and formulation effects as factors. 
Difference between the treatments, period of treatment, sequence of dosing 
was considered statistically significant if probability values of the respective 
effects (p-values) were < 0.05. 
 
4.4.5 Carvedilol 
Male wistar rats (250–300 g) had free access to normal standard chow diet 
(Jae and Chow, Korea) and tap water. Animals were fasted for 24 h prior to 
the experiments and were given water freely. The protocol of the experiment 
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was approved by the Institutional Animal Ethical Committee (IAEC) as per the 
guidance of the Committee for The Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), (SU/DPS/IAEC/9006). The each rat was 
anaesthetized by inhalation of diethyl ether. Drug suspension was prepared 
by adding Carvedilol Phosphate (60 mg/kg) to the 1 % Sodium CMC Solution. 
In the present studythe rats were divided into the following groups: 
Group i:  Rats were given orally a 60 mg/kg of carvedilol 
phosphate with silymarin (100 µm) subsequent to 
carvedilol phosphate administration 
Group ii: Rats were given orally a 60 mg/kg of carvedilol 
phosphate with morin (100 µm) subsequent to carvedilol 
phosphate administration 
Group iii: Rats were given orally a 60 mg/kg of carvedilol 
phosphate with morin (100 µm) subsequent to the 
carvedilol phosphate administration 
Group iv: Rats were given orally a 60 mg/kg of the carvedilol 
phosphate without any subsequent administration 
 
Blood samples were withdrawn from the retro orbital plexus according to a 
predetermined time schedule at 0, 20, 50, 95, 155, 220, 280 and 340 min, and 
collected in EDTA containing tubes. Blood samples were centrifuged at 12000 
rpm for 10 min and the plasma was removed and process for extraction and 
analyzed by HPLC.  
 
4.5.5.2 Extraction procedure for sample preparation 
♦ The spiked plasma 0.1 ml of sample was taken  in the eppendrof  tube. 
♦ 20µl of internal standard (Diclofenac sodium, 60 µg/ml) and 300 µl 
methanol was added in same eppendrof tube and vortex the samples 
thoroughly for 2 min. 
♦ The samples was then centrifuged at 12000 rpm for 10 min at 4 o
♦ The supernant transferred in to another prelabelled eppendrof tube. 
C. 
♦ Inject 20 µl the sample into HPLC system. 
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4.5.5.3 Pharmacokinetics and statistical analysis 
Pharmacokinetic and Statistical analysis for plasma concentration Vs time 
profile of Sildenafil citrate was performed on the data obtained from wistar 
albino rat. 
 
4.5.5.3.1 Pharmacokinetic parameters  
Pharmacokinetic parameters i.e. Tmax, Cmax were calculated using the plasma 
concentration vs. time profile (actual time of the sample collection) data of the 
carvedilol phosphate in the individual wistar rats using graph pad software. 
Pharmacokinetic parameters were calculated by non-compartmental analysis 
using Graph pad software. The peak level Cmax and time to reach peak level 
Tmax was estimated from the plasma concentration time profile data.  
 
4.5.5.3.2 Statistical analysis 
SAS, version 9.1 was used for the statistical analysis of the pharmacokinetic 
parameters i.e. Cmax, Tmax
4.5.6.1 Blood sample collection and processing  
 etc. 
 
4.5.5.3.3 Analysis of variance 
The untransformed and ln-transformed pharmacokinetic parameters Cmax, 
was subjected to Analysis of Variance (ANOVA). ANOVA model was included 
sequence, subject (sequence), period and formulation effects as factors. 
Difference between the treatments, period of treatment, sequence of dosing 
was considered statistically significant if probability values of the respective 
effects (p-values) were < 0.05. 
 
4.5.6 Sildenafil citrate 
Male wistar albino rats (250–300 g) had free access to normal standard chow 
diet (Jae and Chow, Korea) and tap water. Animals were fasted for 24 hr prior 
to the experiments and were given water freely. Each rat was anaesthetized 
by inhalation of Diethyl ether. Drug Suspension was prepared by adding 
Sildenafil citrate (30 mg/kg) to the 1 % CMC Solution (3 mg/mL). Following 
mentioned groups are selected for the study as mentioned below: 
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Group i:  Rats were given orally a 30 mg/kg of sildenafil citrate with 
silymarin (100 µm) subsequent to the sildenafil citrate 
administration 
Group ii: Rats were given orally a 30 mg/kg of sildenafil citrate with 
morin (100 µm) subsequent to the sildenafil citrate 
administration 
Group iii: Rats were given orally a 30 mg/kg of sildenafil citrate with 
(100 µm) subsequent to sildenafil citrate administration 
Group iv: Rats were given orally a 30 mg/kg of the sildenafil citrate 
without any subsequent administration 
 
Blood samples were withdrawn from the Retro orbital plexus according to a 
predetermined time schedule at 0.5, 1, and 2 hr post dose and collected in the  
EDTA containing  tubes. Blood samples were centrifuged at 12000 rpm for 10 
min. and the plasma was removed and process for extraction and analyzed 
analyzed by HPLC.  
 
4.5.6.2 Procedure for extracted sample preparation 
♦ 0.5 ml of the spiked plasma in the eppendrof tube was taken. 
♦  50 µl of TCA was added in the same eppendrof tube and vortex the 
samples thoroughly for 3 min. 
♦ The sample was then centrifuged at 12000 rpm for 10 min at 4 o
♦ 300µl of supernant was transferred in to another pre-labeled eppendrof 
tube. 
C. 
♦ The sample was injected into HPLC system. 
 
4.5.6.3 Data processing 
The chromatograms were acquired by using Class VP, version 1.6 supplied 
by HPLC manufacturers. The calibration curve was plotted as the peak area 
ratio (drug) on Y-axis vs. the nominal concentration of drug on the X-axis. The 
concentrations of the unknown samples were calculated by linear regression 
equation with 1/x2 weighing factor. 
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4.5.6.4 Pharmacokinetics and statistical analysis 
Pharmacokinetic and statistical analysis for plasma concentration Vs time 
profile of Sildenafil citrate was performed on the data obtained from wistar 
albino rat. 
 
4.5.6.4.1 Pharmacokinetic Parameters  
Pharmacokinetic parameters Tmax, Cmax were calculated using plasma 
concentration vs time profile (actual time of sample collection) of the sildenafil 
citrate in individual male wistar rats using the graph pad software. 
Pharmacokinetic parameters were calculated by non-compartmental analysis 
using graph pad software. The peak level Cmax and time to reach peak level 
Tmax was estimated from the plasma concentration time profile data.  
 
4.5.6.4.2 Statistical Analysis 
SAS, version 9.1 was used for the statistical analysis of the pharmacokinetic 
parameters i.e. Cmax, Tmax. etc. 
 
4.5.6.4.3 Analysis of variance 
The untransformed and ln-transformed pharmacokinetic parameters Cmax
4.5.7.1  Blood sample collection and processing 
, 
was subjected to ANOVA. The ANOVA model was included sequence, 
subject (sequence), period and formulation effects as factors. Difference 
between the treatments, period of treatment, sequence of dosing was 
considered statistically significant if probability values of the respective effects 
(p-values) were < 0.05. 
 
4.5.7 Zidovudine 
Male wistar albino rats (250–300 g) had free access to normal standard chow 
diet (Jae and Chow, Korea) and tap water. Animals were fasted for 24 hr prior 
to the experiments and were given water freely. Each rat was anaesthetized 
by the inhalation of diethyl ether. Drug suspension was prepared by adding 
the zidovudine (75 mg/ kg) in to the 1 % CMC solution (3 mg/ml). Following 
mentioned groups are selected for the study as mentioned below: 
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Group i:  Rats were given orally a 75 mg/kg of zidovudine with 
silymarin (100 µm) subsequent to the zidovudine 
administration 
Group ii: Rats were given orally a 75 mg/kg of zidovudine with 
morin (100 µm) subsequent to zidovudine administration. 
Group iii: Rats were given orally a 75 mg/kg of zidovudine with (100 
µm) subsequent to zidovudine administration. 
Group iv: Rats were given orally a 75 mg/kg of zidovudine without 
any subsequent administration 
 
Blood samples were withdrawn from the retro orbital plexus according to a 
predetermined time schedule at 0.5, 1, and 2 hr post dose  and collected in 
EDTA containing  tubes. Blood samples were centrifuged at 12000 rpm for 10 
min and the plasma was removed and process for extraction and analyzed 
analyzed by HPLC.  
 
4.5.7.2 Procedure for extracted sample preparation 
♦ 0.5 ml of the sample spiked plasma in the eppendrof tube was taken. 
♦  50 µl of TCA was added in the same eppendrof tube and vortex the 
samples thoroughly for 3 min. 
♦ The sample was then centrifuged at 12000 rpm for 10 min at 4 o
♦ 300µl of supernant was transferred in to another pre-labeled eppendrof 
tube. 
C. 
♦  The sample was injected into HPLC system. 
 
4.5.7.3 Data processing 
The chromatograms were acquired by using Class VP, version 1.6 supplied 
by HPLC manufacturers. The calibration curve was plotted as the peak area 
ratio (Drug) on Y-axis Vs the nominal concentration of drug on the X-axis. The 
concentrations of unknown samples were calculated by the linear regression 
equation with 1/x2 weighing factor. 
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4.5.7.4  Pharmacokinetics and statistical analysis 
Pharmacokinetic and statistical analysis for plasma concentration vs. time 
profile of zidovudine was performed on the data obtained from male wistar rat. 
 
4.5.7.4.1 Pharmacokinetic parameters  
Pharmacokinetic parameters i.e. Tmax, Cmax were calculated by using the 
plasma concentration vs time profile (Actual time of sample collection) data of 
zidovudine in individual animal using graph pad software. Pharmacokinetic 
parameters were calculated by non-compartmental analysis using graph pad 
software. The peak level (Cmax) and time to reach peak level (Tmax) was 
estimated from the plasma concentration time profile data.  
 
4.5.7.4.2 Statistical analysis 
SAS, version 9.1 was used for the statistical analysis of the pharmacokinetic 
parameters i.e. Cmax, Tmax. etc. 
 
4.5.7.4.3 Analysis of variance 
The untransformed and ln-transformed pharmacokinetic parameters Cmax
For the current study three cell lines were selected for the study i.e. HCT-15 
for expression of CYP 450 activity & MCF 7 for the expression of P-gp 
expression (P. Skehan et al., 1990). The human cancer cell lines were 
procured from National Cancer Institute, Frederick, U.S.A. Cells were grown 
in tissue culture flasks in complete growth medium (RPMI-1640 medium with 
2mmol glutamine, pH 7.4, supplemented with 10 % fetal calf serum, 100 µg/ml 
, 
was subjected to ANOVA. ANOVA model was included sequence, subject 
(sequence), period and formulation effects as factors. Difference between the 
treatments, period of treatment, sequence of dosing was considered 
statistically significant if probability values of the respective effects (p-values) 
were < 0.05. 
 
4.6 In vitro cytotoxicity of selected herbal absorption promoters 
 against human cancer cell lines 
4.6.1 Cell lines preparation 
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streptomycin and 100 units/ml penicillin) in a carbon dioxide incubator (37 °C, 
5 % CO2, 90 % RH). The cells at subconfluent stage were harvested from the 
flask by treatment with trypsin [0.05 % in PBS (pH 7.4) containing 0.02 % 
EDTA]. Cells with viability of more than 98 % as determined by trypan blue 
exclusion, were used for determination of cytotoxicity The cell suspension of 1 
x 105 cells/ml was prepared in complete growth medium (Monks et al., 1991) 
 
4.6.2 Preparation of stock solution of selected HAPs 
The stock solution of selected HAPs i.e. silymarin, morin and naringin were 
prepared in water to obtain strength of 2 x 10-2 
In vitro cytotoxicity against two human cancer cell lines was determined 
(Monks et al., 1991) using 96-well tissue culture plates. The 100 µl of cell 
suspension was added to each well of the 96-well tissue culture plate. The 
cells were allowed to grow in carbon dioxide incubator (37 °C, 5 % CO
mol. The stock solutions were 
serially diluted with complete growth medium containing 50 µg/ml of 
gentamycin to obtain working test solutions of required concentrations. 
 
4.6.3 SRB (Sulforhodamine B dye) assay for measurement of In vitro 
 cytotoxicity study 
2, 90 % 
RH) for 24 hr. Test materials of selected HAPs i.e. silymarin, naringin and 
morin were added in concentration of 25 µmol, 50 µmol, 100 µmol & 200 µmol 
strength and 5-flourouracil (FU) and tamoxifen in concentration of 10 µg/100 
µl strength as positive in complete growth medium (100 µl) were added after 
24 hr of incubation to the wells containing cell suspension. The plates were 
further incubated for indicated time period in a carbon dioxide incubator. The 
cell growth was stopped by gently layering TCA (50 %, 50 µl) on top of the 
medium in all the wells. The plates were incubated at 4 oC for 1 hr to fix the 
cells attached to the bottom of the wells. The liquid of all the wells was gently 
pipetted out and discarded. The plates were washed five times with distilled 
water to remove TCA, growth medium low molecular weight metabolites, 
serum proteins etc. and then it was air-dried completely. The plates were 
stained with Sulforhodamine B dye (0.4 % in 1 % acetic acid, 100 µl) for 30 
min. The plates were washed five times with 1% acetic acid and then air-
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dried. (Skehan et al., 1990). The adsorbed dye was dissolved in Tris-HCl 
Buffer (100 µl, 0.01 mol, pH 10.4) and plates were gently stirred for 10 min on 
a mechanical stirrer. The optical density (OD) was recorded on enzyme linked 
immune sorbent assay (ELISA) reader at 540 nm on GENESIS Work station 
and TECAN multi-plate reader by using Maglon software. 
 
The cell growth was determined by subtracting mean OD value of respective 
blank from the mean OD value of experimental set. % growth in presence of 
test material was calculated considering the growth in absence of any test 
material as 100 % and in turn percent growth inhibition in presence of test 
material was calculated. 
 
4.7 In vitro enzyme assays 
P-gp-ATPase enzyme activity and two subtract of CYP 1A1 (Benzopyrene 
Hydroxylase) and CYP 450 3A4 (Erythromycin demethylase) were selected 
for the study and its activity was measured by in vitro assays as mentioned 
below. 
 
4.7.1 In vitro Pgp-ATPase activity 
4.7.1.1 Animals 
Healthy wistar rats (150–200 g body weight) of both sexes were maintained in 
regulated environmental conditions (well-ventilated with >10 air changes/h; 12 
h light/dark photoperiod; temperature 28 ± 2 ºC; relative humidity, 60 ± 10%), 
according to CPCSEA guidelines. Animals were fed with standard pelleted 
diet and water was provided ad libitum. Seven days after acclimatization, the 
animals were used. 
 
4.7.1.2 Preparation of intestinal membrane fractions 
Crude intestinal membrane fractions were prepared from jejunal mucosa of 
rats as described earlier (Yumoto et al., 2001). Crude membrane fractions 
were prepared from the intestinal mucosa and liver of rats. The luminal 
contents of whole small intestine were thoroughly washed out with a sufficient 
amount of ice-cold saline, and the intestine was divided into two parts of the 
                                                                                     Materials and methods 
 
Department of pharmaceutical Sciences, Saurashtra University, Rajkot, India.  68 
 
same length. The mucosal surface of the lower half of intestine was scraped 
off with a cover glass. The intestinal mucosa collected and the isolated liver 
were homogenized in a buffer containing 250 mM sucrose and 5 mM HEPES-
Tris (pH 7.4) with a tissue homogenizer. The homogenates were centrifuged 
at 3,000 rpm for 10 min. The supernatants were then centrifuged at 24,000 
rpm for 30 min. The pellets containing the crude membrane fractions were 
resuspended in 50 mmol mannitol and 20 mmol HEPES-Tris (pH 7.5). The 
suspension samples were used immediately after preparation. Protein 
determination was done by the method of described earlier (Lowry et al, 1951) 
using bovine serum albumin as standard.  
 
4.7.1.3 Measurement of ATPase activity  
P-gp-dependent ATPase activity was measured by determining vanadate- 
sensitive release of inorganic phosphate (Pi) from ATP as reported earlier 
(Hrycyna et al., 1998). In brief, membrane preparations (15–20 μg 
protein/assay) were pre-incubated for 3 min in the absence and presence of 
10 mm ortho-vanadate in an assay buffer containing (in mm) Tris 100.0 (pH 
7.5), NaN3 10.0, EGTA 4.0, ouabain 2.0, DTT 4.0, KCl 100.0 and MgCl2
The results were stastically analyzed by one way ANOVA test by using 
Dunnett’s test i.e. control group vs. test compound’s group. The graphical 
representative was also performed by using % change vs. control. 
 20.0 
(final volume 100 μl). An addition of 5.0 mm ATP was made in all incubations 
which were allowed to continue for 30 min. The reaction was stopped by 
adding 5 % (w/v) sodium dodecyl sulphate and the released Pi was measured 
as described in the procedure. In one set of identical incubations test 
substances were also added. Vanadate-sensitive activity in the presence and 
absence of a test substance was calculated as the difference between 
ATPase activity obtained in the presence and absence of sodium ortho-
vanadate. Test compounds of selected HAPs i.e. silymarin, naringin and 
morin were added in the concentration of 10 µmol, 30 µmol and 100 µmol 
strength and prepared in 10 % DMSO. All incubations were done in triplicate.  
 
4.7.1.4 Stastical analysis 
                                                                                     Materials and methods 
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4.7.2 CYP 450 1A1Enzyme: Benzopyrene hydroxylase activity 
Microsomal Benzopyrene Hydroxylase (AHH) activity, AHH activity in tissue 
assayed by the procedure described below. (Nebert et al.; Wettenberg et al.). 
The incubation mixture contained in 1.0 ml:50 µmol of Tris-HCl, pH 7.6, 0.5 
µmol of NADPH, 3 µmol of MgCl2
Addition 
, 0.50 to 2.0 mg of cellular protein and 100 
mµmol of substrate, Benzo[a]pyrene, added in 0.040 ml of methanol. The 
reaction was terminated on ice by addition of 4.0 ml of an Acetone: Hexane 
(1:3) mixture. After shaking at the 37 °C for 10 min, 1.0 ml of organic layer 
was extracted in to the 2.0 ml of 1 N NaOH and fluorescent of this extract was 
then immediately measured at 398 nm excuitation and 522 nm emission 
(Weibel et al., 1975). 
 
4.7.2.1 Reagent preparation for assay mixture (1ml) 
The assay mixture required to prepare was 1 ml and for getting the required 
concentration in final assay mixture and volume required in test and control 
assay are mentioned in below Tab.4.1 
 
TABLE 4.1: Reagent preparation for assay mixture for CYP 1A1 (1 ml) 
Final 
Concent
ration 
Control 
Assay 
Test 
Assay 
Tris.HCl 50 mM 560 μl 560 μl 
MgCl 3 mM 2 100 μl 100 μl 
Microsomes ~1 mg 100 μl 100 μl 
Test compounds 
(HAPs) In 10% 
DMSO 
- -  50 μl 
Vehicle  
10 % DMSO 
 50 μl     - 
Preincubate for 5 min in at 37 oC 
Benzo[a]pyrene 100 μmol 40 μl 40 μl 
NADPH 0.5 mmol 100 μl 100 μl 
Acetone hexane 
mixture  
- 4.0 ml - 
Incubate for additional 15 min  at 37 oC 
Acetone Hexane 
mixture 
- - 4.0 ml 
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Test compounds of selected HAPs i.e. silymarin, naringin and morin were 
added in concentration of 10 µmol, 30 µml and 100 µmol strength and 
prepared in 10 % DMSO. 1.0 ml of organic layer was extracted with 2.0 ml of 
1N NaOH, and the fluorescence of the aqueous phase measured immediately 
at 398 nm excitation / 522 nm emission wavelength. 
 
4.7.2.2 Stastical analysis 
The results were stastically analyzed by one way ANOVA test by using 
Dunnett’s test i.e. control group vs. test compound’s group. The graphical 
representative was also performed by using % change vs. control. 
 
4.7.3  CYP 450 3A4 Enzyme: Erythromycin demethylase  
Erythromycin N-demethylation was determined by the earlier reported method 
(Tu and Yang et al., 1983). Erythromycin was incubated at 37 °C for 15 min 
with 1 mg (HL 24493) of human liver microsomes or for 30 min with 1 mg of 
microsomes from human B-lymphoblast cells in the presence of a NADPH-
generating system as described above. Reactions were quenched with 0.05 
ml of 25 % ZnSO4 and 0.05 ml of 0.3 N Ba(OH)2. After the samples were 
vortexed and centrifuged at 14,000 3 g for 10 min, 0.35 ml of supernatant was 
transferred to another tube and then mixed with 0.15 ml of a concentrated 
NASH reagent (15 g of ammonium acetate and 0.2 ml of acetyl acetone in 18 
ml of 3% acetic acid). The mixture was incubated at 56°C for 30 min and 
transferred to a 96-well plate. Samples were analyzed by measuring 
absorbance at 405 nm with Ceres UV 900 HDi spectrophotometer to 
determine the formation of formaldehyde (Wang et al., 1997).   
 
4.7.3.1 Reagent preparation for assay mixture (1ml) 
The assay mixture required to prepare is 1ml and for getting the required 
concentration in final assay mixture and volume required in test and control 
assay are mentioned in below Tab. 4.2 
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TABLE 4.2: Reagent preparation for assay mixture for CYP 450 3A4 (1ml) 
 
Addition Final 
Concen
tration 
Blank Control Test 
Buffer 100 mmol 710 μl 710 μl 660  μl 
MgCl 6 mmol 2 50 μl 50 μl 50 μl 
Erythrpmycin 
 
1 mmol 50 μl 50 μl 50 μl 
Test compound 
in 10 % DMSO 
 -  - 50 μl 
Microsomes 1 mg/ 
assay 
40 μl 40 μl 40 μl 
Preincubate for 5 min in at 37 oC 
NADPH  - 50 μl 50 μl 
                                      Incubate for 30 min  at 37 oC 
ZnSO 25% 4 50 μl 50 μl 50 μl 
Ba(OH) 0.3 N 2    50 μl 50 μl 50 μl 
Centrifuge at 14000 rpm for 10 min and collect supernatant 
Supernatant  350 μl 350 μl 350  μl 
NASH reagent   150 μl 150 μl 150 μl 
Incubate at 56 oC for 30 min: Read OD at 405 nm 
(Plate reader spectrophotometer) 
 
Test compounds of selected HAPs i.e. silymarin, naringin and morin were 
added in concentration of 10 µmol, 30 µmol and 100 µmol strength and 
prepared in 10 % DMSO. Samples were analyzed by measuring absorbance 
at 405 nm with plate reader spectrophotometer to determine the formation of 
formaldehyde.   
 
4.7.3.2 Stastical analysis 
The results were stastically analyzed by one way ANOVA test by using 
Dunnett’s test i.e. control group vs. test compound’s group. The graphical 
representative was also performed by using %change vs. control. 
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4.8 Primary compatibility study of Herbal absorption promoters (HAPs) 
with drugs 
4.8.1 Infrared spectroscopic study 
Sample consisting of HAPs i.e. silymarin, morin, naringin and drugs i.e. 
sildenafil citrate, zidovudine, atorvastatin calcium and carvedilol phosphate 
were mixed in equal proportion were mixed geometrically and analyzed for 
fourier–transformed infrared (FTIR) spectroscopy.  
 
FTIR spectra were obtained on Shimadzu FTIR-8400 spectrophotometer 
using the KBr disk method (2 mg sample in 200 mg KBr). The scanning range 
was 450 to 4000 cm-1 and the resolution was 1 cm-1. 
 
4.8.2 Differential scanning calorimetry 
Sample consisting of HAPs i.e. silymarin, morin, naringin and drugs i.e. 
sildenafil citrate, zidovudine, atorvastatin calcium and carvedilol phosphate 
were mixed in equal proportion were mixed geometrically and analyzed for 
DSC. 
 
DSC curves were obtained by a differential scanning calorimeter (DSC 60, 
TA-60WS, Shimadzu, Japan) at a heating rate of 10°C/min from 30 to 300°C 
in an air atmosphere. 
 
 
Results 
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5. RESULTS 
5.1 High Performance Liquid Chromatography (HPLC) method Validation 
5.1.1 Atorvastatin Calcium 
The various parameters were used to validate the HPLC methods for 
validation of atorvastatin calcium i.e. system suitability, linearity, accuracy and 
precision, intraday accuracy and precision, interday accuracy and precision, 
recovery, limit of detection, limit of quantification and specificity. 
 
TABLE 5.1: System suitability of atorvastatin calcium  
 
 
TABLE 5.2: Back calculated concentration of calibration standards from 
calibration curve of atorvastatin calcium 
 
LINEARITY 
(n=6) 
Concentration (µg/ml) 
CS-1 CS-2 CS-3 CS-4 CS-5 CS-6 CS-7 CS-8 CS-9 
1.000 2.000 4.000 8.000 16.000 32.000 64.000 128.000 188.000 
Mean (n=6) 1.022 2.000 3.980 7.888 15.821 31.165 63.242 125.836 191.287 
% Nominal 
 conc. 102.18 99.99 99.49 98.60 98.88 97.39 98.82 98.31 101.75 
SD 0.039 0.064 0.126 0.242 0.370 1.190 2.527 3.329 3.509 
% CV 3.85 3.22 3.17 3.06 2.34 3.82 4.00 2.65 1.83 
 
 
 
Sr. No. AREA (mAU)  Area Ratio Atorvastatin Ca. Diclofenac Na. 
1 684181 152364 4.49 
2 700451 155640 4.50 
3 698996 155075 4.51 
4 701376 154022 4.55 
5 698688 154081 4.53 
6 696738 154236 4.52 
N 6 
Mean 4.517 
SD 0.023 
% CV 0.517 
Results 
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FIGURE 5.1: Calibration curve for atorvastatin calcium 
TABLE 5.3: Intraday accuracy and precision of atorvastatin calcium  
Concentration 
LLOQ 
 (1.00 
µg/ml) 
LQC  
(3.00 
µg/ml) 
MQC 
 (24.00 
µg/ml) 
HQC  
(158.00 
µg/ml) 
N 6 6 6 6 
Mean 1.060 3.137 24.667 157.588 
SD (n=2) 0.022 0.018 0.461 0.953 
% CV 2.07 0.58 1.87 0.60 
% Nominal conc. 105.957 104.558 102.781 99.739 
 
TABLE 5.4: Interday accuracy and precision of atorvastatin calcium  
Concentration 
LLOQ  
(1.00 
µg/ml) 
LQC  
(3.00 µg/ml) 
MQC  
(24.00 
µg/ml) 
HQC  
(158.00 
µg/ml) 
N 30 30 30 30 
Mean 1.092 3.168 24.549 159.429 
SD (n=6) 0.027 0.030 0.637 4.668 
% CV 2.46 0.96 2.59 2.93 
% Nominal 
 conc. 109.238 105.614 102.287 100.904 
 
 
 
 
Straight line equation                      : y = 0.039 х Conc. – 0.029 
Correlation coefficient (r)                : 0.9995 
Slope                                               : 0.039 
Intercept                                        :                 -0.029 
Atorvastatin calcium calibration curve 
Results 
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TABLE 5.5: Recovery of atorvastatin calcium 
Concent-
ration 
LQC (3.000 µg/ml) MQC (24.000 µg/ml) HQC (158.000 µg/ml) 
Aqueous 
Sample 
Extracted 
Sample 
Aqueous 
Sample 
Extracted 
Sample 
Aqueous 
Sample 
Extracted 
Sample 
Mean (n=6) 344297 266283 1166977 949579 2357307 1917789 
SD  13406 1873 27020 13288 30719 11472 
% CV 3.89 0.70 2.32 1.40 1.30 0.60 
% Recovery 77.341 81.371 81.361 
 
 
TABLE 5.6: Recovery variability across QC levels of atorvastatin calcium 
                     
 
 
 
 
 
 
 
TABLE 5.7: Recovery of diclofenac sodium  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QC LEVELS % Recovery 
LQC 77.34 
MQC 81.37 
HQC 81.36 
Mean 80.02 
SD 2.322 
% CV 2.90 
Concentration 
Diclofenac Na (70 µg/ml) 
Aqueous 
Sample 
Extracted 
Sample 
Mean (n=18) 171057 131163 
SD  2949 3295 
% CV 1.72 2.51 
% Recovery 76.678 
Results 
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TABLE 5.8: Summary of validation parameters of atorvastatin calcium 
 
 
 
5.1.2 Carvedilol phosphate  
The various parameters were used to validate the HPLC methods for 
validation of carvedilol phosphate i.e. system suitability, linearity, accuracy 
and precision, intraday accuracy and precision, interday accuracy and 
precision, recovery, limit of detection, limit of quantification, specificity,  
 
TABLE 5.9: System suitability of carvedilol phosphate  
Sr. No. AREA (mAU)  Carvedilol Diclofenac Na Area Ratio 
1 85167 113849 0.75 
2 85604 112628 0.76 
3 86414 116732 0.74 
4 85508 115863 0.74 
5 86489 115752 0.75 
6 85535 117860 0.73 
N 6 
Mean 0.743 
SD 0.012 
% CV 1.551 
Sr. No. Parameter Results 
1 
 
 
 
Linearity Range  1.000 µg-188 µg  
Co-relation Coefficient 0.9995 
Slope 0.039 
Intercept  -0.029 
2 
  
  
Precision (% CV)   
                      Interday LLOQ-2.46, LQC-0.96,  MQC-2.59, HQC-2.93 
                      Intraday LLOQ-2.07, LQC-0.58,  MQC-1.87, HQC-0.60 
3 Limit of Detection  0.500 µg  
4 Limit of Quantification  1.000 µg 
5 
  
  
Accuracy ( % Recovery)   
Atorvastatin 80.02 %, % CV-2.90 
Diclofenac Sodium 76.678 % 
6 Specificity  Specific  
7 Retention time   
  Atorvastatin calcium 6.20 ± 0.5 
  Diclofenac sodium  8.92 ± 0.5  
Results 
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TABLE 5.10: Back calculated concentration of calibration standards from  
calibration curve of carvedilol phosphate 
LINEARITY 
Concentration (µg/ml) 
CS-1 CS-2 CS-3 CS-4 CS-5 CS-6 CS-7 CS-8 CS-9 
0.500 1.000 4.000 8.000 16.000 32.000 64.000 128.000 208.000 
Mean (n=6) 0.498 0.917 4.023 8.381 16.040 29.430 64.678 127.218 208.494 
% Nominal 
 conc. 99.50 91.69 100.58 104.76 100.25 91.97 101.06 99.39 100.24 
SD 0.009 0.022 0.087 0.281 0.072 0.895 0.306 1.234 1.388 
% CV 1.71 2.41 2.16 3.35 0.45 3.04 0.47 0.97 0.67 
 
 
TABLE 5.11: Intraday accuracy and precision of carvedilol phosphate 
 
Concentration 
LLOQ 
 (0.500 
µg/ml) 
LQC 
 (0.750 
µg/ml) 
MQC 
 (24.00 
µg/ml) 
HQC  
(96.00 
µg/ml) 
N 6 6 6 6 
Mean 0.496 0.748 23.919 96.445 
SD (n=6) 0.008 0.013 0.161 1.275 
% CV 1.66 1.74 0.67 1.32 
% Nominal conc. 99.183 99.722 99.663 100.464 
 
 
Straight line equation                 : y = 0.027 х Conc. +0.163 
Correlation coefficient (r)            : 0.9996 
Slope                                          : 0.027 
Intercept                                     :                 0.163 
FIGURE 5.2: Calibration curve for carvedilol phosphate 
 
Carvedilol phosphate calibration curve 
Results 
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TABLE 5.12: Interday accuracy and precision of carvedilol phosphate 
 
Concentration 
LLOQ 
 (0.500 
µg/ml) 
LQC 
 (0.750 
µg/ml) 
MQC 
 (24.00 
µg/ml) 
HQC  
(96.00 µg/ml) 
N 30 30 30 30 
Mean 0.481 0.739 24.171 95.948 
SD (n=6) 0.014 0.020 0.337 1.702 
%CV 2.88 2.76 1.39 1.77 
%Nominal 
conc. 96.183 98.593 100.714 99.946 
 
 
TABLE 5.13: Recovery of carvedilol phosphate 
 
Concentration 
LQC  
(0.750 µg/ml) 
MQC  
(24.00 µg/ml) 
HQC  
( 96.00 µg/ml) 
Aqueous 
Sample 
Extracted 
Sample 
Aqueous 
Sample 
Extracted 
Sample 
Aqueous 
Sample 
Extracted 
Sample 
Mean (n=6) 5726 4912 85710 75470 315490 273177 
SD  144 147 809 568 2626 6676 
% CV 2.51 2.99 0.94 0.75 0.83 2.44 
% Recovery 85.78 88.05 86.81 
 
TABLE 5.14: Recovery variability across QC Levels of carvedilol phosphate          
 
 
QC LEVELS % Recovery 
LQC 85.78 
MQC 88.05 
HQC 86.59 
Mean 86.81 
SD 1.151 
% CV 1.33 
 
 
TABLE 5.15: Recovery of diclofenac sodium 
 
 
Concentration 
Diclofenac Na (60 µg/ml) 
Aqueous 
Sample 
Extracted 
Sample 
Mean (n=6) 121105 100355 
SD  11656 3550 
% CV 9.62 3.54 
% Recovery 82.86 
 
 
Results 
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TABLE 5.16: Summary of validation parameters of carvedilol phosphate 
 
 
 
5.1.3 Sildenafil citrate 
The various parameters were used to validate the HPLC methods for 
validation of sildenafil citrate i.e. system suitability, linearity, accuracy and 
precision, intraday accuracy and precision, interday accuracy and precision, 
recovery, limit of detection, limit of quantification, specificity.  
 
TABLE 5.17: Precision data for replicate injection of sildenafil citrate 
Sr. no. Retention time Peak area (mAU) 
1 5.33 454668 
2 5.33 453225 
3 5.33 454110 
4 5.32 455263 
5 5.33 452148 
6 5.33 452197 
n 6 
Mean 453601.83 
SD 1294.88 
% CV 0.86 
 
 
SR. No. Parameter Results 
1 
 
 
 
Linearity range  0.500 µg-208.000 µg  
Co-relation coefficient 0.9996 
Slope 0.027 
Intercept  0.163 
2 
  
  
Precision (% CV)   
                                Intraday 
 
LLOQ-1.66, LQC-1.74,  
MQC-0.67, HQC-1.32 
                                Interday 
 
LLOQ-2.88, LQC-2.76,  
MQC-1.39, HQC-1.77 
3 Limit of detection  0.250 µg  
4 Limit of quantification  0.500 µg 
5 
  
  
Accuracy ( % Recovery)   
Carvedilol 86.81 %, % CV-1.33 
Diclofenac sodium 82.86 % 
6 Specificity  Specific  
7 Retention time   
  Carvedilol phosphate 2.78 ± 0.5 
  Diclofenac sodium  8.32 ± 0.5  
Results 
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TABLE 5.18: Calibration data for sildenafil citrate 
 
Sr. No. Conc. of sildenafil citrate (µg/ml) Mean Area ± SD (n=6) % CV 
1 0.1 004110.60 ± 00043.53 1.06 
2 0.3 005184.01 ± 00155.04 2.99 
3 0.6 006093.60 ± 00154.94 2.54 
4 1.2 016792.40 ± 00145.55 0.87 
5 2.4 034556.07 ± 00586.73 1.70 
6 5.0 088044.12 ± 00449.59 0.51 
7 20 352208.60 ± 05494.92 1.56 
8 50 890154.40 ± 11724.92 1.32 
 
 
 
Straight line equation Y =117845 х Conc. – 2912 
Correlation coefficient (r) 0.999 
Slope 17845 
Intercept 2912 
 
FIGURE 5.3: Calibration curve for sildenafil citrate 
TABLE 5.19: Intraday precision data for sildenafil citrate 
Sr. no Conc. of sildenafil citrate (µg/ml) Mean area ± SD (n=6) % CV 
1 0.1 004110.60 ± 00043.53 1.06 
2 0.3 005184.01 ± 00155.04 2.99 
3 0.6 006093.60 ± 00154.94 2.54 
4 1.2 016792.40 ± 00145.55 0.87 
5 2.4 034556.07 ± 00586.73 1.70 
6 5.0 088044.12 ± 00449.59 0.51 
7 20 352208.60 ± 05494.92 1.56 
8 50 890154.40 ± 11724.92 1.32 
 
Calibration curve of sildenafil citrate 
Results 
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TABLE 5.20: Interday precision data for sildenafil citrate  
Sr. no Conc. of sildenafil citrate (µg) Mean area ± SD (n=6) % CV 
1 0.1 004209.49 ± 0152.44 3.62 
2 0.3 005259.68 ± 0153.03 2.91 
3 0.6 006203.50 ± 0162.12 2.61 
4 1.2 016765.77 ± 0249.96 1.49 
5 2.4 034553.59 ± 0262.30 0.76 
6 5.0 088168.28 ± 0324.04 0.37 
7 20 352327.90 ± 3303.69 0.86 
8 50 892792.16 ± 5035.35 0.56 
  
TABLE 5.21: Recovery data for sildenafil citrate 
Conc. of sildenafil 
citrate Taken 
(µg/ml) 
 
Conc. recovered 
(mean ) ± SD 
(µg/injection) 
(n=6) 
 
Accuracy 
± CV (%) 
 
STD 8 49.87 ± 2.14 99.74 ± 0.24 
STD 4 1.17 ± 3.46 98.33 ± 1.46 
 
TABLE 5.22: Summary of validation parameters 
r. No. Parameters Results 
1 Linearity range 0.1-50 µg 
2 Co-relation coefficient 0.999 
3 
Precision % CV 
          Interday 
 
          Intraday 
 
LLOQ-0.37, LQC-3.61 
 
LLOQ-0.51, LQC-2.99 
4 Repeatability 0.29 % 
5 Limit of detection 0.1 µg 
6 Limit of duantification 0.1 µg 
7 Accuracy ( % Recovery) 99.74%, CV-0.83 % 
8 Specificity Specific 
 
 
 
 
Results 
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5.1.4 Zidovudine 
The various parameters were used to validate the HPLC methods for 
validation of zidovudine i.e. system suitability, linearity, accuracy and 
precision, intraday accuracy and precision, interday accuracy and precision, 
recovery, limit of detection, limit of quantification, specificity.  
 
TABLE 5.23: Precision data for replicate injection of zidovudine 
Sr. NO. Retention time (min) Peak area (mAU) 
1 3.36 1321039 
2 3.36 1317146 
3 3.36 1336097 
4 3.37 1315986 
5 3.36 1320061 
6 3.36 1334145 
n 6 
Mean 1324079 
SD 8771.61 
% CV 0.66 
  
TABLE 5.24: Calibration data for zidovudine 
Sr. no Conc. of zidovudine  (µg/ml) Mean Area ± SD (n=6) % CV 
1 0.1 0007408.63 ± 000103.02 1.39 
2 0.3 0015293.40 ± 000274.23 1.79 
3 0.6 0039986.04 ± 001616.64 4.04 
4 1.2 0075354.20 ± 002755.47 3.36 
5 2.4 0157036.47 ± 007153.23 4.56 
6 5.0 0318604.48 ± 014268.97 4.48 
7 20 1310639.18 ± 029247.25 2.23 
8 50 3193729.25± 153794.83 4.82 
 
Results 
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Straight line equation Area=64030 х Conc. + 2662 
Correlation coefficient (r) 0.999 
Slope 64030 
Intercept 2662 
 
FIGURE 5.4: Calibration curve for zidovudine 
TABLE 5.25: Intraday precision data for zidovudine 
Sr. no. Conc. of zidovudine  (µg/ml) Mean area ± SD (n=6) % CV 
1 0.1 0007408.63 ± 000103.02 1.39 
2 0.3 0015293.40 ± 000274.23 1.79 
3 0.6 0039986.04 ± 001616.64 4.04 
4 1.2 0075354.20 ± 002755.47 3.36 
5 2.4 0157036.47 ± 007153.23 4.56 
6 5.0 0318604.48 ± 014268.97 4.48 
7 20 1310639.18 ± 029247.25 2.23 
8 50 3193729.25± 153794.83 4.82 
 
TABLE 5.26: Interday precision data for zidovudine 
Sr. no. Conc. of zidovudine   (µg/ml)  Mean area ± SD (n=6) % CV 
1 0.1 0007347.38 ± 000051.00 0.69 
2 0.3 0015474.67 ± 000161.23 1.04 
3 0.6 0038882.07  ±  00572.07 1.47 
4 1.2 0073580.00 ± 001838.45 2.50 
5 2.4 0152746.12 ± 003010.78 1.97 
6 5.0 0320903.14 ± 013040.03 4.06 
7 20 1324899.30 ± 028514.79 2.15 
8 50 3232159.74 ± 158357.91 4.90 
 
Zidovudine calibration 
  
Results 
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TABLE 5.27: Recovery data for zidovudine 
Conc. of zidovudine 
 taken (µg/ml) 
 
Conc. recovered 
(mean ) ± SD 
(µg/injection) 
(n=6) 
 
Accuracy 
± % CV 
 
STD 8 49.87 ± 2.14 98.87 ± 0.26 
STD 4 1.17 ± 3.46 99.53 ± 1.16 
 
TABLE 5.28: summary of validation parameters of zidovudine  
Sr. No. Parameters Results 
1 Linearity Range 0.1-50 µg 
2 Co-relation Coefficient 0.999 
3 
Precision  % CV 
            Interday 
 
            Intraday 
 
 
LLOQ-0.69, LQC 4.90 
 
LLOQ-1.39, LQC-4.82 
 
4 Repeatability 0.66 % 
5 Limit of Detection 0.1 µg 
6 Limit of Quantification 0.1 µg 
7 Accuracy ( % Recovery) 99.70, CV-0.71 % 
8 Specificity Specific 
 
5.2 In vivo bioavailability study 
5.2.1  Atorvastatin calcium 
5.2.1.1 Effect of silymarin as absorption enhancer 
The method was applied to a bioavailability study for examining the influence 
of the co-administration of silymarin on the absorption of findings of the 
pharmacokinetic studies were shown in Tab. 5.29 and plasma concentration 
profile at different time intervals was depicted in Fig. 5.5  
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FIGURE 5.5: Mean plasma concentration-time profiles of atorvastatin calcium  
following oral (75 mg/kg) administration to rats in the presence and absence of  
silymarin (mean ± SEM, n=6).   : Control (atorvastatin calcium 75 mg/kg, oral).   ::  
Subsequent administration of 100 µm of silymarin with atorvastatin calcium 
 
TABLE 5.29: Mean pharmacokinetic parameters of the atorvastatin calcium 
following oral (75 mg/kg) administration to rats in the presence and absence 
of silymarin (mean ± SEM, n=6). 
 
Parameters 
Atorvastatin  
(75 mg/kg) 
 (control) 
Atorvastatin   
(75 mg/kg) 
+ Silymarin  
(100  µmol) 
% Increase of 
 Bioavailability 
Tmax (min) 35 35 32.31% Cmax (µg/ml) 3.921 ± 0.098 5.188 ± 0.035*** 
***p<0.001, significantly different from control (Atorvastatin calcium) 
 
5.2.1.2 Effect of naringin as absorption enhancer 
Same as above the method was applied to a bioavailability study for 
examining the influence of the co-administration of naringin on the absorption 
of atorvastatin calcium. Findings of the pharmacokinetic studies were shown 
in Tab. 5.30 and the plasma concentration profile at different time intervals 
was depicted in Fig. 5.6.  
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FIGURE 5.6: Mean plasma concentration-time profiles of atorvastatin calcium 
following oral (75 mg/kg) administration to rats in the presence and absence of 
naringin (mean ± SEM, n=6).    : Control (atorvastatin calcium 75 mg/kg, oral).     : 
Subsequent administration of 100 µm of naringin with atorvastatin. 
 
TABLE 5.30: Mean pharmacokinetic parameters of atorvastatin calcium  
following oral (75 mg/kg) administration to rats in the presence and absence 
of naringin (mean ± SEM, n=6). 
 
Parameters 
Atorvastatin  
(75 mg/kg) 
 (control) 
Atorvastatin   
(75 mg/kg) 
+ Naringin  
(100 µmol)  
% Increase of 
 Bioavailability 
Tmax (min)  35 35 19.66% 
Cmax (µg/ml)  3.921±0.098  4.692±0.0298***  
***p<0.001, significantly different from control (Atorvastatin calcium) 
 
5.2.1.3 Effect of morin as absorption enhancer 
Same as above the method was applied to bioavailability study for examining 
the influence of co-administration of morin on the absorption of atorvastatin 
calcium. Findings of the pharmacokinetic studies were shown in Tab. 5.31 
and the plasma concentration profile at different time intervals was depicted in 
Fig. 5.8.  
Results 
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FIGURE 5.7: Mean plasma concentration-time profiles of atorvastatin calcium  
following oral (75 mg/kg) administration to rats in the presence and absence of morin  
(mean ± SEM, n=5).    : Control (Atorvastatin calcium 75 mg/kg, oral).    : Subsequent  
administration of 100 µm of morin with Atorvastatin. 
 
TABLE 5.31: Mean pharmacokinetic parameters of atorvastatin calcium  
following oral (75 mg/kg) administration to rats in the presence and absence 
of morin (mean ± SEM, n=6). 
 
Parameters 
Atorvastatin  
(75 mg/kg) 
(control) 
Atorvastatin   
(75 mg/kg) +  
Morin (100 µmol)  
% Increase of 
Bioavailability 
Tmax (min)  35 35 -14.23% Cmax (µg/ml)  3.921 ± 0.098  3.363 ± 0.011 
 
Results 
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FIGURE 5.8: Comparison of atorvastatin calcium with HAPs 
 
From the experimental analysis the results indicates that the silymarin and 
naringin significantly increase the concentration of drug in rat blood plasma 
while morin not increase significantly  the concentration of drug in rat blood 
plasma, as compare to control (Atorvastatin Calcium).  
 
5.2.2 Carvedilol Phosphate 
5.2.2.1 Effect of silymarin as absorption enhancer  
The method was applied to a bioavailability study for examining the influence 
of the co-administration of silymarin on the absorption of carvedilol. Findings 
of the pharmacokinetic studies were shown in the Tab. 5.32 and the plasma 
concentration profile at different time intervals was depicted in Fig. 5.9.  
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FIGURE 5.9: Mean plasma concentration-time profiles of carvedilol following                                               
oral (75 mg/kg) administration to rats in the presence and absence of  
silymarin (mean ± SEM, n=6).   : Control (Carvedilol 60 mg/kg, oral) .   :  
Subsequent administration of 100 µm of silymarin with carvedilol phosphate 
 
TABLE 5.32: Mean pharmacokinetic parameters of carvedilol following oral  
(60mg/kg) administration to rats in the presence and absence of silymarin  
(mean ± SEM, n=6). 
***p<0.001, significantly different from control (Carvedilol) 
 
5.2.2.2 Effect of naringin as absorption enhancer 
Same as above the method was applied to a bioavailability study for 
examining the influence of the co-administration of naringin on the absorption 
of carvedilol. Findings of the pharmacokinetic studies were shown in Tab. 
5.33 and the plasma concentration profile at different time intervals is depicted 
in Fig. 5.10.  
Parameters 
Carvedilol  
(60 mg/kg) 
(control) 
Carvedilol   
(60 mg/kg)+ 
Silymarin  
(100  µmol) 
% Increase of 
Bioavailability 
Tmax (min) 95 95 
31.95 Cmax 
(µg mL−1) 9.517±0.290 12.558±0.305*** 
Results 
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FIGURE 5.10: Mean plasma concentration-time profiles of carvedilol following  
oral (60 mg/kg) administration to rats in the presence and absence of  
naringin (mean ± SEM, n=5).   : Control (Carvedilol 60 mg/kg, oral).     :  
Subsequent administration of 100 µm of naringin with carvedilol phosphate 
 
TABLE 5.33: Mean pharmacokinetic parameters of carvedilol following oral  
(60 mg/kg) administration to rats in the presence and absence of naringin  
(mean ± SEM, n=6). 
Parameters 
Carvedilol  
(60 mg/kg) 
(control) 
Carvedilol  (60 
mg/kg)+ Naringin 
(100  µmol)  
% Increase of 
Bioavailability 
Tmax 95  (min) 95 28.01 Cmax (µg mL−1 9.517±0.290 ) 12.183±0.110*** 
***p<0.001, significantly different from control (Carvedilol) 
 
5.2.2.3 Effect of morin as absorption enhancer 
Same as above the method was applied to bioavailability study for examining 
the influence of the co-administration of morin on the absorption of Carvedilol. 
Findings of the pharmacokinetic studies were shown in TABLE 5.34 and the 
Plasma concentration profile at different time intervals is depicted in Figure 
5.11.  
Results 
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FIGUE 5.11:Mean plasma concentration-time profiles of Carvedilol following oral  
(60 mg/kg) administration to rats in the presence and absence of morin (mean ±  
SEM, n=6).    : Control (Carvedilol 60 mg/kg, oral).   : Subsequent administration of  
100 µm of morin with carvedilol 
 
TABLE 5.34: Mean pharmacokinetic parameters of Carvedilol following oral  
(75 mg/kg) administration to rats in the presence and absence of Morin  
(mean ± SEM, n=6). 
 
Parameters Carvedilol (60 mg/kg) (control) 
Carvedilol  (75 
mg/kg)+ Morin 
(100  µmol)  
% Increase of 
Bioavailability 
Tmax 95  (min) 95 
5.67 Cmax (µg mL−1 9.517±0.290 ) 10.057±0.145** 
**p<0.01, significantly different from control (Carvedilol) 
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FIGURE 5.12: Comparison of carvedilol HAPs 
From the experimental analysis the results indicates that the Silymarin, 
Naringin and Morin significantly increase the concentration of drug in rat blood 
plasma, as compare to control (Carvedilol).  
 
5.2.3 Sildenafil citrate 
5.2.3.1 Effect of silymarin as absorption enhancer 
The method was applied to a bioavailability study for examining the influence 
of the co-administration of silymarin on the absorption of sildenafil citrate. 
Findings of the pharmacokinetic studies were shown in Tab. 5.35 and the 
Plasma concentration profile at different time intervals is depicted in Fig. 5.13.  
 
Results 
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FIGURE 5.13: Mean plasma concentration–time profiles of sildenafil citrate  
following oral (30 mg/kg) administration to rats in the presence and absence of  
silymarin (mean + S.D., n = 5).    : Control (Sildenafil citrate 30 mg/kg, oral)     :  : 
Subsequent administration of 100 µm of silymarin 
 
Table 5.35: Mean pharmacokinetic parameters of sildenafil citrate following an 
oral (30 mg/kg) administration of sildenafil citrate to rats in the presence and 
absence of silymarin (mean ± SD, n = 6)  
Parameters 
Sildenafil 
Citrate  
(30 mg/kg) 
 (control) 
Sildenafil 
Citrate  
(30 mg/kg) + 
Silymarin 
 
% Increase of 
Bioavailability 
Tmax 40  (min) 40  
24.88 % 
 Cmax 1.049 ± 0.881  (µg/ml) 1.310 ± 0.765** 
    **p<0.01, significantly different from control (Carvedilol) 
 
5.2.3.2 Effect of morin as absorption enhancer 
Same as above method, the method was applied to a bioavailability study for 
examining the influence of the co-administration of morin on the absorption of 
sildenafil citrate. Findings of the pharmacokinetic studies were shown in the 
Tab. 5.36 and the Plasma concentration profile at different time intervals is 
depicted in Fig. 5.14.  
Sildenafil citrate + Silymarin 
Results 
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 FIGURE 5.14: Plasma concentration–time profiles of sildenafil citrate following oral  
 (30 mg/kg) administration to rats in the presence and absence of morin (mean ±   
 SD, n = 6).     :Control (Sildenafil citrate 30 mg kg−1
Parameters 
, oral);     :Subsequent  
 administration of 100 µm of morin. 
 
TABLE 5.36: Mean pharmacokinetic parameters of sildenafil citrate following  
an oral (30 mg/kg) administration of Sildenafil to rats in the presence and  
absence of morin (mean ± SD, n = 6)  
Sildenafil citrate 
(30 mg/kg) 
(control) 
Sildenafil citrate 
(30 mg/kg) 
 + Morin 
 
% Increase of 
Bioavailability 
Tmax 40  (min) 40  
11.09 % 
 Cmax 1.049 ± 0.881  (µg/ml) 1.154 ± 0.347 ** 
**p<0.01, significantly different from control (Carvedilol) 
 
5.2.3.3 Effect of naringin as absorption enhancer 
Same as above methods, the method was also applied to a bioavailability 
study for examining the influence of the co-administration of naringin on the 
absorption of sildenafil citrate. Findings of the pharmacokinetic studies and 
the plasma concentration profile at different time intervals was depicted in the 
Tab. 5.37 and Fig. 5.15 respectively.  
Sildenafil citrate + Morin 
Results 
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 FIGURE 5.15: Mean plasma concentration–time profiles of sildenafil citrate 
following oral (30 mg/kg) administration to rats the presence and absence of  
naringin (mean ±  SD, n = 6).   : Control (Sildenafil citrate 30 mg/kg, oral);     : 
Subsequent administration of 100 µm of naringin. 
TABLE 5.37: Mean pharmacokinetic parameters of sildenafil citrate following 
an oral (30 mg/kg) administration of sildenafil to rats in the presence and 
absence of naringin (mean ± SD, n = 6)  
Parameters 
Sildenafil citrate 
(30mg/kg) 
(control) 
Sildenafil citrate 
(30mg/kg) +  
Naringin 
 
% Increase of 
Bioavailability 
Tmax 40  (min) 40  
-1.90% 
Cmax 1.049 ± 0.881  (µg/ml) 
 
1.029 ± 0.245* 
 
*p>0.05, significantly not different from control (Carvedilol) 
 
 
 
Sildenafil citrate + Naringin 
Results 
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 FIGURE 5.16: Comparison of sildenafil citrate with HAPs 
 
5.2.4 Zidovudine 
5.2.4.1 Effect of naringin as absorption enhancer 
Same as above methods, the method was applied to a bioavailability study for 
examining the influence of the co-administration of Naringin on the absorption 
of Zidovudine. Findings of the pharmacokinetic studies and the plasma 
concentration profile at different time intervals was depicted in Tab. 5.38 and 
Fig. 5.17 respectively.  
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FIGURE 5.17:Mean plasma concentration–time profiles of zidovudine  
following oral (75 mg/kg) administration to rats in the presence and  
absence of naringin (mean ± S.D., n = 6).   :Control (Zidovudine 75  
mg/kg, oral);     : Subsequent administration of 100 µm of naringin. 
 
TABLE 5.38: Mean pharmacokinetic parameters of zidovudine following an  
oral (75 mg/kg) administration of zidovudine to rats in the presence and  
absence of naringin (mean ± SD, n = 6)  
Parameters 
Zidovudine 
(75mg/kg) 
(control) 
Zidovudine 
(75mg/kg)   
+ Naringine 
 
% Increase of 
Bioavailability 
Tmax 35  (min) 35  
60.49% 
 Cmax 5.407± 0.557  (µg/ml) 8.678 ± 0.231** 
**p<0.01, significantly different from control (Zidovudine) 
 
5.2.4.2 Effect of silymarin as absorption enhancer 
Same as above methods, for examining the influence of the co-administration 
of silymarin on the absorption of zidovudine in bioavailability study this 
method was used. Findings of the pharmacokinetic studies and the Plasma 
Zidovudine + Naringin 
Results 
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concentration profile at different time intervals is depicted in Tab. 5.39 and 
Fig. 5.18 respectively.  
 
 
FIGURE 5.18: Mean plasma concentration–time profiles of zidovudine  
 following oral (75 mg/kg) administration to rats in the presence  and absence    
 of silymarin (mean ± SD, n = 6).      : Control (Zidovudine 75 mg/kg, oral)      
   : : Subsequent administration of 100 µm of silymarin 
 
TABLE 5.39: Mean pharmacokinetic parameters of zidovudine following an 
oral (75 mg/kg) administration of zidovudine to rats in the presence and 
absence of silymarin (mean ± SD, n = 6)  
Parameters 
Zidovudine 
(75mg/kg) 
(control) 
Zidovudine 
(75mg/kg)  
+ Silymarin 
 
% Increase of 
Bioavailability 
Tmax 35  (min) 35  
28.31 % 
 
Cmax 5.407± 0.557  (µg/ml) 6.938 ± 0.433** 
**p<0.01, significantly different from control (Zidovudine) 
 
 
 
 
Zidovudine + Silymarin 
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5.2.4.3 Effect of morin as absorption enhancer 
As like above methods, this method also applied for examining the influence 
of the co-administration of morin the absorption of zidovudine in bioavailability 
study. Findings of the pharmacokinetic studies and the plasma concentration 
profile at different time intervals was depicted in Tab. 5.40 and Fig. 5.19 
respectively.  
 
FIGURE 5.19: Mean plasma concentration–time profiles of zidovudine   
following oral (75 mg/kg) administration to rats in the presence and absence 
of  morin (mean ± SD, n = 6).     : Control (Zidovudine 75 mg/kg, oral);     : 
Subsequent administration of 100 µm of morin. 
 
TABLE 5.40: Mean pharmacokinetic parameters of zidovudine following an 
oral (75 mg/kg) administration of zidovudine to rats in presence and absence 
of morin (mean ± SD, n = 6)  
Parameters 
Zidovudine  
(75 mg/kg) 
(control) 
Zidovudine  
(75 mg/kg) 
+ Morin 
 
% Increase of 
Bioavailability 
Tmax 35  (min) 35 16.17% 
Cmax 5.407 ± 0.557  (µg/ml) 6.219 ± 0.453** 
**p<0.01, significantly different from control (Zidovudine) 
 
Zidovudine + Morin 
Results 
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FIGURE 5.20: Comparison of zidovudine HAPs 
 
5.3 In vitro cytotoxicity studies by SRB assay 
The three HAPs named silymarin, morin and naringin were selected for the 
study of its cytotoxicity against colon cancer cell line (HCT-15) and breast 
cancer cell line (MCF-7) by SRB assay method. 
 
5.3.1 In vitro cytotoxicity of HAPs against human cancer cell lines 
The three HAPs named silymarin, morin and naringin were selected for the 
study. In vitro cytotoxicity against two human cancer cell lines was determined 
(Monks et al., 1991) using 96-well tissue culture plates. The 100 µl of cell 
suspension was added to each well of the 96-well tissue culture plate. The 
cells were allowed to grow in carbon dioxide incubator (37 °C, 5 % CO2
 
, 90 % 
RH) for 24 hr.  
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TABLE 5.41: In vitro cytotoxicity of HAPs against human cancer cell lines 
 
Treatment 
 
Conc. 
(µmol) 
% Growth inhibition 
HCT-15 MCF-7 HCT-15 MCF-7 
Incubation  Time 24 hr 48 hr 
Silymarine 25 8 10 0 1 
 50 13 15 9 12 
 100 0 8 10 18 
 200 7 25 10 28 
      
Morine 25 10 8 0 0 
 50 3 11 6 0 
 100 1 17 0 9 
 200 0 19 0 19 
      
Naringin 25 5 15 9 5 
 50 13 8 0 6 
 100 20 14 0 11 
 200 19 2 0 0 
      
5-FU 10 42 53 72* 92* 
Tamoxifen 10 39 67 91* 89* 
* If % growth of cell was inhibited more than 70% than results are believed to be 
significant and compound was cytotoxic 
 
5.4 In Vitro Enzyme Activity 
5.4.1 In vitro Pgp-ATPase activity 
P-gp-dependent ATPase activity was measured by determining vanadate- 
sensitive release of inorganic phosphate (Pi) from ATP as reported earlier 
(Hrycyna et al., 1998). 
 
TABLE 5.42: In vitro Pgp-ATPase activity of silymarin 
Parameters Control Silymarin 
10 µmol 
Silymarin 
30 µmol 
Silymarin 
100 µmol 
Mean 0.584 0.376* 0.305333* 0.301** 
SD 
 
0.118013 0.089939 0.083201 0.026058 
SEM 
 
 
0.068137 0.051928 0.048037 0.015045 
           *P<0.05 & ** P<0.01, Significant different from control (Dunnett’s test) 
 
Results 
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FIGURE 5.21: In vitro Pgp-ATPase activity of silymarin 
TABLE 5.43: In vitro Pgp-ATPase activity of naringin 
Parameters Control Naringin  
10 µmol 
Naringin 
30 µmol 
Naringin 
100 µmol 
Mean 0.584 0.202667*** 0.176*** 0.11*** 
SD 
 
0.118013 0.032716 0.032078 0.022068 
SEM 
 
 
0.068137 0.018889 0.018521 0.012741 
  *** P<0.0001, highly significant different from control (Dunnett’s test)  
 
FIGURE 5.22: In vitro Pgp-ATPase activity of naringin 
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TABLE 5.44: In vitro Pgp-ATPase activity of morin 
Parameters Control Morin 
10 µmol 
Morin 
 30 µmol 
Morin 
100 µmol 
Mean 0.584 0.241333*** 0.169667*** 0.133667*** 
SD 
 
0.118013 0.034443 0.035247 0.050143 
SEM 
 
 
0.068137 0.019886 0.02035 0.028951 
        *** P<0.001, Highly significant different from control (Dunnett’s test)  
 
FIGURE 5.23: In vitro Pgp-ATPase activity of morin 
 
5.4.2 In vitro CYP 450 Enzyme studies 
Two measure subtract of CYP 1A1 (Benzopyrene Hydroxylase) and CYP 450 
3A4 (Erythromycin demethylase) were selected for the study and its activity 
was measured.  
 
5.4.3 CYP450 1A1Enzyme: Benzopyrene Hydroxylase Activity 
Microsomal benzopyrene hydroxylase (AHH) activity, AHH activity in tissue 
assayed as results was shown as below; 
 
TABLE 5.45: In vitro CYP450 1A1 enzyme activity of silymarin 
Parameters Control Silymarin 
10 µmol 
Silymarin 
30 µmol 
Silymarin 
100 µmol 
Mean 617.33 620.67 614.67† 616† † 
SD 
 
58.011 17.67 45.08 17.52 
SEM 
 
 
33.49393 10.20 28.03 10.12 
            †P>0.05, non significant different from control (Dunnett’s test) 
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FIGURE 5.24: In vitro CYP450 1A1 enzyme activity of silymarin 
TABLE 5.46: In vitro CYP450 1A1 enzyme activity of naringin 
Parameters Control Naringin 
10 µmol 
Naringin 
 30 µmol 
Naringin 
100 µmol 
Mean 617.33 490.66 402.00** † 343.33** 
SD 
 
58.01 72.29 75.90 41.48 
SEM 
 
 
33.49 41.74 43.82 23.95 
            †
 
FIGURE 5.25: In vitro CYP450 1A1 enzyme activity of naringin 
P>0.05, non significant different from control (Dunnett’s test) 
         **P<0.05, Significant different from control (Dunnett’s test) 
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TABLE 5.47: In vitro CYP450 1A1 enzyme activity of morin 
Parameters Control Morin 
10 µmol 
Morin 
 30 µmol 
Morin 
100 µmol 
Mean  617.33 580.33 512.67† 465.68† † 
SD 
 
58.01 39.11 104.51 81.82 
SEM 
 
 
33.49 22.58 60.34 47.24 
             †
 
FIGURE 5.26: In vitro CYP450 1A1 enzyme activity of morin 
 
5.4.3 CYP 450 3A4 enzyme: Erythromycin demethylase  
Erythromycin N-demethylation was determined by the earlier reported method 
(Tu et al., 1983). 
 
TABLE 5.48: In vitro CYP 450 3A4 enzyme activity of silymarin  
P>0.05, non significant different from control (Dunnett’s test) 
       
Parameters Control Silymarin 
10 µmol 
Silymarin 
30 µmol 
Silymarin 
100 µmol 
Mean 0.0438 0.0546 0.0669** † 0.05687** 
SD 
 
0.0006 0.0097 0.0076 0.0064 
SEM 
 
 
0.0003 0.0056 0.0044 0.0037 
            †P>0.05, non significant different from control (Dunnett’s test) 
         **P<0.05, Significant different from control (Dunnett’s test) 
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FIGURE 5.27: In vitro CYP 450 3A4 enzyme activity of silymarin 
TABLE 5.49: In vitro CYP 450 3A4 enzyme activity of naringin 
Parameters Control Naringin 
10 µmol 
Naringin 
 30 µmol 
Naringin 
100 µmol 
Mean 0.0438 0.0494 0.0544† 0.0481† † 
SD 
 
0.000651 0.0082 0.0062 0.0038 
SEM 
 
 
0.0003 0.0047 0.0035 0.0022 
            †
 
FIGURE 5.28: In vitro CYP 450 3A4 enzyme activity of naringin 
 
P>0.05, non significant different from control (Dunnett’s test) 
          
 
-24.80974
-52.73973
-29.83257
-60
-50
-40
-30
-20
-10
0
1
%
 ch
an
ge
 v
s c
on
tr
ol
Silymarin
10 umol
30 umol
100 umol
-12.86149
-24.27702
-9.969559
-30
-25
-20
-15
-10
-5
0
1
%
 ch
an
ge
 v
s c
on
tr
ol
Naringin
10 umol
30 umol
100 umol
Results 
 
Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat, India.   107 
 
TABLE 5.50: In vitro CYP 450 3A4 enzyme activity of morin 
Parameters Control Morin 
10 µmol 
Morin 
 30 µmol 
Morin 
100 µmol 
Mean 0.0438 0.0469 0.0534† 0.0533† † 
SD 
 
0.000651 0.0103 0.0088 0.0076 
SE 
 
 
0.0003 0.0059 0.0051 0.0044 
            †
  
FIGURE 5.29: In vitro CYP 450 3A4 enzyme activity of morin 
 
5.5 Primary compatibility study of herbal absorption 
promoters (HAPs) with drugs 
 In this study the IR spectra and DSC spectra were taken of selected drugs i.e. 
atorvastatin calcium, carvedilol phosphate, sildenafil citrate and zidovudine 
with each of the selected HAPs i.e. silymarin, naringin and morin along with 
individual spectra of each drug and HAPs. This will give a conformation about 
the compatibility of selected HAPs with the selected drugs and about the 
physical and chemical change occur due to interaction between them.   
 
 
 
 
P>0.05, non significant different from control (Dunnett’s test) 
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5.5.1 Infrared spectroscopic studies 
5.5.1.1 Herbal absorption promoters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SIL= Silymarin   NAR= Naringin   MOR= Morin 
FIGURE 5.30: FT-IR spectra of HAPs (i.e. silymarin, naringin and morin) 
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 5.5.1.2 Atorvastatin calcium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
ATV=Atorvastatin    ATV+SIL= Atorvastatin + Silymarin 
ATV+NAR= Atorvastatin + Naringin   ATV+MOR= Atorvastatin + Morin 
FIGURE 5.31: FT-IR spectra of atorvastatin and atorvastatin with HAPs 
(i.e. silymarin, naringin and morin) 
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5.5.1.3 Carvedilol phosphate 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
  
 
 
CRV=Carvedilol    CRV +NAR= Carvedilol +Naringin 
CRV +SIL= Carvedilol +Silymarin   CRV +MOR= Carvedilol +Morin 
 
FIGURE 5.32: FT-IR spectra of carvedilol and carvedilol with HAPs 
 (i.e. silymarin, naringin and morin) 
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5.5.1.4 Sildenafil citrate 
 
 Si = Sildenafil citrate    Si + S = Sildenafil citrate + Silymarin  
 Si + M = Sildenafil citrate + Morin  Si + N = Sildenafil citrate + Naringin  
 
FIGURE 5.33: FT-IR spectra of sildenafil and sildenafil with HAPs  
(i.e. silymarin, morin and naringin)       
                       
Results 
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5.5.1.5 Zidovudine 
 
 
 Z = Zidovudine    Z + S = Zidovudine + Silymarin  
 Z + M = Zidovudine + Morin  Z + N = Zidovudine + Naringin  
 
FIGURE 5.34: FT-IR spectra of zidovudine and zidovudine with HAPs         
(i.e. silymarin, morin and naringin) 
                        
Results 
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5.5.2 Differential scanning calorimetry 
5.5.2.1 Herbal absorption promoters 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5.35: DSC thermogram of HAPs (i.e. silymarin, naringin and morin) 
SILYMARIN 
NARINGIN 
MORIN 
Results 
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5.5.2.2 Atorvastatin calcium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ATV=Atorvastatin    ATV+SIL= Atorvastatin + Silymarin 
ATV+NAR= Atorvastatin + Naringin   ATV+MOR= Atorvastatin + Morin 
 
FIGURE 5.36: DSC thermogram of atorvastatin and atorvastatin with HAPs  
(i.e. silymarin, naringin and morin) 
ATV 
ATV+SIL 
ATV+NAR 
ATV+MOR 
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5.5.2.3 Carvedilol 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CRV=Carvedilol    CRV + NAR= Carvedilol + Naringin 
CRV + SIL= Carvedilol + Silymarin   CRV + MOR= Carvedilol + Morin 
 
FIGURE 5.37: DSC thermogram of carvedilol and carvedilol with HAPs 
(i.e. silymarin, naringin and morin) 
CRV 
CRV+SIL 
CRV+NAR 
CRV+MOR 
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5.5.2.4 Sildenafil citrate 
 
 
Si = Sildenafil citrate    Si + S = Sildenafil citrate + Silymarin  
Si + M = Sildenafil citrate + Morin  Si + N = Sildenafil citrate + Naringin  
 
FIGURE 5.38: DSC thermogram of sildenafil and Sildenafil with HAPs  
(i.e. silymarin, morin and naringin) 
 
Results 
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5.5.2.5 Zidovudine 
 
 
Z = Zidovudine     Z + S = Zidovudine + Silymarin  
Z + M = Zidovudine + Morin   Z + N = Zidovudine + Naringin  
 
FIGURE 5.39: DSC thermogram of zidovudine and zidovudine with HAPs  
(i.e. silymarin, morin and naringin) 
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6. DISCUSSION 
6.1 High Performance Liquid Chromatography (HPLC) Method Validation 
6.1.1 Atorvastatin calcium 
6.1.1.1 System suitability 
For the precision of replicate of injection, % CV obtained was 0.517 % (Tab. 5.1) 
and in to system suitability the limit of % CV is not more than 5 %.  So the % CV 
obtained from experimental analysis was within these criteria and on this basis 
method is precise for replicate of injection and suitable for system. 
 
6.1.1.2 Linearity 
The area ratio obtained of different concentration of atorvastatin calcium was 
used to plot a calibration curve of area ratio vs. concentration (µg/ml). Linearity 
range of atorvastatin calcium was found to be 1.0 - 188.0 µg with correlation co-
efficient of 0.9995 (Fig. 5.1). The linearity equation is y =0.039X x –0.029, where 
X is concentration of atorvastatin calcium and Y is Area Ratio. Fig. 5.1 shows the 
calibration curve of atorvastatin calcium according to peak area ratio. The data 
with correlation co-efficient and % CV are given in Tab. 5.2. Which were within 
specified criteria so, this method is linear. 
 
6.1.1.3 Accuracy and Precision 
6.1.1.3.1 Intraday Accuracy and Precision 
Data for intraday reproducibility were given in Tab. 5.3. The % CV obtained for 
intraday precision for atorvastatin calcium was found to be 0.58 - 2.07, which is 
less than 5 %. Nominal concentration was found 105.957 %, 104.558 %, 102.781 
% and 99.739 % of LLOQ, LQC, MQC and HQC respectively which was within 
specified criteria which confirmed that method was precise. 
 
6.1.1.3.2 Interday Accuracy and Precision 
Data for interday reproducibility were given in Tab. 5.4. The % CV obtained for 
intraday precision for the atorvastatin calcium was found to be 0.96 - 2.93. This 
was less than the 5 %. Nominal concentration was found 109.238 %, 105.614 %, 
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102.904 % and 100.904 % of LLOQ, LQC, MQC and HQC respectively which 
was within specified criteria which confirmed that the method was precise. So the 
results of both above two experiments indicate that this method was precise on 
the basis of its reproducibility. 
 
6.1.1.3.3 Recovery  
The % recovery was found 77.34 %, 81.37 % and 81.36 % at the LQC, MQC and 
HQC respective QC level of the atorvastatin (Tab. 5.5). % mean recovery of the 
atorvastatin was 80.02 % and % CV within the QC level was 2.90 which was less 
than 5 % (Tab. 5.6).  The % recovery of internal standard diclofenac sodium was 
76.678 % (Tab. 5.7).  
 
6.1.1.3.4 Limit of Detection 
The detectable limit was 0.500 µg. 
 
6.1.1.3.5 Limit of Quantification 
The quantification limit was 1.000 µg. 
 
6.1.1.3.6 Specificity 
It resolves the peak of atorvastatin calcium (RT at 6.20 ± 0.5 min) and diclofenac 
sodium (RT at 8.92 ± 0.5 min) even in presence of herbal absorption enhancer or 
plasma (Fig. 5.1). In proposed method excipients or plasma did not interfere with 
analysis. This method was specific. 
 
6.1.2 Carvedilol  
6.2.2.1 System suitability 
For the precision of replicate of injection % CV obtained was 1.551 % (Tab. 5.9), 
and in system suitability the limit of % CV not more than 5 %.  So % CV obtained 
from the experimental analysis was within these criteria and on this basis method 
was precise for replicate of injection and suitable for system. 
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6.1.2.2 Linearity 
The area ratio obtained of different concentration of carvedilol was used to plot a 
calibration curve of Area ratio vs. concentration (µg/ml). Linearity range of 
carvedilol was found to be 0.500-208.0 µg with correlation co-efficient of 0.9996 
(Fig. 5.2). The linearity equation was y=0.027х +0.163 where X is concentration 
of carvedilol and Y is area ratio. Fig. 5.2 shows that the calibrations curve of 
carvedilol according to peak area ratio. The data with correlation co-efficient and 
% CV were given in Tab. 6.10. Which were within specified criteria so this 
method was linear. 
 
6.1.2.3 Accuracy and precision 
6.1.2.3.1 Intraday accuracy and precision 
Data for intraday reproducibility were given in Tab. 5.11. The % CV obtained for 
intraday precision for carvedilol was found to be 0.67 - 1.74. This is less than 5 
%. Nominal concentration was found 99.183 %, 99.722 %, 99.663 %, and 
100.464 % of LLOQ, LQC, MQC and the HQC respectively which was within 
specified criteria. So this confirmed that the method was precise. 
 
6.1.2.3.2 Inter day accuracy and precision 
Data for interday reproducibility were given in TAB. 5.12. The %CV obtained for 
intraday precision for carvedilol was found to be 1.39 - 2.88. Which is less than 
5%.% Nominal concentration was found 96.183, 98.593, 100.714, and 99.946 of 
LLOQ, LQC, MQC and HQC respectively which was within specified criteria. That 
confirmed that the method was precise. So, the results of above two experiments 
indicate that this method was precise on the basis of its reproducibility. 
 
6.1.2.3.3 Recovery  
The % recovery was found 85.78 %, 88.05 % and 86.59 % at LQC, MQC and 
HQC respective QC level of carvedilol (Tab. 5.13). % mean recovery of carvedilol 
was 86.81 % and % CV within QC level was 1.33 which was less than 5 % (Tab. 
                                                                                                                Discussion 
 
Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat, India.  121 
 
5.14). The % recovery of internal standard diclofenac sodium was 82.86 % (Tab. 
5.15).  
 
6.1.2.3.4 Limit of detection 
The detectable limit was 0.250 µg. 
 
6.1.2.3.5 Limit of quantification 
The quantification limit was 0.500 µg. 
 
6.1.2.3.6 Specificity 
It resolves the peak of carvedilol (RT at 2.78 ± 0.5 min) and diclofenac sodium 
(RT at 8.32 ± 0.5 min) even in presence of herbal absorption enhancer or plasma 
(Fig. 5.2). In proposed method excipients or plasma did not interfere with 
analysis. This method is specific. 
 
6.1.3 Sildenafil citrate 
6.1.3.1 System suitability  
For the precision of replicate of injection RSD obtained was 0.29 %. Tab. 5.17 
and in system suitability limit of RSD is within ± 2 %. So this method was precise 
for replicate of injection and suitable for system. 
 
6.1.3.2 Linearity 
The peak area obtained at 230 nm of different concentration of sildenafil citrate 
was used to plot a calibration curve. Linearity range of sildenafil citrate was found 
to 0.1-50 µg with correlation co-efficient of 0.999 (Fig. 5.3). The linearity equation 
is Y=17845X – 2912, where X is concentration of sildenafil citrate and Y is peak 
area. Fig. 5.3 shows the calibration curve of sildenafil citrate according to peak 
area. The data of correlation co-efficient and % CV were given in the Tab. 5.18.  
The limit of correlation co-efficient and % CV was not less than a 0.99 and not 
more than 5 % respectively. 
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6.1.3.3 Accuracy and precision 
6.1.3.3.1 Intraday reproducibility 
Data for intraday reproducibility were given in Tab. 5.19. The % CV obtained for 
intraday precision for sildenafil citrate was found to be 0.541 - 2.99. The limit for 
% CV is not more than 5 %. 
 
6.1.3.3.2 Interday reproducibility 
Data for interday reproducibility were given in Tab. 5.20. The % CV obtained for 
interday precision for sildenafil citrate was found to be 0.37 - 3.61. The limit for % 
CV is not more than 5 %. So the result of both reproducible experiments 
indicates that this method is precise. 
 
6.1.3.3.3 Recovery 
The % recovery experiment revealed good accuracy. The % recovery of added 
sample was within ± 2 % (Tab. 5.21). This result clearly indicates that the method 
was accurate.  
 
6.2.3.3.4 Limit of detection 
The detectable limit was 100 ng. 
 
6.1.3.3.5 Limit of quantification 
The quantification limit was 100 ng. 
 
6.1.3.3.6 Specificity 
It resolves the peak of sildenafil citrate (RT at 5.33 ± 0.5 min) even in presence of 
herbal absorption enhancer or plasma. Fig. 5.3 in proposed method excipient or 
plasma did not interfere with analysis. This method is specific. 
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6.1.4 Zidovudine 
6.1.4.1 System suitability  
For the precision of replicate of injection, RSD obtained was 0.66 %. TAB. 5.23, 
and in system suitability the limit of RSD was within ± 2 %. So, this method was 
precise for replicate of injection and suitable for system. 
 
6.1.4.2 Linearity 
The peak area obtained at 266 nm of different concentration of sildenafil citrate 
was used to plot a calibration curve. Linearity range of zidovudine was found to 
be 0.1-50 µg with correlation co-efficient of 0.999 (Fig. 5.4). The linearity 
equation is Y = 64030X + 2662, where X is concentration of sildenafil citrate and 
Y is peak area. Fig. 5.4 shows the calibration curve of zidovudine according to 
peak area. The data with correlation co-efficient and % CV were given in Tab. 
5.24.  The limit of correlation co-efficient and % CV was not less than 0.99 and 
not more than 5 % respectively. 
 
6.1.4.3 Accuracy and precision 
6.2.4.3.1 Intraday reproducibility 
Data for intraday reproducibility were given in Tab. 5.25. The % CV obtained for 
intraday precision for zidovudine was found to be 1.39 - 4.82. The limit for % CV 
is not more than 5 %. 
 
6.1.4.3.2 Interday reproducibility 
Data for interday reproducibility were given in Tab. 5.26. The % CV obtained for 
interday precision for zidovudine was found to be 0.69 - 4.90. The limit for % CV 
is not more than 5 %. So the results of above reproducible experiments indicate 
that this method was precise. 
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6.1.4.3.3 Recovery  
The % recovery experiment revealed good accuracy. The % recovery of added 
sample was within ± 2 % (Tab. 5.27). This result clearly indicates that the method 
was accurate.  
 
6.1.4.3.4 Limit of detection 
The detectable limit was 100 ng. 
 
6.1.4.3.5 Limit of quantification 
The quantification limit was 100 ng. 
 
6.1.4.3.6 Specificity 
It resolves the peak of zidovudine (RT at 3.36 ± 0.5 min) even in presence of 
herbal absorption enhancer plasma (Fig. 5.4). In proposed method excipient or 
plasma did not interfere with analysis. This method was specific. 
 
6.2 In vivo bioavailability study 
6.2.1 Atorvastatin calcium 
6.2.1.1 Effect of silymarin as absorption enhancer 
The method was applied to a bioavailability study for examining the influence of 
the co-administration of silymarin on to the absorption of atorvastatin. Findings of 
the pharmacokinetic studies were shown in Tab. 5.29 and plasma concentration 
profile at different time intervals was depicted in to the Fig. 5.5. It was observed 
that concomitant administration of silymarin and atorvastatin calcium increased 
significantly the bioavailability of atorvastatin calcium. Fig. 5.5 clearly suggests 
that there was no alteration in to the Tmax. In other words, the onset of action of 
atorvastatin calcium remains unaltered but, the maximum concentration Cmax
The mean plasma concentration–time profiles of atorvastatin calcium in the 
presence and absence of silymarin were characterized in rats and illustrated in 
 
increased significantly. 
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Fig. 5.5. The mean pharmacokinetic parameters of atorvastatin calcium were 
also summarized in Tab. 5.29. 
 
Fig. 5.5 displays the atorvastatin plasma concentration–time profiles in the 
animals after orally administration of the atorvastatin suspension with silymarin 
solution. Silymarin increased the Cmax of atorvastatin by approximately 32.31% 
from 3.921 to 5.188 µg/ml while there was no significant change in to the Tmax of 
atorvastatin in the presence of silymarin. These results indicate that co-
administration of atorvastatin with silymarin seems to increase the Cmax.  
 
6.2.1.2 Effect of naringin as absorption enhancer 
Same as above the method was applied to a bioavailability study for examining 
the influence of the co-administration of naringin on the absorption of atorvastatin 
calcium. Findings of the pharmacokinetic studies were shown in Tab. 5.30 and 
the plasma concentration profile at different time intervals was depicted in Fig. 
5.6. It was observed that concomitant administration of naringin and atorvastatin 
calcium increased significantly the bioavailability of atorvastatin calcium. Fig. 5.6 
clearly suggests that there was no alteration in the Tmax. In other words, the 
onset of action of atorvastatin calcium remains unaltered but, the maximum 
concentration Cmax
Fig. 5.6 displays the atorvastatin plasma concentration–time profiles in the 
animals after orally administration of the atorvastatin suspension with naringin 
solution. Naringin increased the C
 increased significantly. 
 
The mean plasma concentration–time profiles of atorvastatin calcium in the 
presence and absence of naringin were characterized in rats and illustrated in 
Fig. 5.6. The mean pharmacokinetic parameters of atorvastatin calcium were 
also summarized in Tab. 5.30. 
 
max of atorvastatin by approximately 19.66 % 
from 3.921 to 4.692 µg/ml while there was no significant change in to the Tmax of 
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atorvastatin in presence of naringin. These results indicate that co-administration 
of atorvastatin with naringin seems to increase the Cmax.  
 
6.2.1.3 Effect of morin as absorption enhancer 
Same as above the method was applied to a bioavailability study for examining 
the influence of the co-administration of morin on the absorption of atorvastatin 
calcium. Findings of the pharmacokinetic studies were shown in Tab. 5.31 and 
the plasma concentration profile at different time intervals was depicted in Fig. 
5.7. It was observed that concomitant administration of morin and atorvastatin 
calcium decreased significantly the bioavailability of atorvastatin calcium. Fig. 5.7 
clearly suggests that there was no alteration in the Tmax. In other words, the 
onset of action of the drug, atorvastatin calcium remains unaltered but, the 
maximum concentration Cmax decreased significantly. 
 
The mean plasma concentration–time profiles of atorvastatin calcium in the 
presence and absence of morin were characterized in rats and illustrated in Fig. 
5.7. The mean pharmacokinetic parameters of atorvastatin calcium were also 
summarized in Tab. 5.31. 
 
Fig. 5.7 displays the atorvastatin plasma concentration–time profiles in the 
animals after orally administration of the atorvastatin suspension with morin 
solution. Morin decrease the Cmax of atorvastatin by approximately -14.23 % from 
3.921 to 3.363 µg/ml while there was no significant change in Tmax of atorvastatin 
in presence of morin. These results indicate that co-administration of atorvastatin 
with morin seems to decrease the Cmax
 
.  
 
From the experimental analysis the results indicates that the silymarin and 
naringin significantly increase the concentration of drug in rat blood plasma while 
morin decrease the concentration as compare to control (Atorvastatin calcium).  
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6.2.2 Carvedilol 
6.2.2.1 Effect of silymarin as absorption enhancer 
The method was applied to a bioavailability study for examining the influence of 
the co-administration of silymarin on the absorption of carvedilol. Findings of the 
pharmacokinetic studies were shown in Tab. 5.32 and the plasma concentration 
profile at different time intervals was depicted in Fig. 5.9. It was observed that 
concomitant administration of silymarin and carvedilol increased significantly the 
bioavailability of carvedilol. Fig. 5.9 clearly suggests that there was no alteration 
in the Tmax. In other words, the onset of action of the drug, carvedilol remains 
unaltered but, the maximum concentration Cmax increased significantly. 
 
The mean plasma concentration–time profiles of carvedilol in the presence and 
absence of silymarin were characterized in rats and illustrated in Fig. 5.9. The 
mean pharmacokinetic parameters of carvedilol were also summarized in Tab. 
5.32. 
 
Fig. 5.9 displays the carvedilol plasma concentration–time profiles in the animals 
after orally administration of the carvedilol suspension with silymarin solution. 
Silymarin increased the Cmax of carvedilol by approximately 31.95 % from 9.517 - 
12.558 µg/ml, while there was no significant change in Tmax of carvedilol in the 
presence of silymarin. These results indicate that co-administration of carvedilol 
with silymarin seems to increase the Cmax
Same as above the method was applied to a bioavailability study for examining 
the influence of the co-administration of naringin on the absorption of carvedilol. 
Findings of the pharmacokinetic studies were shown in Tab. 5.33 and the plasma 
concentration profile at different time intervals was depicted in Fig. 5.10. It was 
observed that concomitant administration of naringin and carvedilol increased 
significantly the bioavailability of carvedilol. Fig. 5.10 clearly suggests that there 
.  
 
6.2.2.2 Effect of naringin as absorption enhancer 
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was no alteration in the Tmax. In other words the onset of action of the carvedilol 
remains unaltered but, the maximum concentration Cmax increased significantly. 
The mean plasma concentration–time profiles of carvedilol in the presence and 
absence of naringin were characterized in rats and illustrated in Fig. 5.10. The 
mean pharmacokinetic parameters of carvedilol were also summarized in Tab. 
5.33. 
 
Fig. 5.10 displays the carvedilol plasma concentration–time profiles in the 
animals after orally administration of the carvedilol suspension with naringin 
solution. naringin increased the Cmax of carvedilol by approximately 28.01 % from 
9.517 - 12.183 µg/ml, while there was no significant change in Tmax of carvedilol 
in the presence of naringin. These results indicate that co-administration of 
carvedilol with naringin seems to increase the Cmax.  
 
6.2.2.3 Effect of morin as absorption enhancer 
Same as above the method was applied to a bioavailability study for examining 
the influence of the co-administration of morin on the absorption of carvedilol. 
Findings of the pharmacokinetic studies were shown in Tab. 5.34 and the plasma 
concentration profile at different time intervals was depicted in Fig. 5.11. It was 
observed that concomitant administration of morin and carvedilol increased 
significantly the bioavailability of carvedilol. Fig. 5.11 clearly suggests that there 
was no alteration in the Tmax. In other words the onset of action of the carvedilol 
remains unaltered but, the maximum concentration Cmax
The mean plasma concentration–time profiles of carvedilol in the presence and 
absence of morin were characterized in rats and illustrated in Fig. 6.9. The mean 
pharmacokinetic parameters of carvedilol were also summarized in Tab. 6.10. 
Fig. 5.11 displays the carvedilol plasma concentration–time profiles in the 
animals after orally administration of the carvedilol suspension with morin 
solution. Morin increase the C
 increased significantly. 
 
max of carvedilol by approximately 5.67 % from 
9.517 - 10.057 µg/ml, while there was no significant change in Tmax of carvedilol 
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in the presence of morin. These results indicate that co-administration of 
carvedilol with morin seems to increase the Cmax
The method was applied to a bioavailability study for examining the influence of 
the co-administration of silymarin on the absorption of sildenafil citrate. Findings 
of the pharmacokinetic studies were shown in to the Tab. 5.35 and the plasma 
concentration profile at different time intervals was depicted in Fig. 5.13. It was 
observed that concomitant administration of silymarin and sildenafil citrate 
increased significantly the bioavailability of sildenafil citrate. Fig. 5.13 clearly 
suggests that there was no alteration in the T
.  
 
From the experimental analysis the results indicates that the silymarin, naringin 
and morin significantly increase the concentration of drug in rat blood plasma, as 
compare to control (Carvedilol).  
 
6.2.3 Sildenafil citrate 
6.2.3.1 Effect of silymarin as absorption enhancer 
max. In other words, the onset of 
action of sildenafil citrate remains unaltered but, the maximum concentration 
Cmax
 
 increased significantly. 
The mean plasma concentration–time profiles of sildenafil citrate in the presence 
and absence of silymarin were characterized in rats and illustrated in Fig. 5.13. 
The mean pharmacokinetic parameters of sildenafil citrate were also summarized 
in Tab. 5.35. 
 
Fig. 5.13 displays the sildenafil citrate plasma concentration–time profiles in the 
animals after orally administration of the sildenafil citrate suspension with 
silymarin solution. Silymarin increase the Cmax of sildenafil citrate by 
approximately 24.88 % from 1.049 to 1.310 µg/ml while there was no significant 
change in Tmax of sildenafil citrate in the presence of silymarin. These results 
indicate that co-administration of sildenafil citrate with silymarin seems to 
increase the Cmax.  
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6.2.3.2 Effect of morin as absorption enhancer 
Same as above method, the method was applied to a bioavailability study for 
examining the influence of the co-administration of morin on the absorption of 
sildenafil citrate. Findings of the pharmacokinetic studies were shown in Tab. 
5.36 and the plasma concentration profile at different time intervals was depicted 
in Fig. 5.14. It was observed that concomitant administration of morin and 
sildenafil citrate increased significantly the bioavailability of sildenafil citrate but it 
was some less as compare to silymarin. Fig. 5.14 clearly suggests that there was 
no alteration in the Tmax. In other words, the onset of action of sildenafil citrate 
remains unaltered but, the maximum concentration Cmax
The mean plasma concentration–time profiles of sildenafil citrate in the presence 
and absence of morin were characterized in rats and illustrated in Fig. 5.14. The 
mean pharmacokinetic parameters of sildenafil citrate were also summarized in 
Tab. 5.36. 
 
Fig. 5.14 displays the sildenafil citrate plasma concentration–time profiles in the 
animals after orally administration of the sildenafil citrate suspension with morin 
solution. Morin increase the C
 increased significantly. 
max of Sildenafil citrate by approximately 11.09% 
from 1.049 to 1.154 µg/ml while there was no significant change in to the Tmax of 
sildenafil citrate in presence morin. These results indicate that co-administration 
of sildenafil citrate with morin seems to increase the Cmax
Same as above methods, the method was also applied to a bioavailability study 
for examining the influence of the co-administration of naringin on the absorption 
of sildenafil citrate. Findings of the pharmacokinetic studies and the plasma 
concentration profile at different time intervals was depicted in Tab. 5.37 and Fig. 
5.15 respectively. It was observed that concomitant administration of naringin 
and sildenafil citrate increased significantly the bioavailability of sildenafil citrate 
but it is some less as compare to silymarin and morin. Fig. 5.15 clearly suggests 
that there was no alteration in the T
.  
 
6.2.3.3 Effect of naringin as absorption enhancer 
max as like as silymarin and morin.  In other 
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words the onset of action of sildenafil citrate remains unaltered but, the maximum 
concentration Cmax
 
 increased significantly. 
The mean plasma concentration–time profiles of sildenafil citrate in the presence 
and absence of naringin were characterized in rats and illustrated in Fig. 5.15. 
The mean pharmacokinetic parameters of sildenafil citrate were also summarized 
in Tab. 5.37. 
 
Fig. 5.15 displays the sildenafil citrate plasma concentration–time profiles in the 
animals after orally administration of the sildenafil citrate suspension with 
naringin solution. Naringin having not any significant effect on to the Cmax of 
sildenafil citrate by approximately -1.90 % from 1.049 to 1.029 µg/ml, while there 
was no significant change in Tmax 
From the experimental analysis the results indicates that the silymarin and morin 
significantly increase the concentration of drug in rat blood plasma, as compare 
to control (Sildenafil citrate) while naringin having not any significant effect on rat 
blog plasma concentration. 
 
6.2.4 Zidovudine 
6.2.4.1 Effect of silymarin as absorption enhancer 
of sildenafil citrate in the presence of naringin.  
 
Same as above methods, for examining the influence of the co-administration of 
silymarin on the absorption of zidovudine in bioavailability study this method was 
used. Findings of the pharmacokinetic studies and the plasma concentration 
profile at different time intervals was depicted in to the Tab. 5.39 and Fig. 5.18 
respectively. Fig. 5.18 clearly suggests that the concomitant administration of 
silymarin and zidovudine increased significantly the bioavailability of zidovudine. 
And there was no alteration in to the Tmax.  In other words, the onset of action of 
zidovudine remains unaltered but, the maximum concentration Cmax
 
 increased 
significantly. 
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The mean plasma concentration–time profiles of zidovudine in the presence and 
absence of silymarin were characterized in rats and illustrated in Fig. 5.18. The 
mean pharmacokinetic parameters of zidovudine were also summarized in Tab. 
5.39. 
 
Fig. 5.18 displays the zidovudine plasma concentration–time profiles in the 
animals after orally administration of the zidovudine suspension with silymarin 
solution. Silymarin having significant effect on the Cmax of zidovudine by 
increasing approximately 28.31 % from 5.407 - 6.938 µg/ml, while there was no 
significant change in Tmax of zidovudine in the presence of silymarin. These 
results indicate that co-administration of zidovudine with the silymarin seems to 
increase the Cmax
As like above methods, this method also applied for examining the influence of 
the co-administration of naringin on the absorption of zidovudine in bioavailability 
study. Findings of the pharmacokinetic studies and the plasma concentration 
profile at different time intervals was depicted in to the 
.  
 
6.2.4.2 Effect of morin as absorption enhancer 
Tab. 5.40 and Fig. 5.19 
respectively. It was observed that concomitant administration of morin and 
zidovudine increased significantly the bioavailability of zidovudine. Fig. 5.19 
clearly suggests that there was no alteration in the Tmax.  In other words, the 
onset of action of the drug, zidovudine remains unaltered but the maximum 
concentration Cmax
 
The mean plasma concentration–time profiles of zidovudine in the presence and 
absence of morin were characterized in rats and illustrated in Fig. 5.19. The 
mean pharmacokinetic parameters of zidovudine were also summarized in Tab. 
5.40. 
 
 increased significantly. 
Fig. 5.19 displays the zidovudine plasma concentration–time profiles in the 
animals after orally administration of the zidovudine suspension with morin 
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solution. morin having significant effect on the Cmax of zidovudine by increasing 
approximately 16.17 % from 5.407 to 6.219 µg/ml while there was no significant 
change in Tmax of zidovudine in the presence of morin. These results indicate that 
co-administration of zidovudine with morin seems to increase the Cmax
Same as above methods, the method was applied to a bioavailability study for 
examining the influence of the co-administration of naringin on the absorption of 
zidovudine. Findings of pharmacokinetic studies and the plasma concentration 
profile at different time intervals was depicted in to the Tab. 5.38 and Fig. 5.17 
respectively. It was observed that concomitant administration of naringin and 
zidovudine increased significantly the bioavailability of zidovudine. Fig. 5.17 
clearly suggests that there was no alteration in the T
.  
 
6.2.4.3 Effect of naringin as absorption enhancer 
max.  In other words the 
onset of action of drug, zidovudine remains unaltered but the maximum 
concentration Cmax
 
 increased significantly. 
The mean plasma concentration–time profiles of zidovudine in the presence and 
absence of naringin were characterized in rats and illustrated in Fig. 5.17. The 
mean pharmacokinetic parameters of zidovudine were also summarized in Tab. 
5.38. 
 
Fig. 5.17 displays the zidovudine plasma concentration–time profiles in the 
animals after orally administration of the zidovudine suspension with naringin 
solution. Naringin having significant effect on the Cmax of zidovudine by 
increasing approximately 60.49 % from 5.407 - 8.678 µg/ml, while there was no 
significant change in Tmax of zidovudine in the presence of naringin. These 
results indicate that co-administration of zidovudine with naringin seems to 
increase the Cmax
From the experimental analysis the results indicates that the silymarin and morin 
significantly increase the concentration of drug in rat blood plasma, as compare 
.  
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to control (zidovudine) while naringin having very significant effect on rat blood 
plasma concentration. 
 
6.3. In vitro cytotoxicity studies by SRB assay 
The three flavanoids named silymarin, morin & naringin were selected for the 
study of its cytotoxicity against colon cancer cell line (HCT-15) and breast cancer 
cell line (MCF-7) by SRB assay method. 
 
6.3.1 In Vitro Cytotoxicity of HAPs against human cancer cell lines 
In vitro cytotoxicity against two human cancer cell lines was determined using 96-
well tissue culture plates. The 100 µl of cell suspension was added to each well 
of the 96-well tissue culture plate. The cells were allowed to grow in carbon 
dioxide incubator (37 °C, 5 % CO2
P-gp ATPase enzyme activity has been found in the present investigation, it 
indicated that silymarin possessed affinity for P-gp and it could be a putative 
modulator of this protein: an inhibition has implications in bioavailability 
enhancement. Tab. 5.42 shows that at the dose level of 10 µmol and 30 µmol the 
, 90 % RH) for 24 hr.  
 
The cell growth was determined by subtracting mean OD value of respective 
blank from the mean OD value of experimental set. Percent growth in presence 
of test material was calculated considering the growth in absence of any test 
material as 100 % and in % growth inhibition in presence of test material was 
calculated.  
 
From the experimental analysis the results indicates that the silymarin and morin 
significantly having not any considerable growth inhibition of selected cell lines 
i.e. HCT-15 and MCF-7 as compare to positive control  5-furouracil and  
temoxifen. 
 
6.4 In Vitro enzyme activity 
6.4.1 In Vitro P-gp ATPase enzyme activity 
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silymarin significantly inhibit the P-gp ATPase enzyme activity as compared to 
control with P < 0.05 when analyzed statically by Dunnett’s test. At the dose level 
of 100 µmol of silymarin significantly inhibited the P-gp ATPase enzyme activity 
as compared to control with P < 0.01 when analyzed statically by Dunnett’s test. 
The P-gp ATPase enzyme inhibition activity of silymarin was also shown in Fig. 
5.21 which was graphical representation as % change vs control. From above 
results for silymarin it can be concluded that silymarin having a significant 
inhibition effect on P-gp ATPase enzyme activity by this in vitro study.   
 
P-gp ATPase enzyme activity has been found in the present investigation, it 
indicated that naringin possessed affinity for P-gp and it could be a putative 
modulator of this protein: an inhibition has implications in bioavailability 
enhancement. Tab. 5.43 shows that at the dose level of 10 µmol, 30 µmol and 
100 µmol naringin highly significantly inhibit the P-gp ATPase enzyme activity as 
compared to control with P < 0.0001 when analyzed statically by Dunnett’s test. 
The P-gp ATPase enzyme inhibition activity of naringin was also shown in Fig. 
5.22 which was graphical representation as % change vs control. From above 
results for naringin it can be concluded that Naringin having a highly significant 
inhibition effect on P-gp ATPase enzyme activity by this in vitro study.   
 
P-gp ATPase enzyme activity has been found in the present investigation, it 
indicated that morin possessed affinity for P-gp and it could be a putative 
modulator of this protein: an inhibition has implications in bioavailability 
enhancement. Tab. 5.44 shows that at the dose level of 10 µmol, 30 µmol and 
100 µmol morin highly significantly inhibit the P-gp ATPase enzyme activity as 
compared to control with P < 0.001 when analyzed statically by Dunnett’s test. 
The P-gp ATPase enzyme inhibition activity of morin was also shown in Fig. 5.23 
which was graphical representation as % change vs control. From above results 
for morin it can be concluded that morin having a highly significant inhibition 
effect on P-gp ATPase enzyme activity by this in vitro study.   
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6.4.2 In Vitro CYP 450 enzyme studies 
6.4.2.1 CYP1A1 Enzyme: Benzopyrene Hydroxylase Activity 
CYP1A1 enzyme activity has been found in the present investigation, it indicated 
that silymarin possessed not having significant affinity for CYP1A1 and it could 
be a putative modulator of this enzyme. Tab. 5.45 shows that at the dose level of 
10 µmol, 30 µmol and 100 µmol silymarin not significantly inhibit the CYP1A1 
enzyme activity as compared to control with P > 0.05 when analyzed statically by 
Dunnett’s test. The CYP1A1 enzyme inhibition activity of silymarin was also 
shown in Fig. 5.24 which was graphical representation as % change vs. control. 
From above results for silymarin it can be concluded that silymarin having a not 
significant inhibition effect on CYP1A1 enzyme activity by this in vitro study.   
 
CYP1A1 enzyme activity has been found in the present investigation, it indicated 
that naringin possessed having significant affinity for CYP1A1 at higher dose 
level and it could be a putative modulator of this enzyme. Tab. 5.46 shows that at 
the dose level of 10 µmol naringin not significantly inhibit the CYP1A1 enzyme 
activity as compared to control with P > 0.05 when analyzed statically by 
Dunnett’s test. At the dose level of 30 µmol and 100 µmol naringin significantly 
inhibit the CYP1A1 enzyme activity as compared to control with P < 0.05 when 
analyzed statically by Dunnett’s test. The CYP1A1 enzyme inhibition activity of 
naringin was also shown in Fig. 5.25 which was graphical representation as % 
change vs control. From above results for naringin it can be concluded that 
naringin having a significant inhibition effect on CYP1A1 enzyme activity at 
higher dose level by this in vitro study.   
 
CYP1A1 enzyme activity has been found in the present investigation, it indicated 
that morin possessed not having significant affinity for CYP1A1 and it could be a 
putative modulator of this enzyme. Tab. 5.47 shows that at the dose level of 10 
µmol, 30 µmol and 100 µmol morin not significantly inhibit the CYP1A1 enzyme 
activity as compared to control with P > 0.05 when analyzed statically by 
Dunnett’s test. The CYP1A1 enzyme inhibition activity of morin was also shown 
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in Fig. 5.26 which was graphical representation as % change vs control. From 
above results for morin it can be concluded that silymarin having a not significant 
inhibition effect on CYP1A1 enzyme activity by this in vitro study.   
 
6.4.2.2 CYP3A4 enzyme: Erythromycin demethylase  
CYP3A4 enzyme activity has been found in the present investigation, it indicated 
that silymarin possessed having significant affinity at higher dose level for 
CYP3A4 enzyme and it could be a putative modulator of this enzyme. Tab. 5.45 
shows that at the dose level of 10 µmol silymarin not significantly inhibit the 
CYP3A4 enzyme activity as compared to control with P > 0.05 when analyzed 
statically by Dunnett’s test. At the dose level of 30 µmol and 100 µmol silymarin 
significantly inhibit the CYP3A4 enzyme activity as compared to control with P < 
0.05 when analyzed statically by Dunnett’s test. The CYP3A4 enzyme inhibition 
activity of silymarin was also shown in Fig. 5.24 which was graphical 
representation as % change vs control. From above results for silymarin it can be 
concluded that silymarin having significant inhibition effect at higher dose level on 
CYP3A4 enzyme activity by this in vitro study.   
 
CYP3A4 enzyme activity has been found in the present investigation, it indicated 
that naringin possessed not having significant affinity for CYP3A4 enzyme and it 
could be a putative modulator of this enzyme. Tab. 5.45 shows that at the dose 
level of 10 µmol, 30 µmol and 100 µmol naringin not significantly inhibit the 
CYP3A4 enzyme activity as compared to control with P > 0.05 when analyzed 
statically by Dunnett’s test. The CYP3A4 enzyme inhibition activity of naringin 
was also shown in Fig. 5.24 which was graphical representation as % change vs 
control. From above results for naringin it can be concluded that naringin having 
a not significant inhibition effect on CYP3A4 enzyme activity by this in vitro study.   
 
CYP3A4 enzyme activity has been found in the present investigation, it indicated 
that morin possessed not having significant affinity for CYP3A4 enzyme and it 
could be a putative modulator of this enzyme. Tab. 5.45 shows that at the dose 
                                                                                                                Discussion 
 
Department of Pharmaceutical Sciences, Saurashtra University, Rajkot, Gujarat, India.  138 
 
level of 10 µmol, 30 µmol and 100 µmol morin not significantly inhibit the 
CYP3A4 enzyme activity as compared to control with P > 0.05 when analyzed 
statically by Dunnett’s test. The CYP3A4 enzyme inhibition activity of morin was 
also shown in Fig. 5.24 which was graphical representation as % change vs 
control. From above results for morin it can be concluded that Morin having a not 
significant inhibition effect on CYP3A4 enzyme activity by this in vitro study.   
 
6.5 Primary compatibility study of HAPs with drugs 
In this study the IR spectra and DSC spectra were taken of selected drugs i.e. 
atorvastatin calcium, carvedilol phosphate, sildenafil citrate and zidovudine with 
each of the selected HAPs i.e. silymarin, naringin and morin along with individual 
spectra of each drug and HAPs. This will give a conformation about the 
compatibility of selected HAPs with the selected drugs and about the physical 
and chemical change occur due to interaction between them. 
 
6.5.1 Infrared spectroscopic study 
6.5.1.1 Atorvastatin calcium 
The FT-IR spectra of atorvastatin with HAPs were shown in Fig. 5.30. Mixture of 
Atorvastatin with HAPs i.e. silymarin, saringin and morin were also found to be 
identical. The principal IR absorption peaks of atorvastatin were all observed in 
the spectra of atorvastatin and solid mixture with HAPs. From these spectral 
observations it was indicated that no significant interaction between the 
atorvastatin and HAPs. So it can be concluded that this herbal ingredients were 
compatible with selected drug. 
 
6.5.1.2 Carvedilol phosphate 
The FT-IR spectra of carvedilol phosphate with HAPs were shown in Fig. 5.31. 
Mixture of carvidilol with HAPs i.e. silymarin, naringin and morin were also found 
to be identical. The principal IR absorption peaks of carvedilol were all observed 
in the spectra of carvedilol and solid mixture with HAPs. From these spectral 
observations it was indicated that no significant interaction between the carvedilol 
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and HAPs. So it can be concluded that this herbal ingredients were compatible 
with selected drug. 
 
6.5.1.3 Sildenafil citrate 
The FT-IR spectra of sildenafil citrate with HAPs were shown in Fig. 5.31. Mixture 
of sildenafil citrate with HAPs i.e. silymarin, naringin and morin were also found 
to be identical. The principal IR absorption peaks of sildenafil citrate were all 
observed in the spectra of sildenafil citrate and solid mixture with HAPs. From 
these spectral observations it was indicated that no significant interaction 
between the sildenafil citrate and HAPs. So it can be concluded that this herbal 
ingredients were compatible with selected drug. 
 
6.5.1.4 Zidovudine 
The FT-IR spectra of zidovudine with HAPs were shown in Fig. 5.31. Mixture of 
zidovudine with HAPs i.e. silymarin, naringin and morin were also found to be 
identical. The principal IR absorption peaks of zidovudine were all observed in 
the spectra of zidovudine and solid mixture with HAPs. From these spectral 
observations it was indicated that no significant interaction between the 
zidovudine and HAPs. So it can be concluded that this herbal ingredients were 
compatible with selected drug. 
 
 
6.5.2 Differential scanning calorimetry 
6.5.2.1 Atorvastatin calcium 
The DSC thermograms of atorvastatin calcium and atorvastatin calcium with 
HAPs i.e. silymarin, naringin and morin were compared. The peak of atorvastatin 
calcium obtained in the DSC thermogram at 161 oC, while peak of atorvastatin 
calcium with HAPs were obtained at the same temperature and there were no 
any changes in thermogram patterns. On the basis of the temperature obtained 
in both cases it was observed that there was no any significant interaction 
between the atorvastatin calcium and HAPs. 
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6.5.2.2 Carvedilol phosphate 
The DSC thermograms of carvedilol phosphate and carvedilol phosphate with 
HAPs i.e. silymarin, naringin and morin were compared. The peak of carvedilol 
phosphate obtained in the DSC thermogram at 158.8 oC while peak of carvedilol 
phosphate with HAPs were obtained at the same temperature and there were no 
any changes in thermogram patterns. On the basis of the temperature obtained 
in both cases it was observed that there was no any significant interaction 
between the carvedilol phosphate and HAPs. 
 
6.5.2.3 Sildenafil citrate 
The DSC thermograms of sildenafil citrate and sildenafil citrate with the HAPs i.e. 
silymarin, naringin and morin were compared. The peak of the sildenafil citrate 
obtained in the DSC thermogram at 192 oC while peak of sildenafil citrate with 
HAPs were obtained at the same temperature and there were no any changes in 
thermogram patterns. On the basis of the temperature obtained in both cases it 
was observed that there was no any significant interaction between the sildenafil 
citrate and HAPs. 
 
6.5.2.4 Zidovudine 
The DSC thermograms of zidovudine and zidovudine with HAPs i.e. silymarin, 
naringin and morin were compared. The peak of the zidovudine obtained in the 
DSC thermogram at 130 oC while peak of zidovudine with HAPs were obtained at 
the same temperature and there were no any changes in thermogram patterns. 
On the basis of the temperature obtained in both cases it was observed that 
there was no significant interaction between the zidovudine and HAPs. 
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7.  SUMMARY AND CONCLUSION
For the current research on effect of bioavailability on the HAPs i.e. silymarin, 
naringin and morin selected with allopathic drugs i.e. atorvastatin calcium, 
carvedilol phosphate, sildenafil citrate and zidovudine. For analysis of these
drugs as such as well from the plasma the sensitive methods was developed 
on HPLC. It was also validated and from results it was clear that the methods 
selected for the analysis of the drugs were selective, sensitive and accurate
with high precision and accuracy and within the statistical limit.
In vitro cytotoxicity HRB assay shows that the selected HAPs silymarin, 
naringin and morin not shows any kind of the membrane damaging activity 
and cytotoxicity, while control group of 5-flurouracil and tamoxifen shows 
significant membrane damage and cytotoxicity after the 24 hr and in MCF-7
and HCT-15 cell lines. These results confirmed that the silymarin, naringine 
and morin were not having a membrane damaging cytotoxicity and safe to 
use.
Silymarin was significantly inhibiting the p-gp ATPase activity when compared 
with the control group at the concentration level of 10 µmol, 30 µmol and 100 
µmol. The results indicate that all three HAPs having a potential inhibitory 
activity of p-gp ATPase enzymes. In vitro assay of CYP 450 1A1 enzyme 
activity of the silymarin and morin shows significant inhibition of enzyme at the 
concentration of 10 µmol, 30 µmol and 100 µmol. In naringin there was no 
significant inhibition of an enzyme activity of CYP 4501A1 at concentration of 
10 µmol but shows significant inhibition at the concentration of 30 µmol and 
100 µmol. In vivo assay CYP 450 3A4 enzyme for silymarin shows that it was 
not significantly inhibit the enzyme activity at the concentration 10 µmol and 
shows significant activity at 30 µmol and 100 µmol. Naringin and morin not 
shows significant inhibition activity at the concentration of 10 µmol, 30 µmol 
and 100 µmol.
The primary compatibility study of selected HAPs i. e. silymarin, naringin and 
morin not shows any significant interaction in FT-IR spectra and in the DSC 
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thermogram in primary compatibility with selected drugs i.e. atorvastatin
calcium, carvedilol phosphate, sildenafil citrate and zidovudine. These studies 
conformed that selected HAPs may not interact potentially with the selected 
modern allopathic drug.
This studies shows that silymarin was increases bioavailability of  atorvastatin 
by 32.31 %, carvedilol by 31.95 %, sildenafil by 24.88 % and the zidovudine
by 28.31 %. It also potentially inhibit the p-gp ATPase activity in to the in vitro 
study at the concentration level of 10 µmol, 30 µmol and 100 µmol.
Naringin was significantly increases the bioavailability of atorvastatin calcium
by 19.66 %, carvedilol phosphate by 28.01 % and Zidovudine by 60.49 % 
while it was not increases the bioavailability of sildenafil citrate significantly.
Naringin having a potential inhibits the activity of p-gp ATPase activity when 
studied the in vitro assay. It was also shows that the significant inhibition of
the in vitro activity of CYP 450 1A1 enzyme at the concentration of 30 µmol 
and 100 µmol and it was not significantly inhibits the activity of cyp 450 3A4 in
the in vitro studies.
Morin was significantly increase the bioavailability of carvedilol phosphate by 
5.07 %, sildenafil citrate by 11.09 % and zidovudine by 16.07 % and not 
having a significant increase in the bioavailability of atorvastatin calcium. 
Morin was significantly inhibits the activity of p-gp ATPase enzyme activity in 
the in vitro studies. At the concentration of 10 µmol, 30 µmol and 100 µmol. 
Marin not having a potential inhibitory activity of the CYP 450 1A1 enzyme 
and CYP 450 3A4 enzyme into the in vitro studies.
From above research work it can be concluded that the selected HAPs 
increases the bioavailability of the drugs which pose poor bioavailability by 
undergoing extensive first pass metabolism i.e. drug from the BCS class II-IV
(poor stability and this may be due to the inhibition of brush border enzyme of 
intestinal wall i.e. CYP 450 and p-gp ATPase enzyme.
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From this research we conclude that HAPs may exhibit high benefit to risk 
ratio to use as permission enhancers with modern drug which will help to 
reduce the dose of the drug and risk of few side effects associated with GI 
track and cost of the therapy may get reduced. This research may be 
extended for the exploration of clinical trials with modern drug which goes 
extensive first pass metabolism in human to establish the use of HAPs in to 
the formulation.
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